Author Index

Abd-Allah SA, 330A
Abdulrazzaq Y, 298A
Abe K, 912
Abe T, 119
Abel K, 555A
Abrams GM, 824
Abrams MT, 325A
Abramsky O, 518A
Abrey LE, 491A
Abu-Shakra SR, 495A, 549A
Acsadi G, 294A, 330A
Adams H, 526A
Adams K, 163
Adams M, 338A
Adams VI, 428
Adler JE, 549A
Adornato BT, 513A, 540A
Agid Y, 922
Aharonson V, 546A
Ahmed K, 308A
Ahn-Ewing J, 303A
Ahn Y, 520A
Ainsworth PJ, 545A
Aisen ML, 522A
Akbar M, 925
Akiguchi I, 508A
Akiyama H, 507A
Alam J, 618
Alavi A, 313A, 325A
Albin RL, 873
Albright AL, 290A
Alderson K, 487A
Alemany M, 301A
Alford M, 759
Al Gazali L, 298A
Alhalabi M, 495A
Alkadhi H, 901
Allen IV, 523A
Allen JC, 290A, 292A, 309A
Allen KM, 289A, 290A
Allen PS, 512A, 538A
Allen R, 302A
Almasy L, 681
Al-Nasser M, 925
Altman N, 91, 286A
Al-Turaiki MHS, 925
Alvarez L, 31, 286A, 302A
Alvarez MG, 289A
Alvarez RB, 864
Al-Yamani S, 295A, 338A
Amaducci L, 503A, 678
Amato AA, 581
Aminoff MJ, 131, 132
Amto AA, 545A
An SF, 611
Anand I, 543A
Andermann F, 446
Anderson DW, 379
Anderson EL, 805
Anderson WR, 428
Ang L, 428
Anslow P, 320A
Antalffy B, 288A, 297A
Antel JP, 469, 516A, 853
Aoki M, 912
Apfel SC, 540A
Appel SH, 530A, 532A
Applegarth DA, 545A
Ardila A, 503A
Arezzo JC, 517A
Argyris E, 521A
Armstrong D, 288A, 297A
Arnason BGW, 520A, 522A
Arnold DL, 446
Aron AM, 307A, 327A
Aronin P, 333A
Arruda F, 446
Arsac C, 695
Asakura T, 628
Asbury AK, 521A, 635
Asherov A, 512A
Ashwal S, 293A, 296A, 314A, 316A, 317A, 330A
Askanas V, 264, 864
Ater J, 292A
Athwal BS, 820
Atzei G, 299A, 312A
Avaneda R, 499A
Averbuch-Heller L, 465
Awaad Y, 308A
Azhar S, 307A
Azizi SA, 549A

Baas F, 672
Bado M, 329A
Bajjalieh M, 287A
Bakay RAE, 355, 488A
Baker N, 544A
Bale JF Jr, 319A
Ballaban-Gil KR, 301A, 307A
Ballantyne A, 318A
Balthazor M, 290A
Bandele AN, 323A, 324A
Banks DL, 320A
Baram TZ, 285A, 322A
Barbano R, 540A
Barker W, 500A
Barkovich AJ, 337A
Barks JDE, 292A
Barnes J, 288A
Barnett D, 512A
Barohn RJ, 544A, 545A, 581
Baron J, 512A
Baron J-C, 216, 498A, 501A, 525A, 536A
Baron MS, 355, 488A
Barré L, 525A
Barshop BA, 293A, 295A
Barton JJS, 387
Baser M, 288A
Bass E, 496A
Bastian AJ, 317A
Bateman D, 323A
Bauer B, 490A
Bauer J, 265
Baumgart S, 319A
Baumgartner I, 527A
Baumgartner RW, 527A
Baumgartner T, 325A
Baumgartner WA, 498A
Baumhefner RW, 552A
Bawden HN, 333A
Beattie EC, 548A
Bebin EM, 307A
Becher B, 516A
Becker C-M, 539A
Beckman JS, 496A
Beersma MFC, 928
Beeson D, 487A, 513A
Behan P, 531A
Behar KL, 506A, 908
Behen M, 313A
Beierwaltes P, 303A
Belden JR, 497A, 498A
Belden M, 534A
Bell JE, 25
Bell WE, 319A
Belman AL, 309A, 494A
Belmar N, 555A
Ben-Arie L, 534A
Benavides J, 315A
Benfield A, 527A
Bennett JL, 453
Bennett JP, 526A
Bennett JP Jr, 663
Ben-Nun A, 551A
Berciano J, 819
Berg AT, 301A
Berg-Dammer E, 527A
Berg M, 290A
Berger JR, 112
Bergeron C, 428, 893
Berges S, 528A
Bergin AM, 307A
Berk J, 494A
Berkovic SF, 227, 290A
Bernardini GL, 300A
Berry GT, 542A
Berry-Kravis E, 294A
Bertini E, 305A
Beyreuther K, 265
Bhagwati S, 543A
Bhambhani K, 333A
Bhardwaj A, 512A
Bhatia KP, 534A
Bhatti MT, 496A
Bianchetti A, 688
Bicknese AR, 286A, 306A
Bidouki SK, 25
Biesecker L, 309A
Bilbao JM, 18
Biller J, 497A
Bindoff LA, 25, 459
Bingham PM, 298A
Bird TD, 149, 829, 912, 932
Bix GJ, 289A
Black SE, 893
Blaivas M, 333A
Blanchet PJ, 535A
Blaser S, 310A
Blasko J, 507A, 537A
Blaxton TA, 525A
Bleck TP, 245
Bloem BR, 266
Blumen S, 512A
Boden-Albala B, 529A
Bodensteiner JB, 312A, 338A
Boecker H, 950
Boemi S, 299A, 312A
Boeve BF, 534A
Bojko A, 301A
Bolhuis PA, 672
Bolton CF, 511A, 545A
Bonanni P, 39
Bonavita V, 767
Bone I, 531A
Borowicz LM, 498A
Borson ND, 514A
Boston Children's Hospital, 300A
Bou S, 514A
Bourdette D, 518A, 550A
Bourque F, 529A
Boustani M, 294A
Bouzat C, 810
Boyd C, 512A
Boyett JM, 290A, 291A, 292A
Boyle S, 553A
Bracco L, 678
Bradley EL Jr, 129
Brady DR, 411
Bramblett GT, 575
Branda J, 334A
Brandt T, 918
Brannagan TH III, 510A
Brashear HR, 492A
Braverman N, 440
Breder CD, 547A
Breiter SN, 335A
Brenner T, 518A
Bressman SB, 681

July issue, pp 1–134; August issue, pp 135–340; September issue, pp 341–556; October issue, pp 557–690; November issue, pp 691–824; December issue, pp 825–1008.

Copyright © 1996 by The American Neurological Association

Briggs M, 55
Bristol LA, 540A
Brocke S, 514A
Brooks DJ, 49, 188, 950
Brosnan CF, 517A
Brown GK, 25
Brown RD Jr, 529A
Brown RH Jr, 603
Brown WD, 335A
Brown WT, 298A, 330A
Bruce J, 286A
Bruck W, 522A
Bruijn LI, 603
Brumback RA, 331A
Brunberg J, 163
Bruno A, 497A
Bruno C, 329A
Brusilow W, 495A, 549A
Bruzzi P, 521A
Bryan W, 544A
Bryan WW, 581
Buchholz DW, 497A
Buck B, 506A
Buehler BA, 312A
Buenafe A, 518A
Buist NRM, 319A
Bureau M, 39
Burger PC, 335A, 491A
Bürk MR, 846
Burleson J, 325A
Burleyson G, 496A
Burns C, 421
Burns RS, 534A
Burt T, 421
Busenbark K, 533A
Bushara KO, 317A, 329A

Cadavid D, 521A
Caemaert J, 538A
Caggiano AO, 547A
Cairncross JG, 491A
Cairns NJ, 149
Calabresi PA, 553A
Calder JS, 523A
Callahan C, 307A
Callanan L, 334A
Calne DB, 545A
Cameron KD, 552A
Camfield CS, 333A, 337A
Camfield PR, 333A, 337A
Campbell KP, 925
Campellone JV, 509A
Campi A, 901
Canadian Pediatric Ischemic Stroke Study Group, 338A
Cannella B, 515A
Canto B, 799
Capello E, 521A
Caplan LR, 497A, 498A, 499A
Carducci CA, 299A
Carelli V, 299A
Carpén O, 587
Carrier DA, 313A
Carson BS, 335A
Carson D, 300A
Carter TA, 293A
Carver V, 782
Carvey PM, 534A
Casey K, 507A
Cassiman J-J, 731
Celnik P, 524A
Cendes F, 446
Cervenáková L, 128
Chabrashvili TZ, 532A
Chaigrecht M, 546A
Chakraborty P, 296A
Chakravorty S, 504A
Challier B, 528A
Chalmers RM, 239
Chamberlain MC, 335A, 490A
Chamberlain P, 320A
Chandrasekaran K, 411
Chang CWJ, 245
Chapman K, 514A
Chari G, 525A
Chase TN, 535A
Chatterjee A, 500A
Chaudhry V, 513A, x40
Chaves-Carballo E, 314A
Chavot D, 528A
Chbihi T, 545A
Chen LS, 306A, 334A
Chen Q, 524A
Chen R, 524A, 536A
Chen X, 207, 489A
Chi S-I, 750
Chiba A, 551A
Child Neurology Inc. of Mishawska, IN, 300A
Chinnery PF, 459
Chiriboga C, 323A
Chisholm M, 302A
Cho TA, 291A
Choi DW, 750
Chou Y, 518A
Christodoulou K, 548A
Chu N-S, 67
Chugani DC, 296A, 313A, 314A
Chugani HT, 296A, 313A, 314A, 333A
Chun MR, 327A
Chung H, 55
Chutorian AM, 301A
Ciurlionis R, 294A
Civitello L, 310A
Clark A, 514A
Clark GD, 288A, 289A, 297A
Clark HB, 199
Clarke W, 526A
Classen J, 524A
Claussen GG, 544A
Clemence W, 534A
Clements J, 515A
Cleveland DW, 603
Cnaan A, 325A
Cohen BH, 324A
Cohen LG, 524A
Cohen S, 495A
Colagrande E, 315A, 323A
Cole SA, 355
Cole TRP, 312A
Coleman D, 530A
Collier TG, 545A
Collins MP, 545A
Comi G, 901
Compston DAS, 239
Çomu S, 319A, 684
Confavreux C, 469
Confort-Gouny S, 524A
Connell F, 330A
Connolly A, 329A
Connolly MB, 320A
Conry JA, 305A, 306A, 332A, 337A
Conti AM, 531A
Cookfair DL, 516A, 550A, 553A
Cordone G, 329A
Corey-Bloom J, 500A
Cornblath DR, 513A, 521A, 635, 949
Cornellier DS, 502A
Corse AM, 513A, 949
Corsillo L, 508A
Cortazzo MH, 290A, 291A
Costa M, 306A
Cote L, 535A
Côté R, 529A
Couraud F, 695
Coutinho P, 199
Covey DF, 286A, 314A
Cox C, 331A
Cox P, 310A
Coyle PK, 494A
Coyne M, 305A, 308A
Cozzone PJ, 524A
Crawford T, 782, 949
Crawley A, 387
Crook R, 149
Cross AH, 520A
Croxen R, 487A, 513A
Csurhes PA, 552A
Cunha L, 526A
Cupido CM, 338A
Cupler E, 792
Curatolo P, 315A, 323A
Currie B, 421
Currie J, 421
Currier R, 542A
Cusmai R, 305A
Cutter G, 469
Cwik VA, 512A
Czorny A, 528A

Dabrowski E, 304A, 317A
Dachman A, 311A
Dalakas MC, 128, 539A, 792
Dalmau J, 491A, 494A
Dambrosia J, 792
Daniel S, 945
Dargent B, 695
Darwish HZ, 318A
Dary M, 501A
Das K, 293A
da Silva EA, 313A, 314A, 333A
DATATOP Steering Committee and Investigators, 947
Dattwyler RJ, 494A
Davis JN, 528A
Davis K, 288A, 440
Davis RE, 663
Dawson TM, 487A, 559
Day AL, 496A
Day RA, 321A
Dayal AS, 520A, 522A
DBS Study Group, 533A
D'Cruz OF, 302A
Dean P, 31, 286A, 302A
DeAngelis LM, 491A
DeCarli C, 505A
de Chadarevian J-P, 309A, 310A
Deck J, 428
Decker R, 805
DeConti R, 490A
DeGasperi R, 300A
Degenhardt A, 491A
deGrauw A, 287A, 304A
Deibert E, 512A
de Leon D, 681
Delgado MR, 334A
Delong MR, 355, 488A
DeLong R, 541A
De Lorey TM, 39
De Luca D, 312A
Demarco R, 309A
Demeritte EL, 305A, 336A
Denckla MB, 325A
De Negri AM, 299A
Deng H-X, 541A
Derdeyn CP, 526A
Derlon J-M, 216
Desai S, 319A
DeSalles AAF, 505A
de Silva HAR, 207, 531A
Desson J-F, 501A
DeTeresa R, 207, 759
Deutsch M, 291A
Deveaux R, 502A
deVeber GA, 338A
Devinsky O, 724
de Visser M, 672
De Vivo DC, 5, 289A, 318A, 329A
Devlieger H, 731
Devare SG, 805
Devriendt K, 731
Dewey RB Jr, 537A
Deymeer F, 548A
Dhib-Jalbut S, 494A, 714
Di Cianno B, 782
Dick DJ, 597
Dickson DW, 139, 501A
Diederich N, 463
Di Iorio G, 767
DiMario FJ Jr, 325A
DiMauro S, 5, 172, 301A, 309A, 318A
di Michele F, 315A, 323A

Dinner A, 526A
Dlugos DJ, 311A
Dobyns WB, 289A, 290A
Doerr HG, 254
Dom R, 731
Donald L, 801
Donaldson D, 690
Donovan C, 333A
Dooley NP, 853
Dooling EC, 338A
Dore-Duffy P, 492A, 516A
Dostert P, 119
Dostrovsky JO, 538A
Douglass LM, 302A
Doyle WK, 724
Drachman DB, 691
Dravet C, 39
Dreisbach JN, 494A
Drescher KM, 517A
Droogan AG, 523A
Dropcho EJ, 489A
Duara R, 500A
Dubeau F, 446
Dubovsky EC, 337A
Duchowny M, 31, 91, 286A, 302A
Duff J, 538A
Dumaguin M, 495A, 549A
Duncan JS, 188
du Plessis A, 818
Dure LS IV, 287A
Durocher A, 497A
Dutch Guillain-Barré Study Group, 511A
Duvoisin RC, 767
Dyck PJ, 509A, 540A, 543A

Early CJ, 497A
Eckel L, 818
Edelman RR, 524A, 527A
Edelstein L, 522A
Eder DN, 327A
Edgar TS, 329A
Edwin D, 675
Eggers SDZ, 518A
Eglehoff JC, 304A
Eidelman BH, 575
El-Fatatry MA, 324A
Elliott MA, 821
Ellison GW, 469, 552A
Engel AG, 508A, 511A, 810
Engel WK, 264, 864
Enzmann D, 322A
Esclaire F, 548A
Eskridge J, 936
Esmonde TF, 523A
Ettinger AB, 306A
Eustache F, 525A
Ewalt D, 334A
Eydoux P, 327A
Eyer J, 513A
Eyman RK, 296A

Factor SA, 534A
Fadic R, 532A
Faerber MA, 108
Fahn S, 535A, 537A, 561, 681, 841
Falsaperla R, 247
Farrell MA, 25
Farrer RG, 792
Fattal-Valevski A, 322A
Faught RE, 236
Faustmann PM, 515A
Fazilat S, 305A
Fazzini E, 267
Feany MB, 139
Fedoseyeva L, 488A
Feeser BR, 497A
Feldman EL, 509A, 510A
Fero ME, 292A
Ferrari A, 521A
Ferrendelli JA, 286A
Ferrer I, 819
Fessler JA, 399
Ficaro EP, 399
Filipov P, 324A
Filippi M, 901
FineSmith R, 322A
Finlay JL, 290A, 292A, 293A
Fiore SM, 528A
Fischer J, 469, 516A, 550A, 553A
Fish DR, 188
Fish I, 308A, 318A, 322A
Fisher PG, 335A
Fisher RS, 287A, 504A
Fishman RA, 1, 133
Fitzmaurice PS, 689
Flanigan K, 487A
Flechter S, 551A
Flerlage N, 494A, 714
Florence R, 500A
Foer DR, 335A
Fogan L, 451
Foley S, 494A
Forbes C, 526A
Ford B, 681
Ford-Jones EL, 310A
Forem S, 318A
Forleo P, 503A
Forman S, 535A
Förstl H, 265
Foster NL, 399, 502A
Fowler JS, 267
France ML, 296A
Francis GS, 853
Frank JA, 505A
Frank N, 324A
Frank Y, 297A
Frankfurter A, 309A
Franzo A, 312A
Fraser RAR, 550A
Fredericks DN, 535A
Freedman MS, 555A
Freudenberg K, 294A
Frey KA, 399, 873, 885
Friedman H, 291A
Frisoni GB, 688
Fry JM, 493A
Fryns J-P, 731
Fuchs S, 254
Fuentes ME, 554A
Fujii T, 289A
Fukui MB, 575
Furlan M, 216, 498A
Furnari C, 323A
Furst M, 546A
Fusco L, 305A
Futamura N, 530A

Gabreëls-Festen AAWM, 672
Gadd M, 334A
Gadoth N, 298A
Gaillard WD, 305A, 306A
Gainey M, 311A
Gajdusek DC, 502A
Galbo H, 655
Galer BS, 823
Galetta SL, 532A
Galvez-Jiménez N, 538A
Gama Sosa MA, 300A
Garcia C, 782
Gardner K, 487A
Garg BP, 328A
Garlepp MJ, 264, 826
Garrett WT, 245
Gaskell PC, 801
Gaspar C, 199
Gastaut J-L, 524A
Gauger I, 534A
Gavini K, 314A
Gearing A, 515A
Genain CP, 555A
Genge A, 327A
Gennaro P, 302A
Genton P, 39
George CFP, 511A
Georgiadis AL, 499A
Georgiou DM, 548A
Gerken S, 520A
Gerloff C, 524A
Geyer JR, 290A, 292A, 293A
Ghaemi M, 501A
Ghatpande A, 543A
Ghetti B, 328A
Ghidoni P, 922
Gibbs CJ Jr, 502A
Gilad GM, 550A
Gilad VH, 550A
Gilat T, 512A
Gilchrist JM, 801
Gilden DH, 453
Gilks CB, 540A
Gilles EE, 316A, 322A
Gilles FH, 306A, 335A
Gilliam FG, 236
Gilliam TC, 293A
Gilman J, 286A
Gilman S, 163, 820, 873, 885
Gingold MK, 309A
Giometto B, 611
Giovannoni G, 128
Giuliani MJ, 509A, 645, 684
Gleeson JG, 289A, 290A
Godbold J, 841
Goel A, 512A
Goetz CG, 258, 463, 534A
Golbe LI, 767
Goldberg MP, 750
Goldfarb LG, 128, 532A
Goldman SA, 550A
Goldsborough MA, 498A
Goldstein G, 333A
Gombosi E, 502A
Gomez-Isla T, 55, 689
Gonzalez RG, 295A
Good MF, 552A
Goodkin D, 516A, 550A, 553A
Goodman R, 550A
Goodwin J, 297A
Gordon K, 337A
Gordon PH, 544A
Gorson KC, 539A
Goshen E, 336A
Goto J, 776
Goumnerova LC, 291A
Govoni S, 688
Goyal M, 337A
Graf WD, 327A
Granger C, 516A, 550A, 553A
Grant AC, 539A
Graus Y, 491A
Graziani L, 319A
Green A, 128
Green J, 355
Green SB, 491A
Greene DA, 510A
Greene PE, 534A, 681
Greenlee JE, 492A
Greenwald D, 496A
Greenwood RS, 302A, 324A
Greer JM, 552A
Gregory E, 207
Grekova MC, 108
Griffin JW, 513A, 521A, 635, 949
Griggs R, 540A
Griggs RC, 544A, 810
Grigsby J, 494A
Grimm P, 507A, 537A
Gringlas M, 319A
Grinnell AD, 739
Groccia M, 502A
Gronseth GS, 581
Gropman AL, 293A, 337A
Grose CF, 319A
Gross-Tsur V, 338A
Grossman RG, 534A, 535A
Grover WD, 309A, 310A
Growdon JH, 689
Gruning J, 506A
Guarnieri BM, 678
Guerrerio A, 497A
Guerrini R, 39
Gultekin SH, 491A
Gupta M, 543A
Gupta R, 304A, 317A

Gusella J, 288A, 440
Guthikonda P, 515A
Guthrie B, 387
Guttman B, 519A
Guy J, 496A
Gwag BJ, 750

Haan J, 928
Haas RH, 293A, 295A
Haase AT, 84
Hacke W, 499A, 539A
Hackett J Jr, 805
Haden E, 285A
Haenggeli CA, 329A
Hafer-Macko C, 543A, 635
Hahn AF, 511A, 545A
Hahn JS, 311A, 322A
Haida M, 493A, 547A
Halber M, 525A
Haldane F, 459
Haley EC, 497A
Hall WH, 714
Hallak A, 512A
Haller RG, 541A, 655
Hallett M, 344, 524A, 525A, 536A, 539A
Haltia M, 149
Hamada H, 549A
Hamed LM, 297A
Hammer MS, 304A
Hammerstad JP, 131
Handa S, 519A, 554A
Hanefeld F, 254
Hanley DF, 496A
Hansen LA, 207, 500A, 759
Hansen M, 526A
Hanstock C, 512A, 538A
Harati Y, 543A
Harden C, 327A
Harding AE, 25, 49, 239, 681
Harding BN, 25
Hardy J, 149
Harel S, 322A
Harper CR, 331A
Harrell LE, 500A
Harrington MG, 502A
Harrison C, 550A
Hart IK, 554A
Hartung H-P, 826
Harvey AS, 31, 91, 286A
Harwood D, 500A
Haselgrove JC, 313A, 325A
Hashida H, 776
Hashim G, 518A
Hashimoto T, 355, 488A
Hastings AE, 521A
Hasuo K, 569
Hatanpää K, 411
Hauptfleish S, 506A
Hauser RA, 534A
Hauser SL, 555A, 846
Hauser WA, 301A
Hawkins SA, 523A
Hays AP, 510A, 544A
He J, 379, 488A
He YY, 314A
Heagarty M, 323A
Heidebrink JL, 502A
Heilbroner P, 318A
Heiman GA, 681
Heinonen E, 946
Heiss W-D, 489A, 490A, 501A, 525A
Helms B, 801
Hempel JD, 319A
Henkes H, 527A
Hentati A, 541A
Hentges F, 463
Herbrink P, 181
Herholz K, 489A, 490A, 501A, 525A
Herkert M, 539A
Herndier B, 493A
Herndon R, 516A, 550A, 553A
Herrera DG, 300A
Hetherington HP, 236
Heurter H, 310A
Hickey C, 506A
Hickey P, 818
Hilger C, 463
Hill A, 321A
Hill K, 520A
Hill MW, 286A
Hills DF, 299A, 323A, 324A
Hinshaw DB Jr, 293A, 314A, 316A
Hirai S, 912
Hirano M, 172, 530A, 537A, 796
Hirasawa M, 296A
Hirsch EC, 922
Ho TW, 521A, 635
Hoang KBN, 297A
Hobbs GR, 295A
Hodder J, 538A
Hoffman EA, 505A, 525A
Hoffman EP, 782
Hofstetter CR, 207
Hogan N, 522A
Holland K, 337A
Holme E, 707
Holshouser BA, 293A, 314A, 316A
Hölzer T, 490A
Homer D, 497A
Hoogendijk JE, 672
Hooijkaas H, 181
Hopman A, 492A
Hopper JL, 227
Hornig G, 303A
Horsfield MA, 901
Hott J, 539A
Houff S, 714
Howell RA, 227
Hsieh S-T, 635
Hsu CY, 314A
Hu Y, 314A
Huber I, 318A
Hugg JW, 236
Hughes RAC, 508A, 551A
Hugon J, 548A
Hulsizer SC, 739
Hund E, 539A
Hung W-Y, 541A
Hunneman DH, 254
Hurley CK, 521A
Hutchinson J, 530A
Hutchinson M, 530A
Hutchison W, 538A
Hutton M, 149
Hyland K, 319A
Hyman BT, 55, 135, 689

Iannaccone S, 544A
Iannetti P, 299A, 312A
Ichord RN, 307A
Ikeda K, 251, 941
Ikeda M, 912
Illarioshkin SN, 75
Ilmberger J, 489A
Imafuku I, 549A
Imai T, 537A, 796
Inagaki M, 316A
Incorpora G, 327A, 336A
Ing D, 918
Inglese M, 521A
Ioannou P, 548A
Ionasescu V, 545A
Iordanidou E, 521A
Iqbal Z, 541A
Ironside JW, 523A
Isaacson SH, 502A
Ishii K, 714
Isozumi K, 541A
Israel JJ, 287A
Ito H, 796
Itoh Y, 243, 500A, 547A
Itoyama Y, 912
Ivanova-Smolenskaya IA, 75
I.W. Killam Hospital for Children-Halifax, 300A
Iwai A, 207
Iwatsubo T, 149
Izumo S, 84

Jabbari B, 331A
Jack CR Jr, 503A
Jackson CE, 545A, 581
Jackson S, 597
Jacobs BC, 181
Jacobs DM, 502A
Jacobs L, 516A, 550A, 553A, 952
Jacobson MA, 330A
Jacobson S, 494A, 714
Jaeckle KA, 492A
Jakacki R, 292A, 293A
Jamieson F, 310A
Jan MMS, 337A
Jani A, 294A, 545A
Jankovic J, 534A, 535A
Jansen PW, 330A
Javoy-Agid F, 922
Jayakar P, 31, 91, 286A, 300A, 302A, 311A
Jaynes M, 309A
Jenkins RB, 509A
Jensen MA, 520A, 522A
Jewett DM, 885
Jiang H, 545A
Jimi T, 511A
Johns DR, 532A
The Johns Hopkins Medical Institutions, 300A
Johnsen SD, 328A
Johnson CJ, 497A
Johnson-Greene D, 163
Johnson MI, 286A
Johnson PC, 328A
Johnston KA, 334A
Johnston KC, 497A
Johnston P, 492A
Johnston S, 489A
Jonas R, 818
Jones-Gotman M, 446
Jones HR Jr, 542A
Jones RM, 334A
Jonkers GJPM, 928
Jope RS, 287A
Jørgensen HS, 130
Joseph A, 338A
Junck L, 163, 820, 885

Kachelhofer RD, 129
Kaczmarski W, 330A
Kaga M, 316A
Kalasinsky K, 428
Kalina P, 297A
Kamholz J, 545A
Kaminski HJ, 547A
Kamo I, 296A
Kanai T, 569
Kanawawa I, 551A
Kanazawa I, 549A, 776
Kaneoke Y, 355
Kang H, 301A
Kapell D, 799
Kaplan J, 541A
Karbe H, 525A
Karjalainen-Lindsberg M-L, 587
Karpati G, 294A
Kasischke K, 548A
Kassell NF, 526A
Kassis ES, 291A
Kaste M, 587
Katayama S, 776
Kato M, 941
Katrina-Craig U, 530A
Katsetos CD, 309A, 310A
Katz D, 714
Katz JS, 581
Katz N, 337A
Katz P, 108
Katzan I, 554A
Katzman R, 207, 500A
Kaufman DM, 327A
Kaufman M, 505A
Kaufmann P, 172, 537A, 561
Kaufmann WE, 287A
Kautzman MG, 287A
Kawamura J, 537A

Kawano Y, 569
Keane JR, 480
Keats B, 542A
Keipes M, 463
Keir G, 128
Kelley K, 305A
Kelly B, 502A
Kenney KL, 502A
Kenworthy LE, 332A
Kerlero-de-Rosbo N, 551A
Kessler J, 501A
Kessler JA, 499A, 540A, 546A
Khilkevich O, 512A
Khoxayo S, 291A
Khuaja GA, 543A
Kida E, 330A
Kieburtz K, 506A, 947
Kieseier BC, 826
Kiesilä P, 157
Kilbourn MR, 873, 885
Killen P, 510A
Killian J, 530A
Kim B, 510A
Kimura J, 508A
King MP, 172
King WM, 533A
Kinkel RP, 519A
Kira J-i, 569
Kiriakopoulos E, 387
Kish SJ, 199, 428
Kishore A, 537A
Kissel JT, 545A
Kittner B, 501A
Kittner SJ, 497A
Klaassen AAG, 266
Klein DM, 509A
Klein KB, 506A
Kline J, 323A
Klinkosz B, 540A
Kliot M, 936
Klucznik R, 337A
Klug JM, 304A
Kluin KJ, 163, 820
Knight JM, 689
Kobayashi T, 569
Koennecke HC, 528A
Koepp MJ, 188
Koeppe RA, 163, 399, 820, 873, 885
Koeppen AH, 199
Koga Y, 172
Koh S, 334A
Kohler W, 675
Kohlschütter A, 294A
Kohout F, 55
Koizumi H, 547A
Kojima H, 511A
Kokmen E, 503A
Koller WC, 266, 269, 533A
Kollros PR, 301A, 303A
Kolodgie M, 305A
Kolodny EH, 300A
Kolodny L, 520A
Kolski HK, 310A
Kompoliti K, 534A
Kondo I, 505A
Kongelbeck SR, 306A
Konno S, 507A
Koo B, 303A, 308A, 328A
Koopmans RA, 555A
Korczyn AD, 268, 512A, 517A, 546A
Korenke GC, 254
Kormanik P, 490A
Korones DN, 331A
Koroshetz W, 497A
Koski CL, 543A
Kosofsky BE, 315A
Kotagal P, 306A
Kothare SV, 295A, 338A
Kottamasu S, 303A, 333A
Kraig RP, 496A, 529A, 547A, 548A
Kramer DJ, 509A, 645
Kramer PL, 681
Krasemann E, 254
Krauss JK, 534A, 535A
Krebs HI, 522A
Krendel DA, 539A, 948
Krishnamoorthy KS, 338A
Krishnan K, 324A
Krivit W, 290A
Kroes ACM, 928
Krupp LB, 494A
Kruse B, 675
Ku N, 489A
Kue I, 547A
Kugler SL, 303A
Kuhl DE, 399, 873
Kühne D, 527A
Kuljis RO, 503A
Kumar R, 504A
Kun L, 291A
Kuncl RW, 513A, 949
Kunkler PE, 496A, 529A
Kupski W, 330A
Kupsky WJ, 492A
Kurczynski E, 292A
Kurdunowicz B, 304A, 317A
Kurita D, 493A, 547A
Kurland LT, 530A
Kusner LL, 547A
Kusunoki S, 551A
Kutai M, 322A
Küther G, 456
Kuwano A, 505A
Kuzniecky RI, 236, 307A
Kwak S, 311A
Kwan AL, 526A
Kwan ES, 497A, 499A
Kwen PL, 504A
Kwiatkowski T, 526A

Labar D, 550A
Lach A, 298A, 330A
Lachance DH, 542A
Lacomis D, 509A, 645
Laffel GL, 306A
Lagenaur C, 319A
Lahad A, 932
Lahat E, 336A
Lai EC, 534A, 535A
Lake BD, 25
Lammens M, 731
Lampe TH, 932
Landeau B, 501A
Landis DMD, 499A
Lang AE, 538A, 893
Lange DJ, 544A
Langston JW, 841
Lantos PL, 149
Larrue V, 499A
La Sala S, 767
Lascola CD, 496A, 529A, 548A
Lassmann H, 522A
Laterra J, 492A
Latimer ME, 296A, 331A
Latorraca S, 503A, 678
Latov N, 510A, 544A
Layzer RB, 823
Lazar L, 301A
Lazzarini AM, 767
Le W-D, 530A
Leahy D, 805
Leake BD, 552A
Lee A, 801
Lee BCP, 337A
Lee JH, 799
Lee KS, 526A
Lee LC, 885
Lefton D, 309A
Legido A, 309A, 310A
Lehky TJ, 714
Lehmann P, 618
Lehto T, 587
Leifert R, 536A
Leigh RJ, 465, 951
Leitner Y, 322A
Lekieffre J, 315A
Lenders MH, 492A
Lennihan L, 529A
Lennon F, 801
Lennon VA, 739
Lennox GG, 820
Leonard JV, 25
Leppert D, 846
Leppert M, 520A
Leuzzi V, 299A
Leventhal P, 509A, 510A
Levey AI, 428
Levin B, 31
Levin MC, 494A
Levine SR, 8
Levrero F, 521A
Levy-Lahad E, 829, 932
Levy M, 306A
LeWitt PA, 502A
Li CY, 521A, 635
Li DKB, 555A, 951
Li J-Y, 528A
Li S, 552A
Li W, 514A
Libenson MH, 308A
Libman RB, 526A
Lieberman D, 322A
Liedtke W, 515A
Light M, 318A
Limperopoulos C, 289A
Lin A, 312A
Lin G, 540A
Lin H-C, 552A
Lin I-F, 529A
Lin X, 514A
Lindsberg PJ, 587
Lippa CF, 501A
Lira SA, 554A
Lischner HW, 309A, 310A
Litt R, 311A
Little R, 820, 885
Litwak M, 517A
Liu Y, 528A
Livet MO, 39
Lochmuller H, 294A
Lockman L, 290A
Lockwood S, 332A
Loegering MB, 286A
Loes D, 290A
Lohman M, 163, 885
Lohman ME, 820
Lomartire M, 490A
Longenecker AM, 295A
Lönnecker S, 367
Lopes-Cendes I, 199
Losseff NA, 531A
Löttgen J, 490A
Lotz BP, 329A
Louie J, 298A
Louis ED, 535A, 537A, 544A, 561
Love LA, 516A
Lovelace RE, 535A, 544A
Lovich S, 323A
Low PA, 517A
Lowenthal A, 526A
Lozano A, 538A
Lu D, 297A
Lublin F, 469
Lucchinetti CF, 522A
Luciano D, 724
Ludolph AC, 456, 548A
Luft BJ, 494A
Luh GY, 316A
Lupton BA, 321A
Luzi P, 116
Lynch DR, 532A
Lynch S, 520A
Lynch T, 535A, 537A, 561, 945
Lynn P, 530A
Lyons K, 533A

Ma W, 528A
Maas JJ, 928
Mabie PC, 546A
MacCollin M, 288A, 440
MacGregor D, 310A
Macias C, 542A
Maciel P, 199
Mackey A, 529A
Macko RF, 497A
MacLean D, 541A
MacLennan C, 513A
Magee JF, 321A
Magnus-Miller L, 287A

Mahalingam R, 453
Maiese K, 547A
Majnemer A, 289A
Mäki-Ikola O, 946
Mallia RS, 501A
Mallory M, 759
Malzac P, 39
Mancardi GL, 521A
Mancias P, 782
Mandelbaum DE, 303A
Mangner T, 296A
Mani A, 336A
Mann DMA, 149
Mannheim G, 337A
Manning PT, 520A
Manor O, 338A
Maraganore DM, 534A, 681
Marchal G, 216, 498A
Marcon G, 503A
Maria BL, 297A
Marié RM, 525A, 536A
Markova ED, 75
Marks H, 782
Markusic DM, 318A
Marmur R, 546A
Marsden CD, 534A
Marson D, 500A
Martin WRW, 512A, 538A
Martin-Moutot N, 695
Martorello S, 163, 885
Maruff P, 421
Maruyama W, 119
Mash DC, 523A
Masini T, 922
Masliah E, 207, 759
Mass M, 518A
Massaquoi S, 532A
Mast H, 528A
Mastaglia FL, 264, 826
Masters CL, 265
Matsuda H, 541A
Matsumoto M, 528A
Matsumoto S, 796
Matsumura R, 530A
Matsushita M, 243, 500A
Matsushita S, 569
Matsuura T, 531A
Matthews P, 327A
Matthijs G, 731
Mattson D, 515A
Mattson RH, 506A, 908
May EF, 821
Mayer SA, 529A
Mayeux R, 502A, 799
Mayk A, 495A
Maytal J, 312A
McAllister RMR, 523A
McAvoy K, 326A
McCarter RJ, 497A
McCarthy M, 488A
McCombe PA, 552A
McConnell JR, 338A
McCormick ME, 330A
McDermott M, 506A
McDonald JW, 750
Mcdonald SB, 533A
McDonald WI, 531A
McDonald WM, 355
McFarland HF, 108, 514A, 553A, 714
McFerrin J, 264
McGrath M, 493A
McGuire D, 493A
McGuire P, 290A
McIntosh A, 227
McKhann GM, 498A, 521A, 635
McNeil RS, 289A
McRae BL, 519A
McShane MA, 302A, 320A
Mehler MF, 546A
Meijerink PHS, 672
Meiner Z, 518A
Melani E, 521A
Melberg A, 707
Mellman TA, 536A
Mendel I, 551A
Mendell JR, 512A, 545A
Mendoza G, 490A
Menichella D, 545A
Meola G, 544A
Meri S, 587
Meriney SD, 739
Metz H, 463
Meulstee J, 511A
Mewes K, 488A
Meyer B, 456
Meyer G, 515A
Meyer JS, 507A
Meyer T, 456
Middleton LT, 548A
Mielke R, 501A
Mikulis D, 387
Milazzo MC, 309A
Millar W, 318A
Miller A, 469
Miller DH, 531A
Miller FW, 516A
Miller L, 504A
Miller M, 315A
Miller R, 513A
Miller RG, 514A
Miller S, 328A
Miller SW, 663
Miller VS, 319A
Milo R, 551A
Mink JW, 317A
Minoshima S, 399
Minshew NM, 333A
Mirabella M, 264, 864
Mirakhur M, 25
Misko TP, 520A
Mitchell A, 227
Mitchell GW, 3
Mitchell JD, 689
Mitchell WG, 285A
Mitsias P, 8
Mitsumoto H, 540A
Mittleman RE, 523A
Miyasaki J, 538A
Mizuguchi M, 288A, 296A, 941
Mobley WC, 346, 548A
Mohr JP, 528A
Mokri B, 506A
Molho ES, 534A
Molloy PT, 313A, 325A
Moncla A, 39
Monken C, 714
Monos DS, 521A
Montefiore Medical Center-NY, 300A
Moore GJ, 299A, 313A, 336A
Moorjani B, 324A
Moraes CT, 542A
Morawetz RB, 236
Moritoyo H, 84
Moritoyo T, 84
Moriwaka F, 531A
Morris AAM, 25, 459
Morrison G, 286A
Morrison K, 318A
Morse RP, 313A, 336A
Mortel KF, 507A
Moscarello MA, 18
Moser HW, 675
Moshe SL, 301A, 307A
Mosier DR, 532A
Moslemi A-R, 707
Mosley PD, 313A
Mott SH, 325A, 332A
Motte J, 290A
Motti EDF, 922
Moulin T, 528A
Mountz JM, 307A
Mouradian MM, 549A
MS Collaborative Research Group, 516A, 550A, 553A, 952
Mu X, 379
Muenter MD, 537A
Mufson EJ, 523A
Mullan M, 500A
Mullett M, 295A
Murahashi M, 511A
Murakami T, 505A
Murata K, 530A
Murayama S, 776
Muriello MA, 337A
Murphy CC, 301A
Murphy J, 303A
Murphy P, 544A
Murray PD, 517A
Muzik O, 296A
Myers LW, 552A

Nachamkin I, 521A
Nachman S, 309A
Nacmias B, 503A, 678
Nadell JM, 315A
Nadiv O, 551A
Nagamatsu M, 509A
Nagano I, 542A
Nagle J, 128
Nahser HC, 527A
Naidu S, 675
Nakamura S, 776
Nakano M, 528A
Nakano S, 508A
Nakayama H, 130
Nam MJ, 492A
Namba Y, 251
Nance M, 199
Naoi M, 119
Naqvi SZ, 302A
Narayanan V, 319A, 684
Nasirian F, 295A
Naviaux RK, 293A, 295A
Nedergaard M, 550A
Nee L, 912
Needle M, 292A, 313A, 325A
Nelson MD, 334A
Nemens E, 932
Neumeyer A, 338A
Nevala W, 514A
Newburger J, 818
Newland C, 487A
Newsom-Davis J, 487A, 513A, 554A
Newstein D, 301A
NGF Study Group, 540A
Nguyen D, 315A
Nguyen K, 299A
Nguyen V, 555A
Nichols S, 55
Nicholson HS, 292A
Nicoli F, 524A
Nigro MA, 294A, 299A, 303A, 304A, 305A, 308A, 317A, 330A, 336A
Nikolskaya NN, 75
Nishimura Y, 569
Nishiyama K, 776
Nisipeanu P, 268, 517A
Nizam MF, 307A, 327A
Niznik HB, 428
Nochlin D, 149
Noetzel MJ, 321A, 337A
Nomura Y, 776
Nork M, 298A
Noronha A, 519A
Novotny EJ, 285A
Nuovo GJ, 510A
Nygaard TG, 681
Nyhan WL, 293A, 295A
Nyormoi O, 701
Nystrom GA, 293A, 314A

Oakes D, 947
Oberlander D, 497A
O'Brien PC, 503A
O'Connors P, 18
Oda N, 912
Odel J, 535A, 537A, 561
O'Dell C, 301A, 307A
Oexle K, 294A
O'Fallon WM, 529A
Offner H, 518A
Oger J, 540A
Oh SJ, 544A
O'Hagan D, 294A
Öhman J, 587
Ohno K, 810
Ohnuki Y, 523A

Ojemann R, 440
Okada S, 516A
Okazawa H, 549A
Oksenberg JR, 557, 846
Okuizumi K, 251
Olanow CW, 266, 269, 341, 841
Oldfors A, 707
Oleszak EL, 310A
Olichney J, 500A
Olinski S, 319A
Olivier A, 446
Oliviero A, 628
Olsen TS, 130
Olson JM, 293A
Oniki H, 511A
Ono S, 530A
Onodera O, 251
O'Reilly K, 550A
Orlov E, 535A
Orr D, 534A, 535A
Ortenzi L, 678
Osame M, 84
Ostrow P, 504A
Otero C, 792
Otomo E, 243
Otsubo H, 310A
Otterud B, 520A
Ottonello C, 521A
Overby AS, 534A, 535A
Oxbury J, 320A
Ozawa H, 316A
Ozcelik T, 548A
Ozdemir C, 548A
Ozo CO, 925

Pachner AR, 521A
Pacia SV, 724
Packer RJ, 291A, 292A, 293A, 325A, 332A, 337A
Paetau A, 587
Pahwa R, 533A
Palumbo DR, 331A, 506A
Pamarthi L, 533A
Paolini JL, 302A
Papa SM, 535A
Papaioakim M, 521A
Pappas MM, 286A
Pappert EJ, 258, 534A
Pappo M, 307A
Parano E, 247, 315A, 326A, 327A, 336A
Parisi J, 522A
Park TS, 321A
Parker WD Jr, 663
The Parkinson Study Group, 99
Parks JK, 663
Parodi RC, 521A
Parrish B, 298A
Parrish JA, 500A
Parry DM, 288A, 440
Pascual-Leone A, 525A
Paty DW, 555A, 951
Paulus W, 367
Pavkovic I, 333A
Pavlakis SG, 297A
Pavone L, 247, 312A, 336A
Pavone P, 326A
Pearce WJ, 317A
Pease LR, 517A
Pedersen PM, 130
Pegoraro E, 782
Pelfrey CM, 553A
Pellock JM, 287A
Penchaszadeh GK, 293A
Pender MP, 552A
Pendlebury WW, 502A
Penney JB, 947
Penovich P, 287A
Peppler R, 553A, 618
Perbellini L, 922
Percy AK, 297A
Pereira JK, 299A
Peretti F, 428
Pericak-Vance MA, 207, 251, 541A, 801
Perkin RM, 314A, 330A
Perlman J, 295A, 321A
Peroutka SJ, 821
Perrine K, 724
Pessin MS, 497A, 498A, 499A
Peter JB, 552A
Petersen RC, 503A, 530A
Peterson A, 513A
Petit-Taboué MC, 501A, 536A
Petito C, 112
Petkau J, 469
Petrella J, 505A
Petric M, 310A
Petroff OAC, 506A, 908
Petruzzi C, 678
Pettorini JM, 338A
Petty GW, 529A
Pezzoli G, 922
Phelix CF, 532A
Phillips JP, 328A
Phillips P, 292A, 293A
Phillips PC, 313A, 325A
Phuphanich S, 489A, 490A
Piacentini S, 503A, 678
Piccini P, 49
Piccoli DA, 542A
Piepgras DG, 506A
Pillet S, 321A
Pincus DW, 550A
Pioro EP, 540A
Pisani P, 520A
Pivetti-Pezzi P, 299A
Planeta CS, 315A
Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group, 551A
Platika D, 489A
Plevak DJ, 505A
Poda M, 548A
Podolnick P, 287A
Podratz JL, 491A
Poeppel D, 137
Polizzi A, 312A
Pollanen MS, 893
Polymenis M, 334A
Pomeroy SL, 291A
Pon R, 555A
Poorkaj P, 149, 912, 932
Poplawski T, 302A
Porfirio C, 323A
Porter SD, 540A
Posewitz AE, 507A, 537A
Posner E, 322A
Posner JB, 491A, 494A
Pouget J, 695
Poulin C, 327A
Poulin N, 446
Powers WJ, 526A
Prats A, 91, 286A
Preston T, 306A, 309A
Price TR, 497A
Prihar G, 149
Prockop L, 489A
Pryor A, 302A
Przedborski S, 534A, 690
Ptacek L, 487A, 544A
Ptak T, 295A
Pulaski-Salo D, 501A
Pulliam L, 493A
Pullicino P, 504A

Quarles RH, 792
Quigley L, 514A
Quinn N, 945, 951
Quisling RG, 297A

Raaschou HO, 130
Rabey JM, 535A, 551A
Rabinovich H, 301A, 303A
Raffel C, 306A
Rafi MA, 116
Raikow RB, 782
Raine CS, 515A, 555A
Rajanayagum V, 290A
Rajput AH, 950
Ramsby GR, 325A
Ranga K, 324A
Ransohoff RM, 516A, 553A, 554A, 618
RANTTAS Investigators, 497A
Rao S, 469
Rapoport SI, 411
Rask C, 540A
Raucci U, 299A, 312A
Ravdin L, 724
Raymond C, 695
Raymond D, 681
Reale M, 323A
Reaman G, 292A
Reddy PA, 286A
Rees JH, 508A
Reeves P, 305A
Reid E, 531A
Reilly D, 309A
Reingold S, 469
Reinhart TA, 84
Reiss AL, 325A
Relin M, 502A
Relman DA, 535A
Remler BF, 465
Remtulla H, 511A
Rendell M, 540A
Renfroe JB, 91
Resnick T, 31, 91, 286A, 302A
Reulen H-J, 489A
Rhine W, 322A
Richard S, 543A
Richards KC, 336A
Richardson MP, 188
Richardson S, 310A
Richert JR, 108, 516A, 521A, 550A, 553A
Riepe MW, 548A
Riley DE, 534A
Rimmler JB, 207
Rioux P, 525A, 536A
Risch NJ, 681
Risser R, 295A, 321A
Rivera-Quinones C, 517A
Rivkin MJ, 292A
Roach ES, 334A
Roberts J, 292A
Roberts-Warrior D, 534A, 535A
Robertson N, 239
Robertson PL, 290A, 333A
Robinson ED, 108, 521A
Robitaille Y, 199
Roche K, 322A
Rodriguez E, 321A
Rodriguez M, 514A, 517A, 522A
Rogaeva EA, 912
Rogers LR, 492A
Rohlicek C, 289A
Roland EH, 321A
Romeo E, 315A, 323A
Roos RP, 805
Ropper AH, 539A
Rorke LB, 290A
Rose JW, 520A
Rosen EM, 492A
Rosenbaum DM, 499A
Rosenberg DP, 555A
Rosenberg NL, 494A, 517A
Rosenblatt B, 289A
Rosenblum MK, 491A
Rosenfeld M, 494A
Roses AD, 207, 251, 264, 801
Rosi BL, 207
Rosman NP, 302A, 337A
Ross ME, 289A, 290A
Rosselli M, 503A
Rossor MN, 149
Rothermel R, 317A
Rothman DL, 285A, 506A, 908
Rothman SM, 286A, 337A
Rothner AD, 324A
Rothstein JD, 540A, 542A
Rothwell JC, 628
Rotterdam H, 535A

Rouleau GA, 199
Rovaris M, 901
Rowland LP, 544A
Rowley HA, 137, 824
Rubin M, 325A
Rudick RA, 469, 516A, 550A, 553A, 554A, 618
Rueger D, 286A
Ruff RL, 507A, 508A, 509A
Ruggieri M, 302A, 312A
Rumbach L, 528A
Russell J, 510A
Russell JA, 542A
Russell MJ, 532A
Rust RS, 317A, 329A
Rustigi A, 334A
Ruttledge M, 440

Sabbagh MN, 500A, 530A
Sabina RL, 328A
Sacco RL, 528A, 529A
Sachdeo RC, 287A, 303A
Sadek AH, 325A
Sadlier L, 320A
Sahenk Z, 512A, 545A
Sahgal A, 525A
Said SM, 324A
Saitoh T, 207
Sakuragawa N, 296A
Salazar A, 516A, 550A, 553A
Salih MAM, 925
Salmelin R, 157
Salmon D, 500A
Salonen O, 157
Salvan A-M, 524A
Sanchez-Ramos J, 523A
Sandbrink R, 265
Sanders VJ, 505A
Sanges G, 767
Sangiorgi S, 299A
Sano M, 502A
Sansaricq C, 318A
Sansone V, 544A
Sardanelli F, 521A
Sartucci F, 39
Sasaki H, 531A
Sato E, 84
Sato S, 805
Satoh S, 500A
Saunders AM, 251, 264
Saver JL, 497A
Scaravilli F, 611
Scarlato G, 922
Schaefer GB, 312A, 338A
Schaefer J, 597
Schaefer PW, 295A, 338A
Schaefer S, 521A
Schaeffer S, 265
Schaid DJ, 509A
Schallert G, 303A
Schapira A, 487A
Scheffer I, 290A
Scheithauer BW, 522A
Schellenberg GD, 912, 932
Schenone A, 518A
Scher MS, 320A
Scheuer B, 500A
Schiff S, 305A
Schifitto G, 506A
Schlaug G, 527A
Schmelzer JD, 517A
Schmidt EV, 334A
Schmitz PIM, 181, 511A
Schochet SS, 309A
Schollen E, 731
Schon EA, 172
Schor NF, 290A, 291A
Schraufnagel CD, 331A
Schupf N, 799
Schut L, 199
Schwartz K, 534A
Schwartz M, 495A
Schwartzman RJ, 822
Sclabassi RJ, 320A
Scott JN, 514A
Scott W, 544A
Scottish Rite Children's Hospital-Atlanta, 300A
Seagar M, 695
Seal ECJ, 534A
Segal RA, 291A
Seibert CE, 494A
Seki K, 251
Sekul EA, 792
Selcen D, 336A, 549A
Selman WR, 499A
Sequeiros J, 199
Serdaroglu P, 548A
Serratosa JM, 39
Service E, 157
Sevush S, 501A
Shafrir Y, 296A
Shah NS, 308A, 322A
Shahar E, 336A
Shahrokh S, 496A
Shaibani A, 543A
Shalev RS, 338A
Shannak K, 428
Shanske S, 172
Shapiro E, 290A
Sharma K, 514A
Sharma V, 912, 932
Shavelle R, 296A
Shaw IC, 689
Shaw PJ, 525A
Sheehan JP, 663
Sheffield E, 334A
Sheffield LJ, 227
Sheikh K, 635
Shelton D, 295A
Shen C, 322A
Sheremata WA, 520A
Sherman WH, 544A
Sherrington R, 912
Sheth RD, 295A
Shevell M, 289A, 327A, 328A
Shibuya S, 511A
Shimizu J, 551A
Shinnar S, 301A, 307A
Shinohara Y, 493A, 523A, 541A, 547A
Shiria T, 507A
Shoji M, 912
Short MP, 311A
Shoubridge EA, 693
Shoulson I, x44
Shu S, 293A, 316A
Shulman LM, 536A
Shungu D, 318A
Shy ME, 545A
Sicsic C, 518A
Siddique T, 541A
Siegel DJ, 333A
Siewert B, 527A
Siklós L, 532A
Silani V, 922
Silveira I, 199
Silver K, 327A, 328A
Silverstein FS, 292A
Sima AAF, 820, 945
Simi P, 39
Simon JH, 516A, 550A, 553A, 952
Simpson T, 387
Sims KB, 338A
Sine SM, 810
Singer C, 536A
Sirikonda P, 322A
Sitte W, 456
Sivak M, 327A
Sivakumar K, 128
Sivenius J, 526A
Sklower-Brooks S, 298A, 330A
Sladky JT, 326A
Sloan MA, 497A
Slovis TL, 313A
Small SL, 575
Smialek J, 428
Smietana S, 333A
Smith AJ, 327A
Smith D, 533A
Smith K, 504A
Smith RE, 312A
Smith RG, 530A
Smith TW, 501A
SmithKline Beecham Alzheimer's Disease Study Group, 504A
Snead OC III, 306A
Snodgrass R, 489A
Snodgrass S, 112
Snow BJ, 537A
Snyderman SE, 318A
Solenski NJ, 526A
Solomon PR, 502A
Song Q, 546A
Sorbi S, 503A, 678
Sormani MP, 521A
Soueidan S, 792
Spalice A, 299A, 312A
Sparaganna S, 334A
Speedie LJ, 675
Speer A, 294A, 456
Speiser Z, 495A
Spencer SS, 123
Spiegelman R, 535A
Springer JE, 379
Sproul KA, 291A
Spuler S, 511A
Squier M, 320A
Srivastava AK, 289A
Staats PS, 512A
Stack CV, 304A
Stahl JS, 465
Stajich JM, 801
Staley JK, 523A
Stanley C, 319A
Stanley P, 290A
Stebbins GT, 534A
Steddin S, 918
Steers JL, 505A
Stefanatos G, 301A, 303A
Stein DP, 792
Steinhoff BJ, 367
Steinitz M, 518A
Stephure D, 318A
Steppe DA, 320A
Stern BJ, 497A
Stern Y, 502A
Stevens KR, 290A
Stevens M, 510A
Stevenson DK, 322A
Stewart C, 387
Stewart DB, 332A
St George-Hyslop PH, 500A, 912
Stiles CD, 291A
Stillman A, 290A
Stokes A, 333A
Stoll J, 411
Strada O, 922
Strauss D, 296A
Straussberg R, 298A
Streletz LJ, 303A, 319A
Sturtz F, 489A
Stüve O, 853
Suarez JI, 499A
Subramony SH, 533A, 542A
Suematsu N, 243
Suisse G, 39
Sullivan TD, 332A
Sum JM, 311A, 322A
Sumi SM, 149, 912
Sun H, 513A, 514A
Sun M, 320A
Sunada Y, 925
Sundsmo M, 207
Sung G, 496A
Sutton MA, 291A
Swann JW, 288A, 289A
Swanson P, 805
Swanson RA, 822
Swartz BE, 505A
Swerdlow RH, 663
Swerdlow SH, 782
Syndulko K, 469, 552A
Sztriha L, 298A

Tadmor R, 546A
Tagawa Y, 519A, 554A
Takai E, 323A
Takashima S, 941

Takayanagi T, 530A
Tamaru Y, 537A, 796
Tan CC, 545A
Tanaka H, 75, 251
Tang M-X, 502A
Tani M, 554A
Tapscott SJ, 936
Tarr R, 499A
Tashiro K, 531A
Tasker R, 538A
Tatke M, 543A
Tatu L, 528A
Tauber Z, 336A
Tavaré CJ, 335A
Tawil R, 544A
Taylor CNR, 304A
Taylor CV, 287A
Taylor FL, 309A
Taylor RW, 459
Tchervenkov C, 289A
Tedde A, 503A, 678
Teitelbaum D, 518A
TenBroeke M, 547A
Terenghi G, 523A
Thach WT, 317A
Thal LJ, 207, 500A
Thangavel R, 296A
Theodore WH, 305A, 505A, 525A
Thiel A, 489A, 490A
Thomas CE, 529A
Thomas P, 39
Thomas PRM, 291A
Thomas RG, 207
Thompson A, 469
Thompson AJ, 531A
Thompson EJ, 128
Thompson JLP, 528A
Thompson RD, 508A
Tilton AH, 315A
Tilton C, 303A
Timmis J, 304A
Tio-Gillen AP, 181
Tiomni E, 512A
TOAST Investigators, 526A
Tobimatsu S, 569
Tohgi H, 119
Tokimura H, 628
Tokimura Y, 628
Tokunaga M, 505A
Tomasi LG, 314A, 316A
Tomer A, 322A
Tomiyasu H, 523A
Tone B, 317A
Toni D, 499A
Tonsgard JH, 311A
Torres CF, 331A
Torres OA, 319A
Tourtellotte WW, 505A, 552A
Trabucchi M, 688
Tranquill LR, 553A
Trapp BD, 554A
Trauner DA, 318A
Travère JM, 536A
Trescher WH, 288A
Trevathan E, 301A
Trifiletti RR, 247, 299A, 300A, 301A, 315A, 323A, 324A, 326A, 327A, 336A
Trimmer PA, 663
Trocio SH Jr, 528A
Trojaborg W, 544A
Trojanowski JQ, 379
Truskowski LL, 497A
Tsai LH, 292A
Tsuda T, 912
Tsuji S, 75, 251
Tuchman R, 300A, 311A
Tuohy VK, 519A
Tupler LA, 324A
Turnbull DM, 25, 459, 597
Turner RS, 355
Tuttle JB, 663
Twijnstra A, 492A
Tycko B, 799
Tyler P, 421

UBC MS/MRI Research Group, 555A
Uccelli A, 521A
Uchino M, 505A
Ueda H, 528A
Ueno S, 530A, 537A, 796
Uhm JH, 853
Uitti RJ, 681
Ulatowski JA, 512A
University of Texas Medical School, 300A
Uutela K, 157
Uyama E, 505A

Vadasz E, 331A
Valentine C, 304A
Valletta JS, 548A
Vanasse M, 327A
Vance JM, 801
Van Cott AC, 509A, 645
Vandenbark A, 518A
Vander Borght TM, 873, 885
VanderBrug Medendorp S, 553A, 618
van der Linden C, 538A
van der Meché FGA, 181, 511A
Vandewalle V, 538A
van Doorn PA, 181, 511A
van Hilten JJ, 266
Van Hole C, 731
van Oostenbrugge RJ, 492A
van Seventer GA, 519A
Vasconcelos O, 532A
Vaughan SN, 313A, 325A
Vazquez B, 724
Vechio JD, 603
Veldman H, 672
Ventimiglia J, 305A
Verma A, 112, 542A
Vermeulen SS, 507A, 537A
Vezina LG, 305A, 325A, 337A
Viader F, 216
Vieira L, 529A
Vieregge P, 463
Vigevano F, 305A
Villalobos R, 300A
Villemure JG, 446
Vincent A, 487A, 513A, 691
Vinik A, 540A
Vion-Dury J, 524A
Viskochil D, 440
Visser LH, 181, 511A
Vissing J, 541A, 655
Vissing S, 541A
Vitale KC, 286A
Vitek JL, 355, 488A
Volcjac J, 306A
Volkow ND, 267
Volpe BT, 522A
Volpe J, 818
Voltz R, 901
von Kummer R, 499A
von Stockhausen H-M, 489A

Wada Y, 500A
Waddell K, 489A
Wagner A, 332A
Wagner J, 299A
Wakayama Y, 511A
Wakisaka A, 531A
Wallace R, 55
Wallace S, 307A, 327A
Wallenberg J, 469
Walsh CA, 289A, 290A
Walsh GO, 505A
Walsh K, 322A
Wang C, 247
Wang CH, 293A
Wang P, 292A
Wang X, 325A
Warach S, 524A, 527A
Waring SC, 503A, 530A
Warnatz H, 515A
Warner TT, 681
Washington R, 516A
Wasserman G, 323A
Wassermann EM, 524A, 525A, 536A
Watanabe M, 776, 912
Waters C, 554A
Waubant E, 846
Webb S, 530A
Weber-Luxemburger G, 490A
Webster HdeF, 514A
Weeks RA, 49
Wei R-Q, 519A
Weig SG, 326A
Weimer LH, 544A
Weinberg WA, 331A
Weiner WJ, 523A, 536A
Weingart JD, 335A
Weinshenker B, 469
Weinstein S, 305A, 306A
Weinstein SL, 332A
Weinstock A, 324A
Weisgraber KH, 264, 864
Weiss IP, 332A
Weller A, 517A
Wellish MC, 453
Wende K, 553A
Weng W, 319A
Wenger DA, 116
Wenger E, 303A
Wertz RT, 129
Wettstein P, 514A
Weyer L, 893
Wharam MD, 335A
Whisnant JP, 529A
Whitaker JN, 3, 129, 297A
White CA, 552A
White JT, 338A
Whitham R, 518A
Whitt JK, 324A
Wiebers DO, 529A
Wieland DM, 399
Wiesner RH, 505A
Wijdicks EFM, 505A
Wilhelmsen KC, 541A
Wilichowski E, 254
Wilkins AS, 315A
Wilkinson S, 533A
Will RG, 523A
Willcox N, 513A
Williams G, 853
Williams JA, 335A
Williams LS, 497A
Willoughby E, 469
Wills PM, 507A
Wilson AD, 329A
Wilson J, 459
Wilson JM, 428
Windebank AJ, 491A, 518A, 531A
Windebank KA, 491A
Wirguin I, 518A
Wisniewsky KE, 298A, 330A
Wisoff J, 290A
Wissler KH, 331A
Wityk RJ, 497A
Wolfe GI, 581
Wolfson C, 529A
Wollack JB, 330A
Wollert H-G, 818
Wong BLY, 287A
Wong PC, 542A
Wood C, 488A
Wood DD, 18
Wood M, 387
Woodard JL, 355
Woodward CE, 25
Woolfenden AR, 540A
Wozniak MA, 497A
Wright R, 319A
Wuorimaa T, 587
Wyllie E, 306A

Xia J, 494A
Xia Y, 207
Xu J, 293A

Xu W, 545A
Xu Z, 603

Yachnis AT, 297A
Yafo A, 322A
Yahalom J, 491A
Yamada KA, 314A, 337A
Yamada M, 243, 500A
Yamamoto Y, 499A
Yamanouchi H, 941
Yamaoka LH, 207, 801
Yamasaki K, 569
Yan Q, 540A
Yanagihara T, 528A
Yanamoto H, 526A
Yao D-L, 514A
Yaylali I, 286A, 300A, 302A, 311A
Ye Z, 496A
Yeargin-Allsopp M, 301A
Yeh TL, 324A
Yellin P, 322A
Yoles E, 495A
Yong VW, 853
Yoshii F, 523A, 541A
Yoshiki T, 531A
Youle R, 539A
Young RF, 507A, 537A
Younger DS, 544A
Yousry T, 901
Yu M, 519A
Yuen EC, 346, 548A
Yuki N, 519A, 554A
Yum SW, 326A

Zackai E, 298A
Zaiwalla Z, 320A
Zecchinelli A, 922
Zeine R, 555A
Zelko FA, 332A
Zeltzer PM, 290A
Zhang B-J, 514A
Zhang D, 265
Zhao G, 555A
Zhong N, 298A, 330A
Zhou J, 548A
Ziemann U, 367
Zifko U, 511A
Zigman W, 799
Zimmerman C, 506A
Zimmerman RA, 298A
Zochodne D, 513A, 514A
Zorn I, 672
Zvas Z, 336A
Zwirner A, 294A

Subject Index

Abducens nerve
abducens palsy predicts pathology and outcome in brainstem gliomas (Fisher et al) 1996;40:335A
Abnormalities; *see also specific abnormalities*
congenital anomalies in children with perisylvian dysgenesis (Bingham et al) 1996;40:298A
Absence seizures; *see* **Epilepsy, absence**
Academics; *see* **Education**
Acetazolamide
acetazolamide challenge confirms vascular versus tension headaches (Meyer et al) 1996;40:507A
acetazolamide responsiveness in familial hemiplegic migraine (Athwal and Lennox) (Letter); (Elliott et al) (Reply) 1996;40:820
Acetylcholine receptors; *see* **Receptors, cholinergic**
Acidosis
does dichloroacetate minimize the neurotoxicity of chronic cerebral acidosis? (De Vivo et al) 1996;40:318A
severe acidosis is required for astrocytes to undergo clasmatodendrosis (Kraig et al) 1996;40:529A
Acquired immunodeficiency syndrome
HIV-1 DNA in brains in AIDS and pre-AIDS: correlation with the stage of disease (An et al) 1996;40:611
Actins
neuronal protection from excitotoxic injury by depolymerization of actin may also be due to a concomitant induction of reactive astrocytes (Kunkler et al) 1996;40:496A
Action potentials
action potential thresholds are elevated near the end-plate but not elsewhere in myasthenia gravis and passive transfer experimental myasthenia gravis (Ruff) 1996;40:507A
impact of changes in muscle fiber length on membrane excitability near and away from the end-plate (Ruff) 1996;40:509A
Adenosine
bivalent analogs of adenosine: generation of receptor subtype specificity (Wollack and Jacobson) 1996;40:330A
Adenosine receptors; *see* **Receptors, purinergic**
Adenoviruses
interferons are major determinants in efficacy of gene therapy in the neuromuscular system by adenoviral vectors (Acsadi et al) 1996;40:294A
remyelinating peripheral nerves of Po knockout mice with a Po expressing adenovirus (Shy et al) 1996;40:545A
Adie's syndrome
Adie-Holmes pupils, motor and sensory neuropathy, pyramidal tract involvement and autosomic dysfunction in a family (Haenggeli and De Vivo) 1996;40:329A
Adjuvant chemotherapy; *see* **Drug therapy**
Adrenalectomy
neuroprotective effects of adrenalectomy in the kainic acid model of limbic status epilepticus in adult rat (Dure et al) 1996;40:287A
Adrenoleukodystrophy
cerebral adrenoleukodystrophy (ALD) in only one of monozygotic twins with an identical ALD genotype (Korenke et al) 1996;40:254
predicting dementia in white matter disease: magnetic resonance imaging, magnetic resonance spectroscopy, and neuropsychology (Balthazor et al) 1996;40:290A
Adrenomyeloneuropathy
cognitive and brain magnetic resonance imaging findings in adrenomyeloneuropathy (Edwin et al) 1996;40:675
Age factors
maturation increases cerebral nitric oxide synthase activity in spontaneously hypertensive rats by decreasing the K_m for L-arginine (Ashwal et al) 1996;40:317A
wide range in age of onset for chromosome 1–related familial Alzheimer's disease (Bird et al) 1996;40:932
Aged
apolipoprotein E and cognitive change in an elderly population (Hyman et al) 1996;40:55
apolipoprotein E genotype in elderly nondemented subjects without senile changes in the brain (Yamada et al) 1996;40:243
Aging
effects of healthy aging on regional cerebral metabolic rates of glucose: assessment with positron emission tomography and statistical parametric mapping (Petit-Taboué et al) 1996;40:501A
in vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease (Kuhl et al) 1996;40:399
presynaptic monoaminergic vesicles in Parkinson's disease and normal aging (Frey et al) 1996;40:873
similar telomere lengths in normal and dystrophic muscle indicate that replicative aging is not the cause of progression in Duchenne muscular dystrophy (Oexle et al) 1996;40:294A
Agmatine
synthesis and metabolism of agmatine, a novel neuroprotectant, in the brain (Gilad and Gilad) 1996;40:550A
AIDS dementia complex
marked discordance of serial cerebrospinal fluid P24 antigen and brain viral burden in pure AIDS dementia (McGuire et al) 1996;40:493A
Alcohol, ethyl
specificity of ethanol in essential tremor (Rajput) (Letter); (Boecker and Brooks) (Reply) 1996;40:950
Alcoholism
positron emission tomographic studies of cerebral benzodiazepine-receptor binding in chronic alcoholics (Gilman et al) 1996;40:163
Alzheimer's disease, diagnosis
toward a "7-minute" screening battery sensitive to Alzheimer's disease (Solomon et al) 1996;40:502A
Alzheimer's disease, drug therapy
activation positron emission tomography demonstrates neurotrophic properties of propentofylline in Alzheimer's disease (Mielke et al) 1996;40:501A
efficacy and safety of SB 202026 as a symptomatic treatment for Alzheimer's disease (Kumar) 1996;40:504A
Alzheimer's disease, etiology
risk factors for Alzheimer's disease in women (Duara et al) 1996;40:500A

July issue, pp 1–134; August issue, pp 135–340; September issue, pp 341–556; October issue, pp 557–690; November issue, pp 691–824; December issue, pp 825–1008.

Copyright © 1996 by the American Neurological Association

Alzheimer's disease, genetics
Alzheimer's disease or Alzheimer's diseases? clues from molecular epidemiology (Hyman) 1996;40:135 (Editorial)
amyloid β protein (Aβ) deposition in chromosome 14–linked Alzheimer's disease: predominance of $A\beta_{42(43)}$ (Mann et al) 1996;40:149
apolipoprotein E and α_1-antichymotrypsin polymorphism in Alzheimer's disease (Nacmias et al) 1996;40:503A, 1996;40:678
apolipoprotein E and cognitive change in an elderly population (Hyman et al) 1996;40:55
clinical correlates of apolipoprotein E in Alzheimer's disease (Frisoni et al) (Letter); (Hyman et al) (Reply) 1996;40:688
clinical phenotype of two missense mutations in the presenilin I gene in Japanese patients (Ikeda et al) 1996;40:912
genetic factors in Alzheimer's disease: a review of recent advances (Levy-Lahad and Bird) 1996;40:829 (Neurological progress)
genetic studies in Alzheimer's disease with an NACP/α-synuclein polymorphism (Xia et al) 1996;40:207
lack of association of very low density lipoprotein receptor gene polymorphism with caucasian Alzheimer's disease (Okuizumi et al) 1996;40:251
missense mutations of the *PS-1/S182* gene in German early-onset Alzheimer's disease patients (Sandbrink et al) 1996;40:265 (Letter)
presenilin gene analysis in Italian families with early-onset Alzheimer's disease (Sorbi et al) 1996;40:503A
prion-containing Kuru-like plaques in familial Alzheimer-like disease with concomitant β/A4 amyloid–containing plaques and a single mutation in the presenilin 1 gene (Kuljis et al) 1996;40:503A
wide range in age of onset for chromosome 1–related familial Alzheimer's disease (Bird et al) 1996;40:932

Alzheimer's disease, pathology
Alzheimer's disease versus Lewy body disease: differences in perforant pathway pathology (Lippa et al) 1996;40:501A
Alzheimer's disease without neocortical tangles: a second look (Sabbagh et al) 1996;40:500A
deficient glutamate transport is associated with neurodegeneration in Alzheimer's disease (Masliah et al) 1996;40:759
in vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease (Kuhl et al) 1996;40:399
neuronal activity and early neurofibrillary tangles in Alzheimer's disease (Hatanpää et al) 1996;40:411
serum uric acid, age at disease onset, and rate of disease progression in Alzheimer's disease (Sevush and Mallia) 1996;40:501A

Alzheimer's disease, physiopathology
further studies validating the Severe Mini-Mental State Examination for use in severely impaired Alzheimer's patients (Harrell et al) 1996;40:500A

Amino acids, branched-chain
oral branched-chain amino acids do not improve exercise capacity in McArdle's disease (Haller et al) 1996;40:541A

Amiodarone
multifocal demyelinating neuropathy due to amiodarone (Grant and Krendel) 1996;40:539A

Amitriptyline
sleep and amitriptyline enhance the sensitivity of electroencephalograms in children with a pervasive developmental disorder and language regression (Kollros et al) 1996;40:303A

Amniocentesis
amniocentesis and fetal brain injury (Squier et al) 1996;40:320A

Amniotic fluid
expression of markers for both neuronal and glial cells in human amniotic epithelial cells: possible multipotential neural stem cells for transplantation in human brain (Sakuragawa et al) 1996;40:296A

AMP deaminase
molecular genetic defect in muscle AMP deaminase deficiency: relationship to phenotype (Sahenk et al) 1996;40:512A

Amygdaloid body
mesial atrophy and outcome after amygdalohippocampectomy or temporal lobe removal (Arruda et al) 1996;40:446

Amyloid
amyloid neuropathy: a potential role for complement activation in its pathogenesis (Hafer-Macko et al) 1996;40:543A
genetic factors in Alzheimer's disease: a review of recent advances (Levy-Lahad and Bird) 1996;40:829 (Neurological progress)
genetic studies in Alzheimer's disease with an NACP/α-synuclein polymorphism (Xia et al) 1996;40:207
prion-containing Kuru-like plaques in familial Alzheimer-like disease with concomitant β/A4 amyloid–containing plaques and a single mutation in the presenilin 1 gene (Kuljis et al) 1996;40:503A

Amyloid beta-protein
amyloid β protein (Aβ) deposition in chromosome 14–linked Alzheimer's disease: predominance of $A\beta_{42(43)}$ (Mann et al) 1996;40:149

Amyotrophic lateral sclerosis
abnormal mRNA leads to downregulation of glutamate transporter EAAT2 (GLT-1) expression in familial amyotrophic lateral sclerosis (Lin et al) 1996;40:540A
altered expression of *bcl-2* and *bax* mRNA in amyotrophic lateral sclerosis spinal cord motor neurons (Mu et al) 1996;40:379
amyotrophic lateral sclerosis and antibodies to voltage-gated calcium channels—new doubts (Vincent and Drachman) 1996;40:691 (Editorial)
amyotrophic lateral sclerosis and vitamin E (Keane) 1996;40:480 (Historical intelligence)
CNS distribution of free-radical inactivating enzymes in amyotrophic lateral sclerosis (Mitchell et al) (Letter); (Przedborski and Donaldson) (Reply) 1996;40:689
detection of motor cortex activation in paralytic amyotrophic lateral sclerosis patients without apparent muscle contraction (Shinohara et al) 1996;40:547A
glial glutamate transporter complementary DNA in patients with amyotrophic lateral sclerosis (Meyer et al) 1996;40:456
Guamanian neurodegenerative disease: ultrastructural studies of skin (Ono et al) 1996;40:530A
immunoassays fail to detect antibodies against neuronal calcium channels in amyotrophic lateral sclerosis serum (Arsac et al) 1996;40:695
motor unit alterations may contribute to excessive fatigue in patients with amyotrophic lateral sclerosis (Sharma and Miller) 1996;40:514A

nitration of glutamate transporters in transgenic mice with a familial amyotrophic lateral sclerosis-linked SOD1 mutation (Nagano et al) 1996;40:542A
pharmacological evidence for peripheral autonomic dysfunction in patients with Parkinson's disease and amyotrophic lateral sclerosis (Smith et al) 1996;40:530A
proteolytic activity in amyotrophic lateral sclerosis IgG preparations (Nyormoi) 1996;40:701
quantification of brainstem neuronal loss in amyotrophic lateral sclerosis with in vivo proton magnetic resonance spectroscopy (Cwik et al) 1996;40:512A
selective resistance of extraocular motoneuron terminals to effects of sera from patients with amyotrophic lateral sclerosis (Mosier et al) 1996;40:532A
sequence variants in human neurofilament proteins: absence of linkage to familial amyotrophic lateral sclerosis (Vechio et al) 1996;40:603

Andersen's syndrome; *see* **Glycogen storage disease type IV**

Aneurysm
late clinical outcome of the permanent balloon occlusion of the internal artery for aneurysm therapy (Berg-Dammer et al) 1996;40:527A

Angelman syndrome
cortical myoclonus in Angelman syndrome (Guerrini et al) 1996;40:39
epilepsy and Angelman syndrome (Ruggieri et al) 1996;40:302A

Anions
cytoskeleton-dependent anion channel may underlie morphology-dependent changes in the functional capacities of neocortical astrocytes (Lascola and Kraig) 1996;40:548A

Anoxia
aurintricarboxylic acid prevents hypoxia-induced apoptosis: evidence for a mechanism other than interfering with overactivation of the glutamate receptor (Rosenbaum et al) 1996;40:499A
increased hypoxic tolerance by systemic pretreatment of experimental animals with 3-nitropropionic acid is reversed by APV, an NMDA antagonist (Riepe et al) 1996;40:548A
neuroprotection by rasagiline mesylate (TVP-1012) in experimental models of hypoxia and ischemia (Speiser et al) 1996;40:495A

Antibodies
acute motor axonal neuropathy: an antibody-mediated attack on axolemma (Hafer-Macko et al) 1996;40:635
amyotrophic lateral sclerosis and antibodies to voltage-gated calcium channels—new doubts (Vincent and Drachman) 1996;40:691 (Editorial)
anti-HuD reactivity in neoplasms of the central nervous system (Gultekin et al) 1996;40:491A
anti-SGPG antibody in chronic inflammatory demyelinating polyneuropathy: nosological position of polyneuropathy associated with IgM anti-MAG/SGPG antibody (Tagawa et al) 1996;40:519A
Campylobacter jejuni infections and anti-GM1 antibodies in Guillain-Barré syndrome (Jacobs et al) 1996;40:181
cerebrospinal fluid and serum from acquired neuromyotonia patients seropositive for anti–potassium channel antibodies label dentate nucleus neurons (Hart et al) 1996;40:554A
close association of Guillain-Barré syndrome with antibodies to minor monosialogangliosides GM_{1b} and $GM_{1\alpha}$ (Tagawa et al) 1996;40:554A
immune deviation worsens antibody-mediated experimental allergic encephalomyelitis in a nonhuman primate (Genain et al) 1996;40:555A
immunoassays fail to detect antibodies against neuronal calcium channels in amyotrophic lateral sclerosis serum (Arsac et al) 1996;40:695
motor neuron disease: a paraneoplastic process associated with anti-Hu antibody and small-cell lung carcinoma (Verma et al) 1996;40:112

Antichymotrypsin; *see* **Chymotrypsin**

Anticonvulsants
γ-butyrolactones and lactams: a new class of anticonvulsants (Rothman et al) 1996;40:286A
effects of antiepileptic drugs on motor cortex excitability in humans: a transcranial magnetic stimulation study (Ziemann et al) 1996;40:367
is early complete response in recurrent malignant gliomas treated with cisplatin, VP-16, and vincristine related to anticonvulsants? (Phuphanich et al) 1996;40:490A
phase I trial of a novel anticonvulsant for infantile spasms: safety and hormonal effects of a corticotropin-releasing hormone antagonist in humans (Baram et al) 1996;40:285A
transcranial magnetic stimulation: a useful tool for clinical neurophysiology (Hallett) 1996;40:344 (Editorial)
what happens to children with epilepsy who experience a seizure recurrence after withdrawal of antiepileptic drugs? (Shinnar et al) 1996;40:301A

Antigens
marked discordance of serial cerebrospinal fluid P24 antigen and brain viral burden in pure AIDS dementia (McGuire et al) 1996;40:493A

Anti-GM1 antibodies; *see* **Antibodies**

Anti-Hu antibody; *see* **Antibodies**

Aphasia
aphasia in acute stroke: incidence, determinants, and recovery (Wertz) (Letter); (Pedersen et al) (Reply) 1996;40:129
epileptic aphasia (Landau-Kleffner syndrome) secondary to progressive encephalitis (Bicknese et al) 1996;40:306A
pervasive developmental disorder/autism versus Landau-Kleffner syndrome: steroid-responsive encephalopathy characterized by language and social interactive impairment (Mott et al) 1996;40:332A

Apolipoprotein E
Alzheimer's disease or Alzheimer's diseases? clues from molecular epidemiology (Hyman) 1996;40:135 (Editorial)
apolipoprotein E alleles in sporadic inclusion-body myositis and hereditary inclusion-body myopathy (Askanas et al) (Letter); (Garlepp and Mastaglia) (Reply) 1996;40:264
apolipoprotein E and α_1-antichymotrypsin polymorphism in Alzheimer's disease (Nacmias et al) 1996;40:503A, 1996;40:678
apolipoprotein E and apolipoprotein E messenger RNA in muscle of inclusion body myositis and myopathies (Mirabella et al) 1996;40:864
apolipoprotein E and cognitive change in an elderly population (Hyman et al) 1996;40:55
apolipoprotein E and inclusion body myositis (Garlepp and Mastaglia) 1996;40:826 (Editorial)
apolipoprotein E genotype in elderly nondemented subjects without senile changes in the brain (Yamada et al) 1996;40:243

Apolipoprotein E (*continued*)
clinical correlates of apolipoprotein E in Alzheimer's disease (Frisoni et al) (Letter); (Hyman et al) (Reply) 1996; 40:688
onset of dementia is associated with apolipoprotein E ϵ4 in Down's syndrome (Schupf et al) 1996;40:799
volumetric magnetic resonance imaging measurements of the hippocampal formation and apolipoprotein E genotypes (Petersen et al) 1996;40:503A
Apoptosis; *see* **Cell death**
Apraxia
carbamazepine-responsive epileptic oral motor and oculomotor apraxia (Naqvi et al) 1996;40:302A
APV; *see* ***N*-methylaspartate**
Arachnoid
leptomeningeal metastases due to melanoma: combined-modality therapy (Chamberlain and Kormanik) 1996; 40:490A
primary immature teratoma of the leptomeninges in an 8-year-old child: unusual presentation with recurrent transient oculomotor nerve palsies and rapid progression to diffuse cerebral infarction (Robertson et al) 1996;40:333A
Arm
application of robotics to assess the effect of manipulation of the impaired upper limb in stroke recovery (Aisen et al) 1996;40:522A
Arteriovenous malformations
intravascular pressure measurements of brain arteriovenous malformations (Henkes et al) 1996;40:527A
Artifacts
functional magnetic resonance imaging of the brain without magnetic susceptibility artifact (Edelman et al) 1996;40:524A
Astrocytes
astrocytes from adult brains as vehicles for gene transfer into the central nervous system: grafting and the host response (Azizi) 1996;40:549A
cytoskeleton-dependent anion channel may underlie morphology-dependent changes in the functional capacities of neocortical astrocytes (Lascola and Kraig) 1996;40: 548A
grading and naming of pediatric supratentorial astrocytic tumors (Brown et al) 1996;40:335A
neuronal protection from excitotoxic injury by depolymerization of actin may also be due to a concomitant induction of reactive astrocytes (Kunkler et al) 1996;40:496A
oligodendroglial and astroglial differentiation during development and remyelination (Mabie et al) 1996;40: 546A
severe acidosis is required for astrocytes to undergo clasmatodendrosis (Kraig et al) 1996;40:529A
Astrocytoma
bone metastases with meningeal gliomatosis as a progression from hypothalamic low-grade astrocytoma and complete response by chemotherapy (Johnston et al) 1996;40:489A
interferon-β-1b decreases induced nitric oxide production by a human astrocytoma cell line (Mattson and Guthikonda) 1996;40:515A
loss of tuberin from cerebral tissues with tuberous sclerosis and astrocytoma (Mizuguchi et al) 1996;40:941
Ataxia
episodic ataxia and myokymia syndrome: a new mutation of potassium channel gene Kv1.1 (Çomu et al) 1996; 40:684
evidence of genetic heterogeneity within the Friedreich's ataxia phenotype (Christodoulou et al) 1996;40:548A
Friedreich's ataxia mutation does not always result in ataxia (Subramony et al) 1996;40:542A
sensitization with GB_{1b} ganglioside induced ataxic sensory neuropathy in rabbits (Kusunoki et al) 1996;40:551A
somatic mosaicism in the central nervous system in spinocerebellar ataxia type 1 and Machado-Joseph disease (Lopes-Cendes et al) 1996;40:199
Atrophy
cerebral atrophy in multiple sclerosis: a neglected but important phenomenon (Losseff et al) 1996;40:531A
decreased striatal monoaminergic terminals in olivopontocerebellar atrophy and multiple system atrophy demonstrated with positron emission tomography (Gilman et al) 1996;40:885
differences between multiple system atrophy and olivopontocerebellar atrophy (Quinn and Daniel) (Letter); (Sima and Lynch) (Reply) 1996;40:945
early poliodystrophy with mitochondrial defect: two cases (Trifiletti et al) 1996;40:301A
mesial atrophy and outcome after amygdalohippocampectomy or temporal lobe removal (Arruda et al) 1996;40: 446
Attention
attention performance test: a test of a different color (Sullivan et al) 1996;40:332A
computerized testing of cognitive function in motor neuron disease: evidence of attention deficit (Chari et al) 1996;40:525A
effect of methylphenidate in the postradiation attention and memory deficits in children (Torres et al) 1996;40: 331A
phentolamine pretreatment prevents a component of growth retardation and of inattention induced by prenatal cocaine exposure (Kosofsky et al) 1996;40:315A
Attention deficit disorder with hyperactivity
attention performance test: a test of a different color (Sullivan et al) 1996;40:332A
Auditory evoked potentials; *see* **Evoked potentials, auditory**
Aurintricarboxylic acid
aurintricarboxylic acid prevents hypoxia-induced apoptosis: evidence for a mechanism other than interfering with overactivation of the glutamate receptor (Rosenbaum et al) 1996;40:499A
Autism
brain serotonin synthesis rate measured with [^{11}C]α-methyl-tryptophan positron emission tomography in normal and autistic subjects (Chugani et al) 1996;40: 296A
complex memory impairments in autism: evidence of cortical dysfunction (Minshew et al) 1996;40:333A
pervasive developmental disorder/autism versus Landau-Kleffner syndrome: steroid-responsive encephalopathy characterized by language and social interactive impairment (Mott et al) 1996;40:332A
Autism, infantile
infantile autism: brain glucose metabolism abnormalities (da Silva et al) 1996;40:313A
Autoantibodies
autoantibodies produced by patients with HTLV-I–associated myelopathy/tropical spastic paraparesis react exclusively with neurons: implications for immune-mediated damage to the CNS in retroviral-associated neurological disease (Levin et al) 1996;40:494A

IgG subclasses of autoantibodies associated with human paraneoplastic neurological syndromes (Greenlee et al) 1996;40:492A

Autoimmune diseases
limited heterogeneity of γ/Δ T cells in autoimmune diseases: analysis of the VΔ2/JΔ3 T-cell receptor rearrangement in peripheral blood lymphocytes (Liedtke et al) 1996;40:515A

Autonomic nervous system
Epstein-Barr virus–associated acute autonomic neuropathy (Bennett et al) 1996;40:453

Autoregulation; *see* **Homeostasis**

Axolemma
acute motor axonal neuropathy: an antibody-mediated attack on axolemma (Hafer-Macko et al) 1996;40:635

Axons
acute motor axonal neuropathy: an antibody-mediated attack on axolemma (Hafer-Macko et al) 1996;40:635
axonal neuropathy associated with monoclonal gammopathy of uncertain significance (Gorson and Ropper) 1996;40:539A
diabetic neuropathy in axons without neurofilaments (Zochodne et al) 1996;40:513A
excess nerve growth factor inhibits axonal growth and induces apoptosis in sensory neurons (Conti and Windebank) 1996;40:531A
is there chronic immune-mediated axonal polyneuropathy? (Oh and Claussen) 1996;40:544A

AY9944
characterization of the AY9944 rat model of absence epilepsy (Smith and Fisher) 1996;40:504A

B-lymphocytes
Epstein-Barr virus transformation induces expression of *trk b* messenger RNA in human B lymphocytes (Eggers et al) 1996;40:518A

Baclofen
intrathecal baclofen for the treatment of severe generalized tetanus (Deibert et al) 1996;40:512A

Balloon dilatation
late clinical outcome of the permanent balloon occlusion of the internal artery for aneurysm therapy (Berg-Dammer et al) 1996;40:527A

Basal ganglia
clinical presentation and pharmacological therapy in cortico–basal ganglionic degeneration (Kompoliti et al) 1996;40:534A
unusual clinical presentations of cortical-basal ganglionic degeneration (Bergeron et al) 1996;40:893

Basal lamina; *see* **Basement membrane**

Basement membrane
immunogold and freeze etch electron microscopic studies of merosin localization in basal lamina of human skeletal muscle fibers (Wakayama et al) 1996;40:511A

Basic fibroblast growth factor; *see* **Fibroblast growth factor, basic**

Basilar artery
basilar artery occlusion in children: clinical presentations and pathogenetic implications of accompanying vertebral artery occlusion (Muriello et al) 1996;40:337A

Batten disease; *see* **Neuronal ceroid-lipofuscinosis**

bcl-2; *see* **Genes**

Becker's muscular dystrophy; *see* **Muscular dystrophy**

Behavior disorders
behavioral differences in children with nephropathic cystinosis (Markusic et al) 1996;40:318A
second year of prospective validation of a treatment approach for children with behavior disorders referred for pediatric neurology evaluation (Weinberg et al) 1996;40:331A

Benign paroxysmal positioning vertigo; *see* **Vertigo**

Beta-thalassemia major; *see* **Thalassemia**

Bias
do satellite diagnostic and treatment centers overcome referral bias in dementia research? (Heidebrink et al) 1996;40:502A

Bilirubin encephalopathy; *see* **Kernicterus**

Binaural task performance; *see* **Task performance and analysis**

Biopsy
biopsy findings link multifocal motor neuropathy to chronic inflammatory demyelinating polyneuropathy (Krendel) (Letter); (Corse et al) (Reply) 1996;40:948
diagnostic utility of the nerve-muscle-skin biopsy in pediatric neurology practice (Miller et al) 1996;40:328A

Biotin
multitude of biotinylated proteins in neural cells: alteration by oxidative stress (Nguyen et al) 1996;40:299A

Blepharoptosis
bilateral ptosis and upgaze palsy with right hemispheric lesions (Averbuch-Heller et al) 1996;40:465

Blood–brain barrier
complement activation in the central nervous system following blood–brain barrier damage in man (Lindsberg et al) 1996;40:587

Blood pressure
intravascular pressure measurements of brain arteriovenous malformations (Henkes et al) 1996;40:527A

Blood transfusion
stroke in children with β-thalassemia major: role of hypertransfusion (Trifiletti et al) 1996;40:336A

Bone neoplasms
bone metastases with meningeal gliomatosis as a progression from hypothalamic low-grade astrocytoma and complete response by chemotherapy (Johnston et al) 1996;40:489A

Books
The Babinski Sign: A Centenary, by van Gijn (Aminoff) 1996;40:132
Brain Mapping: The Methods, edited by Toga and Mazziotta (Rowley) 1996;40:823
Charcot: Constructing Neurology, by Goetz et al (Aminoff) 1996;40:131
Movement Disorders 1 and 2, edited by Marsden and Fahn (Hammerstad) 1996;40:131
Neuroglia, edited by Kettenmann and Ransom (Swanson) 1996;40:822
Neurologic Rehabilitation: Contemporary Neurology Series, Vol 47, by Dobkin (Abrams) 1996;40:824
Neurology in Clinical Practice, Vols I and II, ed 2, edited by Bradley et al (Fishman) 1996;40:132
Pain Management: Theory and Practice: Contemporary Neurology Series, Vol 48, edited by Portenoy and Kanner (Galer) 1996;40:822
Reflex Sympathetic Dystrophy: A Reappraisal: Progress in Pain Research and Management, Vol 6, edited by Jänig and Stanton-Hicks (Schwartzman) 1996;40:822
Resolving Ethical Dilemmas: A Guide for Clinicians, by Lo (Layzer) 1996;40:823

Borrelia burgdorferi
cerebrospinal fluid culture positive for North American Lyme meningitis (Coyle et al) 1996;40:494A

Botulinum toxins
botulinum toxin is a safe and effective treatment for children with dystonias and spasticity and in some cases obviates the need for surgical intervention (Latimer and Jabbari) 1996;40:331A
clinical outcomes of botulinum toxin use in children with spasticity (Tilton et al) 1996;40:315A
treatment of childhood myoclonus with botulinum toxin type-A (Awaad et al) 1996;40:308A
Brachial plexus
acquired brachial plexopathy in neonates: an early sign of osteomyelitis (Sadlier and Connolly) 1996;40:320A
bilateral brachial plexus neuritis following parvovirus B19 and cytomegalovirus infection (Maas et al) 1996;40:928
prospective analysis of recovery following brachial plexus injury (Noetzel et al) 1996;40:321A
Bradykinesia; *see* **Movement disorders**
Brain, abnormalities
linkage analysis of "double cortex"/X-linked lissencephaly (Gleeson et al) 1996;40:290A
localization of the Miller-Dieker lissencephaly gene product to Cajal-Retzius cells (Clark et al) 1996;40:288A
neuroimaging features of Sotos syndrome (Schaefer et al) 1996;40:312A
normal radial glia in two Miller-Dieker lissencephaly fetal brains (Clark et al) 1996;40:297A
physical mapping of X-linked lissencephaly and SBH (XLIS) (Ross et al) 1996;40:289A
Brain, blood supply
cerebral vasoreactivity in patients with epilepsy (DeCarli et al) 1996;40:505A
Brain, surgery
motor function is preserved after neonatal hemispherectomy by maintenance of primitive bilateral corticospinal projections (Bicknese et al) 1996;40:286A
Brain-derived neurotrophic factor; *see* **Neurotrophic factors**
Brain diseases; *see also specific diseases*
early poliodystrophy with mitochondrial defect: two cases (Trifiletti et al) 1996;40:301A
novel mitochondrial DNA G8313A mutation associated with severe childhood encephalomyopathy (Verma et al) 1996;40:542A
reversible occipital encephalopathy: a new name for an old syndrome (Frank et al) 1996;40:297A
Brain injuries
amniocentesis and fetal brain injury (Squier et al) 1996;40:320A
epilepsy in children with brain injuries: impact on sleep (Gupta et al) 1996;40:304A
increased neurosteroid synthesis after brain injury (Romeo et al) 1996;40:315A
prospective study of the effect of open heart surgery on cerebral and ventricular volume in children (Bodensteiner et al) 1996;40:338A
proton magnetic resonance spectroscopy in children with acute brain injury: outcome prediction for different ages (Holshouser et al) 1996;40:316A
sleep disorders after traumatic brain injury: analysis of common moderating variables (Dabrowski et al) 1996;40:317A
Brain neoplasms
abducens palsy predicts pathology and outcome in brainstem gliomas (Fisher et al) 1996;40:335A
clinical application of thallium 201 single-photon emission-computed tomography and fluorodeoxyglucose-positron emission tomography in childhood brain tumors (Smietana et al) 1996;40:333A
grading and naming of pediatric supratentorial astrocytic tumors (Brown et al) 1996;40:335A
malignant transformation of cerebral low-grade gliomas in adults: an analysis of risk factors (Dropcho) 1996;40:489A
recurrent supratentorial gliomas: salvage therapy with oral etoposide (Chamberlain) 1996;40:335A
Brain stem
abducens palsy predicts pathology and outcome in brainstem gliomas (Fisher et al) 1996;40:335A
brainstem and thalamic lesions in dentatorubropallidoluysian atrophy (Tomiyasu et al) 1996;40:523A
correspondence of binaural task performance to location of brainstem lesions (Aharonson et al) 1996;40:546A
Branched-chain amino acids; *see* **Amino acids, branched-chain**
Breast neoplasms
carcinomatous meningitis secondary to breast cancer: combined-modality therapy (Chamberlain and Kormanik) 1996;40:490A
Brn-4; *see* **Transcription factors**
Butyrolactone
γ-butyrolactones and lactams: a new class of anticonvulsants (Rothman et al) 1996;40:286A

c-*myc*; *see* **Proto-oncogenes**
CAG repeats; *see* **Trinucleotide repeats**
Cajal-Retzius cells
localization of the Miller-Dieker lissencephaly gene product to Cajal-Retzius cells (Clark et al) 1996;40:288A
Calcium
iodoacetate-induced muscle contracture results from elevated intracellular calcium and increased myofibrillar calcium sensitivity (Ruff and Corsillo) 1996;40:508A
selective resistance of extraocular motoneuron terminals to effects of sera from patients with amyotrophic lateral sclerosis (Mosier et al) 1996;40:532A
subnecrotic doses of calcium ionophore injury induce apoptosis of differentiated skeletal muscle (Abu-Shakra et al) 1996;40:495A
Calcium channels
amyotrophic lateral sclerosis and antibodies to voltage-gated calcium channels—new doubts (Vincent and Drachman) 1996;40:691 (Editorial)
immunoassays fail to detect antibodies against neuronal calcium channels in amyotrophic lateral sclerosis serum (Arsac et al) 1996;40:695
Lambert-Eaton myasthenic syndrome immunoglobulins react with multiple types of calcium channels in small-cell lung carcinoma (Meriney et al) 1996;40:739
Campylobacter jejuni
Campylobacter jejuni infections and anti-GM1 antibodies in Guillain-Barré syndrome (Jacobs et al) 1996;40:181
Canalolithiasis
horizontal canal benign paroxysmal positioning vertigo (h-BPPV): transition of canalolithiasis to cupulolithiasis (Steddin and Brandt) 1996;40:918
Cancer; *see* **Neoplasms**
Carbamazepine
carbamazepine-responsive epileptic oral motor and oculomotor apraxia (Naqvi et al) 1996;40:302A
Carbon monoxide poisoning
magnetic resonance imaging findings in an infant with in utero carbon monoxide poisoning (Sum and Hahn) 1996;40:311A

Carboplatin
factors predicting disease control in children with progressive low-grade gliomas treated with carboplatin and vincristine chemotherapy (Packer et al) 1996;40:292A
Carcinoma
carcinomatous meningitis secondary to breast cancer: combined-modality therapy (Chamberlain and Kormanik) 1996;40:490A
Carcinoma, oat cell
Lambert-Eaton myasthenic syndrome immunoglobulins react with multiple types of calcium channels in small-cell lung carcinoma (Meriney et al) 1996;40:739
motor neuron disease: a paraneoplastic process associated with anti-Hu antibody and small-cell lung carcinoma (Verma et al) 1996;40:112
Career choice
careers in academic neurology, 1996 (Spencer) 1996;40:123 (Point of view)
Carotid artery diseases
late clinical outcome of the permanent balloon occlusion of the internal artery for aneurysm therapy (Berg-Dammer et al) 1996;40:527A
Carotid stenosis
cost-effectiveness of Doppler ultrasound screening for asymptomatic carotid stenosis (Powers and Derdeyn) 1996;40:526A
fibrinogen is associated with high-grade carotid stenosis and vascular events (Vieira et al) 1996;40:529A
CD8; *see* **T-lymphocytes**
CD4$^+$ T-lymphocytes; *see* **T-lymphocytes**
Cell adhesion molecules
multiple sclerosis: effect of clinical disease activity, disability status, and interferon beta-1b treatment on blood and CSF-ICAM-1, tumor necrosis factor receptor, and other immunological parameters (Baumhefner et al) 1996;40:552A
Cell adhesion molecules, neuronal
molecular characterization of P84 neuronal adhesion molecule (Comu et al) 1996;40:319A
Cell death
aurintricarboxylic acid prevents hypoxia-induced apoptosis: evidence for a mechanism other than interfering with overactivation of the glutamate receptor (Rosenbaum et al) 1996;40:499A
cyclosporine induces neuronal apoptosis and selective oligodendrocyte death in cortical cultures (McDonald et al) 1996;40:750
decreased expression of the apoptosis inhibitor Bcl-2 in T cells in the central nervous system in experimental autoimmune encephalomyelitis (Pender et al) 1996;40:552A
excess nerve growth factor inhibits axonal growth and induces apoptosis in sensory neurons (Conti and Windebank) 1996;40:531A
exploiting up-regulation of *bcl-2* in the development of targeted strategies for treatment of neural crest cancers: turning adversity into advantage (Schor and Cortazzo) 1996;40:290A
low levels of oxidative injury induce apoptosis of differentiated skeletal muscle cells (Selcen et al) 1996;40:549A
neurotrophin-3 receptor activation induces apoptosis of a medulloblastoma cell line (Sutton et al) 1996;40:291A
nitric oxide–induced programmed cell death: a rapid, dynamic molecular process that is reversible by peptide growth factors (Maiese et al) 1996;40:547A
subnecrotic doses of calcium ionophore injury induce apoptosis of differentiated skeletal muscle (Abu-Shakra et al) 1996;40:495A
Cellular inclusions
apolipoprotein E alleles in sporadic inclusion-body myositis and hereditary inclusion-body myopathy (Askanas et al) (Letter); (Garlepp and Mastaglia) (Reply) 1996;40:264
apolipoprotein E and apolipoprotein E messenger RNA in muscle of inclusion body myositis and myopathies (Mirabella et al) 1996;40:864
apolipoprotein E and inclusion body myositis (Garlepp and Mastaglia) 1996;40:826 (Editorial)
differences between multiple system atrophy and olivopontocerebellar atrophy (Quinn and Daniel) (Letter); (Sima and Lynch) (Reply) 1996;40:945
glial and neuronal cytoplasmic inclusions in familial olivopontocerebellar atrophy (Berciano and Ferrer) (Letter); (Gilman et al) (Reply) 1996;40:819
inclusion body myositis: clinical and pathological boundaries (Amato et al) 1996;40:581
is hereditary inclusion body myopathy a "familial prion disease"? (Cervenáková et al) 1996;40:128 (Letter)
Central nervous system, injuries
predictive value of proton magnetic resonance spectroscopy in perinatal central nervous system insults (Shu et al) 1996;40:293A
Central nervous system neoplasms
anti-HuD reactivity in neoplasms of the central nervous system (Gultekin et al) 1996;40:491A
long-term survival in primary central nervous system lymphoma (Abrey et al) 1996;40:491A
Cerebellar diseases
specific movement deficit due to focal lesion of the inferior cerebellar vermis in children (Bastian et al) 1996;40:317A
X-linked nonprogressive congenital cerebellar hypoplasia: clinical description and mapping to chromosome Xq (Illarioshkin et al) 1996;40:75
Cerebral acidosis; *see* **Acidosis**
Cerebral angiography
clinical relevance and complications of cerebral angiography in a population-based study of young patients with ischemic stroke (Wozniak et al) 1996;40:497A
misleading magnetic resonance angiography in patients with posterior circulation occlusive disease (Belden et al) 1996;40:498A
Cerebral arteries
clinical-anatomical correlation of sensory findings in posterior artery territory infarction (Georgiadis et al) 1996;40:499A
Cerebral arteriovenous malformations
intravascular pressure measurements of brain arteriovenous malformations (Henkes et al) 1996;40:527A
Cerebral artery diseases
cerebral autosomal dominant arteriopathy with subcortical infarctions and leukoencephalopathy in context: data from two Scottish pedigrees (de Silva et al) 1996;40:531A
Cerebral atrophy; *see* **Atrophy**
Cerebral cortex
benzodiazepine receptors in focal epilepsy with cortical dysgenesis: an ^{11}C-flumazenil PET study (Richardson et al) 1996;40:188
clinical features of neocortical temporal lobe epilepsy (Pacia et al) 1996;40:724
clinical presentation and pharmacological therapy in cor-

Cerebral cortex (*continued*)
tico–basal ganglionic degeneration (Kompoliti et al) 1996;40:534A
cyclosporine induces neuronal apoptosis and selective oligodendrocyte death in cortical cultures (McDonald et al) 1996;40:750
fragmentation of neocortical neurites in pediatric human immunodeficiency virus-1-associated central nervous system disease: an immunoperoxidase study of tubulin epitopes in postmortem brains (Katsetos et al) 1996;40:309A
impairment of cortical inhibition in focal dystonia (Chen et al) 1996;40:536A
language cortex representation: effects of developmental versus acquired pathology (Duchowny et al) 1996;40:31
single-photon emission computed tomography and developmental disorders of the neocortex (Spalice et al) 1996;40:299A
unusual clinical presentations of cortical-basal ganglionic degeneration (Bergeron et al) 1996;40:893
Cerebral embolism and thrombosis
microvascular endothelial cell activation in the central nervous system is associated with cancer and cerebral thromboembolism (Rogers et al) 1996;40:492A
Cerebral hemorrhage
case-control analysis of risk factors for intracerebral hemorrhage: the Northern Manhattan Stroke Study (Thomas et al) 1996;40:529A
cerebrospinal fluid nitrite/nitrate in normal neonates and those with intraventricular hemorrhage (Filipov et al) 1996;40:324A
costs and outcomes of brain hemorrhage in Maryland (Sung et al) 1996;40:496A
elevated uric acid levels in the first postnatal day are associated with periventricular hemorrhage and cystic periventricular leukomalacia in premature infants (Perlman and Risser) 1996;40:321A
evolving trends in neonatal intraventricular hemorrhage: a 10-year perspective (Sheth et al) 1996;40:295A
periventricular-intraventricular hemorrhage (1993–1995) following introduction of antenatal steroids (Perlman and Risser) 1996;40:295A
Cerebral infarction
cerebral autosomal dominant arteriopathy with subcortical infarctions and leukoencephalopathy in context: data from two Scottish pedigrees (de Silva et al) 1996;40:531A
clinical-anatomical correlation of sensory findings in posterior artery territory infarction (Georgiadis et al) 1996;40:499A
infarct volume as a surrogate measure of functional outcome: experience from the RANTTAS trial (Saver et al) 1996;40:497A
mechanisms and clinical features of posterior border zone infarcts (Belden et al) 1996;40:497A
mitochondrial encephalopathy with infantile onset and multiple symmetrical infarcts (Gingold et al) 1996;40:309A
primary immature teratoma of the leptomeninges in an 8-year-old child: unusual presentation with recurrent transient oculomotor nerve palsies and rapid progression to diffuse cerebral infarction (Robertson et al) 1996;40:333A
Cerebral ischemia
increased brain hydroxyl radical production during reversible focal cerebral ischemia (Solenski et al) 1996;40:526A
metabolic status of the ultimately noninfarcted ischemic penumbra: a positron emission tomography study in humans (Baron et al) 1996;40:498A
multifocal neuronal migration disorder as a probable result of a well-documented ischemic event at 18 weeks' gestation (Shafrir et al) 1996;40:296A
Cerebral ischemia, transient
cerebral autoregulation is exhausted in limb-shaking transient ischemic attacks (Baumgartner and Baumgartner) 1996;40:527A
incidence of transient ischemic attack in Rochester, Minnesota, 1985 to 1989 (Brown et al) 1996;40:529A
regional *N*-acetyl aspartate level as an index for neuronal viability in experimental ischemic/postischemic injury (Nakano et al) 1996;40:528A
transient forebrain ischemia in mice (Davis et al) 1996;40:528A
Cerebral palsy
3-methylglutaconic aciduria: a new etiology of cerebral palsy (Straussberg et al) 1996;40:298A
Cerebrospinal fluid
cerebrospinal fluid abnormalities in a Phase III trial interferon beta-1a (Avonex) for relapsing multiple sclerosis (Rudick et al) 1996;40:516A
cerebrospinal fluid culture positive for North American Lyme meningitis (Coyle et al) 1996;40:494A
cerebrospinal fluid nitrite/nitrate in normal neonates and those with intraventricular hemorrhage (Filipov et al) 1996;40:324A
cerebrospinal fluid protein tyrosine nitration in neonates: marker of brain NO production (Hills et al) 1996;40:324A
clinical utility of cerebrospinal fluid electrophoresis in Creutzfeldt-Jakob disease (Isaacson et al) 1996;40:502A
detection of numerical chromosomal aberrations by fluorescence in situ hybridization in cells from cerebrospinal fluid (van Oostenbrugge et al) 1996;40:492A
Epstein-Barr virus–associated acute autonomic neuropathy (Bennett et al) 1996;40:453
marked discordance of serial cerebrospinal fluid P24 antigen and brain viral burden in pure AIDS dementia (McGuire et al) 1996;40:493A
orthostatic headaches and diffuse pachymeningeal gadolinium enhancement due to cerebrospinal fluid (CSF) leak but with normal CSF opening pressures (Mokri and Piepgras) 1996;40:506A
Cerebrovascular disorders, classification
stroke subtypes and results of European Stroke Prevention Study 2 (Cunha et al) 1996;40:526A
vascular distribution of stroke—implications for treatment trials (Libman et al) 1996;40:526A
Cerebrovascular disorders, complications
case-control analysis of risk factors for intracerebral hemorrhage: the Northern Manhattan Stroke Study (Thomas et al) 1996;40:529A
prospective clinical study of congenital heart disease in pediatric stroke (Cupido et al) 1996;40:338A
status epilepticus after cerebral stroke (Berges et al) 1996;40:528A
stroke in four girls with nosologically overlapping mitochondrial disease (Al-Yamani et al) 1996;40:338A
Cerebrovascular disorders, diagnosis
clinical relevance and complications of cerebral angiography in a population-based study of young patients with ischemic stroke (Wozniak et al) 1996;40:497A

Cerebrovascular disorders, drug therapy
outcome of neonatal seizures associated with neonatal strokes in term infants (Wong and DeGrauw) 1996;40:287A
reduction of lesion volume in human stroke by citicoline detected by diffusion weighted magnetic resonance imaging: a pilot study (Warach et al) 1996;40:527A
urokinase for acute ischemic stroke (Suarez et al) 1996;40:499A
Cerebrovascular disorders, epidemiology
variation in stroke occurrence in cardiac surgical patients (McKhann et al) 1996;40:498A
Cerebrovascular disorders, etiology
causes of ischemic stroke in young adults: a comparison of two registries (Williams et al) 1996;40:497A
cerebrovascular complications of Fabry's disease (Mitsias and Levine) 1996;40:8 (Neurological progress)
familial hypomagnesemia with seizures, migraine, and stroke-like events (Selcen et al) 1996;40:336A
stroke in children with β-thalassemia major: role of hypertransfusion (Trifiletti et al) 1996;40:336A
Cerebrovascular disorders, genetics
new autosomal dominant stroke syndrome (Noetzel et al) 1996;40:337A
Cerebrovascular disorders, physiopathology
aphasia in acute stroke: incidence, determinants, and recovery (Wertz) (Letter); (Pedersen et al) (Reply) 1996;40:129
application of robotics to assess the effect of manipulation of the impaired upper limb in stroke recovery (Aisen et al) 1996;40:522A
Cerebrovascular disorders, prevention and control
stroke subtypes and results of European Stroke Prevention Study 2 (Cunha et al) 1996;40:526A
Cerebrovascular disorders, rehabilitation
spontaneous neurological recovery after stroke and the fate of the ischemic penumbra (Furlan et al) 1996;40:216
Cerebrovascular disorders, therapy
safety and efficacy of intravenous recombinant tissue plasminogen activator in acute ischemic stroke: results of the ECASS three-hour cohort (Hacke et al) 1996;40:499A
Cervical nerves
surgical management of superficial siderosis following cervical nerve root avulsion (Tapscott et al) 1996;40:936
Charcot-Marie-Tooth disease
X-linked dominant Charcot-Marie-Tooth disease: novel connexin 32 mutations and their relationship to clinical and pathological disease (Tan et al) 1996;40:545A
Chemotherapy; *see* **Drug therapy**
Child abuse
early posttraumatic seizures are more common after nonaccidental head injury than other types of head injury (Gilles) 1996;40:316A
Child behavior disorders
behavioral differences in children with nephropathic cystinosis (Markusic et al) 1996;40:318A
second year of prospective validation of a treatment approach for children with behavior disorders referred for pediatric neurology evaluation (Weinberg et al) 1996;40:331A
Child development disorders
prognosis for survival and improvement in children with severe developmental disabilities (Strauss et al) 1996;40:296A
Child development disorders, pervasive
pervasive developmental disorder/autism versus Landau-Kleffner syndrome: steroid-responsive encephalopathy characterized by language and social interactive impairment (Mott et al) 1996;40:332A
prolonged electroencephalographic monitoring findings in children with pervasive developmental disorder and regression (Villalobos et al) 1996;40:300A
sleep and amitriptyline enhance the sensitivity of electroencephalograms in children with a pervasive developmental disorder and language regression (Kollros et al) 1996;40:303A
Cholinergic fibers
in vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease (Kuhl et al) 1996;40:399
Chorea
progressive choreic and dystonic dyskinesias induced by a D1 agonist in nonprimed MPTP-treated primates (Papa et al) 1996;40:535A
Choristoma
physical mapping of X-linked lissencephaly and SBH (XLIS) (Ross et al) 1996;40:289A
Chromosome abnormalities
detection of numerical chromosomal aberrations by fluorescence in situ hybridization in cells from cerebrospinal fluid (van Oostenbrugge et al) 1996;40:492A
Chromosome deletion
clonal expansion of mitochondrial DNA with multiple deletions in autosomal dominant progressive external ophthalmoplegia (Moslemi et al) 1996;40:707
molecular characterization of gene deletions in families with spinal muscular atrophy and intrafamilial phenotypic variations (Wang et al) 1996;40:293A
Chromosome mapping
candidate gene analysis in spinocerebellar ataxia type 4 (SCA4) (Flanigan et al) 1996;40:487A
linkage analysis of "double cortex"/X-linked lissencephaly (Gleeson et al) 1996;40:290A
Chromosome X; *see* **X chromosome**
Chromosomes, human, pair 1
wide range in age of onset for chromosome 1–related familial Alzheimer's disease (Bird et al) 1996;40:932
Chromosomes, human, pair 12
linkage of scapuloperoneal spinal muscular atrophy to chromosome 12q24.1-q24.31 (Isozumi et al) 1996;40:541A
Chromosomes, human, pair 14
amyloid β protein (Aβ) deposition in chromosome 14–linked Alzheimer's disease: predominance of $A\beta_{42(43)}$ (Mann et al) 1996;40:149
confirmation of linkage of oculopharyngeal muscular dystrophy to chromosome 14q11.2-q13 (Stajich et al) 1996;40:801
missense mutations of the *PS-1/S182* gene in German early-onset Alzheimer's disease patients (Sandbrink et al) 1996;40:265 (Letter)
Chromosomes, human, pair 15
cortical myoclonus in Angelman syndrome (Guerrini et al) 1996;40:39
Chronic inflammatory demyelinating polyneuropathy; *see* **Demyelinating diseases**
Chronic progressive external ophthalmoplegia; *see* **Ophthalmoplegia**
Chymotrypsin
apolipoprotein E and α_1-antichymotrypsin polymorphism in Alzheimer's disease (Nacmias et al) 1996;40:503A, 1996;40:678

Cisplatin
is early complete response in recurrent malignant gliomas treated with cisplatin, VP-16, and vincristine related to anticonvulsants? (Phuphanich et al) 1996;40:490A
Citicoline; *see* **Cytidine diphosphate choline**
Clasmatodendrosis
severe acidosis is required for astrocytes to undergo clasmatodendrosis (Kraig et al) 1996;40:529A
Clinical outcomes assessment; *see* **Outcomes assessment**
Clinical trials
are "double-blind" trials truly "double-blind"? implications for prospective clinical trials (Rosman et al) 1996;40:302A
Cocaine
cocaine delirium and sudden death: a possible cocaine variant of neuroleptic malignant syndrome? (Mash et al) 1996;40:523A
fetal cocaine exposure and neurological outcome in school-aged children (Chiriboga et al) 1996;40:323A
phentolamine pretreatment prevents a component of growth retardation and of inattention induced by prenatal cocaine exposure (Kosofsky et al) 1996;40:315A
striatal dopamine, dopamine transporter, and vesicular monoamine transporter in chronic cocaine users (Wilson et al) 1996;40:428
Codon
clinically distinct codon 69 mutations in major myelin protein zero in demyelinating neuropathies (Meijerink et al) 1996;40:672
Coenzyme A dehydrogenase
case of 2-methyl, 3-hydroxy butyryl-CoA dehydrogenase deficiency (Sansaricq et al) 1996;40:318A
Cognition
apolipoprotein E and cognitive change in an elderly population (Hyman et al) 1996;40:55
cognitive and brain magnetic resonance imaging findings in adrenomyeloneuropathy (Edwin et al) 1996;40:675
computerized testing of cognitive function in motor neuron disease: evidence of attention deficit (Chari et al) 1996;40:525A
effects of estrogen on cognitive function in nondemented postmenopausal women (Jacobs et al) 1996;40:502A
Cognition disorders; *see also specific disorders*
altered mental status in thrombotic thrombocytopenic purpura is secondary to nonconvulsive status epilepticus (Garrett et al) 1996;40:245
cognitive deficits in Machado-Joseph disease (Maruff et al) 1996;40:421
comorbidity of developmental language disorders and cognitive dysfunction (Gross-Tsur et al) 1996;40:338A
psychiatric disorders and cognitive dysfunction in human immunodeficiency virus–infected individuals (Schifitto et al) 1996;40:506A
toward a "7-minute" screening battery sensitive to Alzheimer's disease (Solomon et al) 1996;40:502A
Coma
discrimination of facial expression in vegetative state. mismatch negativity of visual event-related potential study (Kaga et al) 1996;40:316A
Community health centers
do satellite diagnostic and treatment centers overcome referral bias in dementia research? (Heidebrink et al) 1996;40:502A
Complement
sarcolemmal complement and IgM deposits in immune-mediated myopathies (Spuler and Engel) 1996;40:511A
Complement activation
amyloid neuropathy: a potential role for complement activation in its pathogenesis (Hafer-Macko et al) 1996;40:543A
complement activation in the central nervous system following blood–brain barrier damage in man (Lindsberg et al) 1996;40:587
Complementary DNA; *see* **DNA**
Complex I
deficiency of respiratory chain complex I is a common cause of Leigh disease (Morris et al) 1996;40:25
genetic heterogeneity in Leigh syndrome (DiMauro and De Vivo) 1996;40:5 (Editorial)
origin and functional consequences of the complex I defect in Parkinson's disease (Swerdlow et al) 1996;40:663
Complex partial epilepsy; *see* **Epilepsy, complex partial**
Computed tomography; *see* **Tomography, x-ray computed**
Congenital bilateral perisylvian syndrome; *see* **Perisylvian syndrome**
Congenital defects; *see* **Abnormalities**
Congenital heart defects; *see* **Heart defects, congenital**
Congenital hypomyelinating neuropathy; *see* **Hypomyelinating neuropathy, congenital**
Congenital toxoplasmosis; *see* **Toxoplasmosis, congenital**
Conjunctiva
topical transconjunctival therapy for typical face pain (Casey) 1996;40:507A
Contursi, Italy
clinical genetic analysis of Parkinson's disease in the Contursi kindred (Golbe et al) 1996;40:767
Convulsions, febrile
recurrent afebrile seizures in children initially diagnosed as having febrile seizures (Trifiletti et al) 1996;40:327A
Copolymer 1
copolymer-1 suppresses the T-cell proliferative response to myelin oligodendrocyte glycoprotein (Milo et al) 1996;40:551A
effect of copolymer 1 on serial gadolinium-enhanced magnetic resonance scans in relapsing multiple sclerosis (Mancardi et al) 1996;40:521A
humoral responses to copolymer 1 in multiple sclerosis patients: preferential production of IgG1 over IgG2 (Brenner et al) 1996;40:518A
safety profile of copolymer 1 in multiple sclerosis (Korczyn and Nisipeanu) 1996;40:517A
Corpus callosum
language processing in the dominant cerebral hemisphere inhibits transcallosal activity (Karbe et al) 1996;40:525A
neurofibromatosis type 1: corpus callosum enlarged beyond megencephaly (Mott et al) 1996;40:325A
Corpus striatum
decreased striatal monoaminergic terminals in olivopontocerebellar atrophy and multiple system atrophy demonstrated with positron emission tomography (Gilman et al) 1996;40:885
mapping afferents of rabbit neostriatum: serotonin (anatomical evaluation of rabbit as a potential model of Huntington's disease) (Phelix and Russell) 1996;40:532A
striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease (Weeks et al) 1996;40:49
striatal dopamine, dopamine transporter, and vesicular monoamine transporter in chronic cocaine users (Wilson et al) 1996;40:428

Corrections
β-subunit mutation in the acetylcholine receptor channel gate causes severe slow-channel syndrome (Gomez et al) (1996;39:712) 1996;40:690
familial cerebral cavernous angioma: a gene localized to a 15-cM interval on chromosome 7q (Gil-Nagel et al) (1996;39:807) 1996;40:480
GTP-cyclohydrolase I gene mutations in hereditary progressive and dopa-responsive dystonia (Furukawa et al) (1996;39:609) 1996;40:134
intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis (Jacobs et al) (1996;39:285) 1996;40:480
Letter (Major) (1996;39:685) 1996;40:134
MELAS- and Kearns-Sayre-type *co-mutation* with myopathy and autoimmune polyendocrinopathy (Ohno et al) (1996;39:761) 1996;40:480
Corticotropin-releasing hormone
chronic stress in infancy results in downregulation of corticotropin-releasing hormone gene expression in the hypothalamus (Gilles and Baram) 1996;40:322A
phase I trial of a novel anticonvulsant for infantile spasms: safety and hormonal effects of a corticotropin-releasing hormone antagonist in humans (Baram et al) 1996;40:285A
Cost-benefit analysis
cost-effectiveness of Doppler ultrasound screening for asymptomatic carotid stenosis (Powers and Derdeyn) 1996;40:526A
costs and outcomes of brain hemorrhage in Maryland (Sung et al) 1996;40:496A
seizure precautions: are they appropriate in patients with seizures? (Conry et al) 1996;40:306A
Creutzfeldt-Jakob disease
clinical utility of cerebrospinal fluid electrophoresis in Creutzfeldt-Jakob disease (Isaacson et al) 1996;40:502A
first Irish case of a newly recognized phenotype of Creutzfeldt-Jakob disease (Hawkins et al) 1996;40:523A
Critical illness
acute myopathy of intensive care: clinical, electromyographic, and pathologic aspects (Lacomis et al) 1996;40:645
humoral neurotoxic factor in sera of patients with critical illness polyneuropathy (Hund et al) 1996;40:539A
Cupulolithiasis
horizontal canal benign paroxysmal positioning vertigo (h-BPPV): transition of canalolithiasis to cupulolithiasis (Steddin and Brandt) 1996;40:918
Cyclin
aberrant expression of cyclin-dependent kinases in myofibrillar myopathy with abnormal foci of desmin positivity: analysis of 8 cases (Nakano et al) 1996;40:508A
Cyclooxygenase-2; *see* **Prostaglandin-endoperoxide synthase**
Cyclosporine
cyclosporine induces neuronal apoptosis and selective oligodendrocyte death in cortical cultures (McDonald et al) 1996;40:750
immunosuppressants, immunophilins, and the nervous system (Dawson) 1996;40:559 (Editorial)
Cyclothiazide
cyclothiazide-induced hippocampal injury in immature rat brain (Trescher) 1996;40:288A
Cystic periventricular leukomalacia; *see* **Leukomalacia, periventricular**
Cystinosis
behavioral differences in children with nephropathic cystinosis (Markusic et al) 1996;40:318A
Cytidine diphosphate choline
reduction of lesion volume in human stroke by citicoline detected by diffusion weighted magnetic resonance imaging: a pilot study (Warach et al) 1996;40:527A
Cytochrome c oxidase
cerebral near-infrared spectroscopy in children undergoing heart surgery (Wollert and Eckel) (Letter); (du Plessis et al) (Reply) 1996;40:818
Cytochrome P450
genetic variability of the CYP 2D6 gene is not a risk factor for sporadic Parkinson's disease (Diederich et al) 1996;40:463
Cytokines
different cytokine families regulate neuronal and glial differentiation from neural progenitor cells (Mehler et al) 1996;40:546A
scatter factor enhances glioma malignancy (Laterra et al) 1996;40:492A
Cytomegalic inclusion disease
congenital lymphocytic choriomeningitis virus infection: a disorder closely mimicking congenital toxoplasmosis and cytomegalovirus infection (Wright et al) 1996;40:319A
Cytomegaloviruses
bilateral brachial plexus neuritis following parvovirus B19 and cytomegalovirus infection (Maas et al) 1996;40:928
molecular mimicry between cytomegalovirus and GM_2 ganglioside: pathogenesis of Guillain-Barré syndrome (Yuki et al) 1996;40:519A
Cytoplasm
differences between multiple system atrophy and olivopontocerebellar atrophy (Quinn and Daniel) (Letter); (Sima and Lynch) (Reply) 1996;40:945
glial and neuronal cytoplasmic inclusions in familial olivopontocerebellar atrophy (Berciano and Ferrer) (Letter); (Gilman et al) (Reply) 1996;40:819
Cytoskeleton
cytoskeleton-dependent anion channel may underlie morphology-dependent changes in the functional capacities of neocortical astrocytes (Lascola and Kraig) 1996;40:548A

Death
Selegiline and mortality in Parkinson's disease (Olanow et al) 1996;40:841 (Point of view)
Death, sudden
cocaine delirium and sudden death: a possible cocaine variant of neuroleptic malignant syndrome? (Mash et al) 1996;40:523A
Deep brain stimulation; *see* **Electric stimulation**
Dementia
apolipoprotein E genotype in elderly nondemented subjects without senile changes in the brain (Yamada et al) 1996;40:243
do satellite diagnostic and treatment centers overcome referral bias in dementia research? (Heidebrink et al) 1996;40:502A
Guamanian neurodegenerative disease: ultrastructural studies of skin (Ono et al) 1996;40:530A
onset of dementia is associated with apolipoprotein E ε4 in Down's syndrome (Schupf et al) 1996;40:799
predicting dementia in white matter disease: magnetic resonance imaging, magnetic resonance spectroscopy, and neuropsychology (Balthazor et al) 1996;40:290A

Dementia (*continued*)
"pure" autosomal dominant spastic paraplegia with late-onset dementia: a family study (Webb et al) 1996;40: 530A
Demyelinating diseases; *see also specific diseases*
α/β T cells and immunoglobulins protect mice from Theiler's virus–induced encephalitis whereas Class I MHC/CD8$^+$ T cells protect against demyelination (Drescher et al) 1996;40:517A
anti-SGPG antibody in chronic inflammatory demyelinating polyneuropathy: nosological position of polyneuropathy associated with IgM anti-MAG/SGPG antibody (Tagawa et al) 1996;40:519A
biopsy findings link multifocal motor neuropathy to chronic inflammatory demyelinating polyneuropathy (Krendel) (Letter); (Corse et al) (Reply) 1996;40:948
chronic inflammatory demyelinating polyneuropathy: a retrospective study in 25 children (Yum and Sladky) 1996;40:326A
chronic inflammatory demyelinating polyneuropathy: one disease or many? (Lovelace et al) 1996;40:544A
clinically distinct codon 69 mutations in major myelin protein zero in demyelinating neuropathies (Meijerink et al) 1996;40:672
controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy (Dalakas et al) 1996;40:792
detection of nitrotyrosine immunoreactivity in experimental autoimmune encephalomyelitis–affected CNS tissues: evidence for the presence of peroxynitrite in inflammatory CNS demyelination (Cross et al) 1996;40: 520A
is there chronic immune-mediated axonal polyneuropathy? (Oh and Claussen) 1996;40:544A
multifocal demyelinating neuropathy due to amiodarone (Grant and Krendel) 1996;40:539A
Dendrites
characteristic patterns of dendritic protein expression in Down and Rett syndromes (Kaufmann et al) 1996;40: 287A
therapeutic levels of phenobarbital inhibit development and maintenance of dendrites induced by osteogenic protein-1 (Johnson et al) 1996;40:286A
Dentatorubropallidoluysian atrophy
brainstem and thalamic lesions in dentatorubropallidoluysian atrophy (Tomiyasu et al) 1996;40:523A
Deprenyl; *see* **Selegiline**
Desmin
aberrant expression of cyclin-dependent kinases in myofibrillar myopathy with abnormal foci of desmin positivity: analysis of 8 cases (Nakano et al) 1996;40:508A
Developmental disabilities; *see* **Child development disorders**
Diabetes mellitus, experimental
neurofilament gene expression in experimental diabetes (Scott et al) 1996;40:514A
Diabetes mellitus, insulin-dependent
juvenile diabetes mellitus: early identification of neuropathy (Darwish et al) 1996;40:318A
Diabetic neuropathies
diabetic neuropathy in axons without neurofilaments (Zochodne et al) 1996;40:513A
juvenile diabetes mellitus: early identification of neuropathy (Darwish et al) 1996;40:318A
results of a double-blind, placebo-controlled trial of recombinant human nerve growth factor in diabetic polyneuropathy (Apfel et al) 1996;40:540A
Diagnostic errors
guidelines to avoid errors in the diagnosis of multiple sclerosis (Katzan and Rudick) 1996;40:554A
Dichloroacetate
does dichloroacetate minimize the neurotoxicity of chronic cerebral acidosis? (De Vivo et al) 1996;40:318A
Diencephalon
treatment of diencephalic syndrome with chemotherapy—growth, tumor response, and long-term control (Gropman et al) 1996;40:293A
Diet
complications of the ketogenic diet (Ballaban-Gil et al) 1996;40:307A
electroencephalographic analysis in the ketogenic diet (Demeritte et al) 1996;40:305A
ketogenic diet in children with medically resistant epilepsy (Resnick et al) 1996;40:302A
multi-center study of the efficacy of the ketogenic diet (The Johns Hopkins Medical Institutions et al) 1996; 40:300A
organic acid disorders and the ketogenic diet (Demeritte et al) 1996;40:305A
Diffusion
clinical utility of diffusion-weighted magnetic resonance imaging in pediatric population (Kothare et al) 1996; 40:295A
Dihydroxyacetonephosphate
abnormal myelination in isolated dihydroxyacetonephosphate acyltransferase deficiency (Sztriha et al) 1996;40: 298A
Disability evaluation
worsening on DSS is not a useful entry criterion for multiple sclerosis clinical trials to prevent progression (Myers et al) 1996;40:552A
Dislocations
atlanto-axial dislocation with quadriplegia in one of the twins in a family with autosomal dominant odontoid hypoplasia (Shah and Fish) 1996;40:308A
DNA
glial glutamate transporter complementary DNA in patients with amyotrophic lateral sclerosis (Meyer et al) 1996;40:456
HIV-1 DNA in brains in AIDS and pre-AIDS: correlation with the stage of disease (An et al) 1996;40:611
DNA, mitochondrial
autosomal dominant chronic progressive external ophthalmoplegia: a tale of two genomes (Shoubridge) 1996;40: 693 (Editorial)
clonal expansion of mitochondrial DNA with multiple deletions in autosomal dominant progressive external ophthalmoplegia (Moslemi et al) 1996;40:707
DNA polymerase γ deficiency in mitochondrial disease (Naviaux et al) 1996;40:295A
early poliodystrophy with mitochondrial defect: two cases (Trifiletti et al) 1996;40:301A
MELAS associated with a mutation in the valine transfer RNA gene of mitochondrial DNA (Taylor et al) 1996; 40:459
mitochondria . . . 1989–1996 (Schapira) 1996;40:487A
mitochondrial DNA and RNA processing in MELAS (Kaufmann et al) 1996;40:172
mitochondrial neurogastrointestinal encephalomyopathy with multiple deletions of mitochondrial DNA (Collier et al) 1996;40:545A
novel mitochondrial DNA G8313A mutation associated with severe childhood encephalomyopathy (Verma et al) 1996;40:542A

reverse transcription and the bipotential replication of mitochondrial DNA (Naviaux et al) 1996;40:293A
sequence of mitochondrial DNA in patients with multiple sclerosis (Chalmers et al) 1996;40:239
DNA, viral
presence of herpes simplex DNA in surgical tissue from human epileptic seizure foci detected by polymerase chain reaction (Tourtellotte et al) 1996;40:505A
DNA polymerase III
DNA polymerase γ deficiency in mitochondrial disease (Naviaux et al) 1996;40:295A
Dopamine
dopaminergic neurotoxin, (*R*)-N-methylsalsolinol, increases in parkinsonian cerebrospinal fluid (Maruyama et al) 1996;40:119
impaired set-shifting ability in Parkinson's disease: relationships with striatofrontal circuit disruption and caudate nucleus dopamine denervation assessed with positron emission tomography (Marié et al) 1996;40:525A
striatal dopamine, dopamine transporter, and vesicular monoamine transporter in chronic cocaine users (Wilson et al) 1996;40:428
Dopamine receptors; *see* **Receptors, dopamine**
Doppler ultrasonography; *see* **Ultrasonography**
Dorsal root ganglia; *see* **Ganglia, spinal**
Double-blind method
are "double-blind" trials truly "double-blind"? implications for prospective clinical trials (Rosman et al) 1996;40:302A
Down syndrome
characteristic patterns of dendritic protein expression in Down and Rett syndromes (Kaufmann et al) 1996;40:287A
onset of dementia is associated with apolipoprotein E ϵ4 in Down's syndrome (Schupf et al) 1996;40:799
Drug abuse; *see* **Substance abuse**
Drug therapy
adjuvant chemotherapy for malignant gliomas: who benefits? (DeAngelis et al) 1996;40:491A
in vitro model system for predicting neurotoxicity of new chemotherapeutic agents (Windebank et al) 1996;40:491A
interference with p75 binding of nerve growth factor as a means of overcoming chemotherapeutic resistance of neural crest tumors (Schor et al) 1996;40:291A
survival and prognostic factors following radiation and chemotherapy for ependymomas in children: a children's cancer group study (Robertson et al) 1996;40:290A
DSS; *see* **Disability evaluation**
Duchenne muscular dystrophy; *see* **Muscular dystrophy**
Dyskinesia; *see* **Movement disorders**
Dyslexia
impaired visual word processing in dyslexia revealed with magnetoencephalography (Salmelin et al) 1996;40:157
magnetic source imaging and the neural basis of dyslexia (Poeppel and Rowley) 1996;40:137 (Editorial)
Dystonia
botulinum toxin is a safe and effective treatment for children with dystonias and spasticity and in some cases obviates the need for surgical intervention (Latimer and Jabbari) 1996;40:331A
exclusion of the DYT1 locus in familial torticollis (Bressman et al) 1996;40:681
impairment of cortical inhibition in focal dystonia (Chen et al) 1996;40:536A
long-term follow-up of levodopa responsiveness in generalized dystonia (Dewey et al) 1996;40:537A
marked enhancement of brain protein tyrosine nitration by dystonia-producing toxin 3-nitropropionic acid: implications for mechanisms of neurotoxicity (Takai et al) 1996;40:323A
mutant GTP cyclohydrolase I mRNA levels contribute to dopa-responsive dystonia onset (Hirano et al) 1996;40:796
progressive choreic and dystonic dyskinesias induced by a D1 agonist in nonprimed MPTP-treated primates (Papa et al) 1996;40:535A
three novel mutations in the GTP cyclohydrolase I gene in 3 Japanese families with dopa-responsive dystonia (Ueno et al) 1996;40:537A
Dystroglycan
muscular dystrophy associated with β-dystroglycan deficiency (Salih et al) 1996;40:925

ECMO; *see* **Extracorporeal membrane oxygenation**
Education
careers in academic neurology, 1996 (Spencer) 1996;40:123 (Point of view)
early American professorships in neurology (Goetz and Pappert) 1996;40:258 (History of neurology)
eIF-4
c-*myc* acts as a transcription factor for the eIF-4E promoter (Jones et al) 1996;40:334A
Elderly; *see* **Aged**
Electric stimulation
efficacy of deep brain stimulation in the treatment of essential tremor and Parkinson's disease: 12-month follow-up (Busenbark et al) 1996;40:533A
high-frequency pallidal stimulation in Parkinson's disease (Pahwa et al) 1996;40:533A
unilateral stimulation of the globus pallidus internus in Parkinson's disease: bilateral improvement of major symptoms (van der Linden et al) 1996;40:538A
Electrical status epilepticus; *see* **Status epilepticus**
Electroencephalography
dysmaturity index derived from electroencephalographic sleep analyses to document brain adaptation to conditions of prematurity (Scher et al) 1996;40:320A
electroencephalographic analysis in the ketogenic diet (Demeritte et al) 1996;40:305A
improved localization of epileptic focus by ictal single-photon emission computed tomography using continuous electroencephalographic analysis and background subtraction to determine time of injection (Koo et al) 1996;40:303A
prolonged electroencephalographic monitoring findings in children with pervasive developmental disorder and regression (Villalobos et al) 1996;40:300A
relationship between electroencephalographic abnormalities and cortical auditory evoked potentials in children with severe language deficits (Mott and Weiss) 1996;40:332A
sleep and amitriptyline enhance the sensitivity of electroencephalograms in children with a pervasive developmental disorder and language regression (Kollros et al) 1996;40:303A
study of brain adaptation from neonatal to infancy periods using spectral electroencephalographic-sleep analyses (Scher et al) 1996;40:320A

Electromyography
acute myopathy of intensive care: clinical, electromyographic, and pathologic aspects (Lacomis et al) 1996; 40:645
Electron microscopy; *see* **Microscopy, electron**
Electronystagmography
posturography and electronystagmography discriminate between spinocerebellar ataxia type 1 (SCA1) and type 3 (SCA3/Machado-Joseph disease) patients (Subramony et al) 1996;40:533A
Electrophoresis
clinical utility of cerebrospinal fluid electrophoresis in Creutzfeldt-Jakob disease (Isaacson et al) 1996;40:502A
Embolism
cardiac sources of embolism are a determinant of microemboli in patients with vertebrobasilar ischemia (Koennecke et al) 1996;40:528A
Emergency service, hospital
emergency computed tomography utilization in a children's hospital (Chaves-Carballo and Gavini) 1996;40: 314A
Encephalitis
epileptic aphasia (Landau-Kleffner syndrome) secondary to progressive encephalitis (Bicknese et al) 1996;40: 306A
role of *Mycoplasma pneumoniae* in acute childhood encephalitis (Kolski et al) 1996;40:310A
Encephalitogenic basic proteins
acute multiple sclerosis (Marburg type) is associated with developmentally immature myelin basic protein (Wood et al) 1996;40:18
discordance of the myelin basic protein gene in familial multiple sclerosis (Rose et al) 1996;40:520A
myelin basic protein-like material in urine: a developmental profile (Percy et al) 1996;40:297A
possible role for altered myelin basic protein in multiple sclerosis (Whitaker and Mitchell) 1996;40:3 (Editorial)
recognition of myelin basic protein by mutated human T-cell receptors (Robinson et al) 1996;40:521A
T-cell reactivity to peptides of proteolipid protein and myelin basic protein in multiple sclerosis (Pender et al) 1996;40:552A
urinary myelin basic protein-like material as a correlate of the progression of multiple sclerosis (Giovannoni et al) (Letter); (Whitaker et al) (Reply) 1996;40:128
Encephalomyelitis
progressive encephalomyelitis with rigidity responsive to plasmapheresis and immunosuppression (Fogan) 1996; 40:451
Encephalomyelitis, allergic
immune deviation worsens antibody-mediated experimental allergic encephalomyelitis in a nonhuman primate (Genain et al) 1996;40:555A
matrix metalloprotease inhibitor is effective in treatment of chronic relapsing murine experimental allergic encephalomyelitis (Liedtke et al) 1996;40:515A
Encephalomyelitis, autoimmune
decreased expression of the apoptosis inhibitor Bcl-2 in T cells in the central nervous system in experimental autoimmune encephalomyelitis (Pender et al) 1996;40: 552A
detection of nitrotyrosine immunoreactivity in experimental autoimmune encephalomyelitis–affected CNS tissues: evidence for the presence of peroxynitrite in inflammatory CNS demyelination (Cross et al) 1996;40: 520A
early insulin-like growth factor-I treatment reduces clinical deficits and lesion severity in relapses of chronic experimental autoimmune encephalomyelitis (Li et al) 1996; 40:514A
immune deviation from a Th1 toward a Th2-type T-cell response occurs during recovery from monophasic experimental autoimmune encephalomyelitis (Jensen et al) 1996;40:522A
Encephalomyelitis virus, murine
α/β T cells and immunoglobulins protect mice from Theiler's virus–induced encephalitis whereas Class I MHC/$CD8^+$ T cells protect against demyelination (Drescher et al) 1996;40:517A
identification of a novel H-$2D^b$–restricted cytotoxic T-cell epitope in the VP-2 capsid protein of Theiler's virus (Borson et al) 1996;40:514A
Encephalopathy; *see* **Brain diseases**
Endothelial cells
microvascular endothelial cell activation in the central nervous system is associated with cancer and cerebral thromboembolism (Rogers et al) 1996;40:492A
Energy metabolism
brain energy metabolism in Huntington's disease measured with in vivo proton magnetic resonance spectroscopy (Martin et al) 1996;40:538A
Enzymes
CNS distribution of free-radical inactivating enzymes in amyotrophic lateral sclerosis (Mitchell et al) (Letter); (Przedborski and Donaldson) (Reply) 1996;40:689
trifunctional enzyme deficiency: adult presentation of a usually fatal β-oxidation defect (Schaefer et al) 1996; 40:597
Eosinophilia-myalgia syndrome
eosinophilia myalgia syndrome: development of a murine model and roles of "pure" and "contaminated" L-tryptophan (Rosenberg et al) 1996;40:517A
Ependymoma
survival and prognostic factors following radiation and chemotherapy for ependymomas in children: a children's cancer group study (Robertson et al) 1996;40: 290A
Epilepsy, absence
accuracy of hyperventilation in predicting the activity of absence seizures (Ahmed and Libenson) 1996;40:308A
characterization of the AY9944 rat model of absence epilepsy (Smith and Fisher) 1996;40:504A
single-photon emission computed tomography in childhood absence epilepsy (Spalice et al) 1996;40:312A
Epilepsy, analysis
cerebral glutamate and γ-aminobutyric acid in pediatric epilepsy (Novotny and Rothman) 1996;40:285A
low brain GABA level is associated with poor seizure control (Petroff et al) 1996;40:908
presence of herpes simplex DNA in surgical tissue from human epileptic seizure foci detected by polymerase chain reaction (Tourtellotte et al) 1996;40:505A
Epilepsy, complex partial
low brain GABA levels remote from the seizure focus are associated with poor seizure control in patients with complex partial epilepsy (Petroff et al) 1996;40:506A
Epilepsy, complications
epilepsy and Angelman syndrome (Ruggieri et al) 1996; 40:302A
epileptic aphasia (Landau-Kleffner syndrome) secondary to progressive encephalitis (Bicknese et al) 1996;40: 306A

Epilepsy, diagnosis
improved localization of epileptic focus by ictal single-photon emission computed tomography using continuous electroencephalographic analysis and background subtraction to determine time of injection (Koo et al) 1996;40:303A
paroxysmal nonepileptic events in children and adolescents (Costa et al) 1996;40:306A
Epilepsy, diet therapy
complications of the ketogenic diet (Ballaban-Gil et al) 1996;40:307A
electroencephalographic analysis in the ketogenic diet (Demeritte et al) 1996;40:305A
ketogenic diet in children with medically resistant epilepsy (Resnick et al) 1996;40:302A
multi-center study of the efficacy of the ketogenic diet (The Johns Hopkins Medical Institutions et al) 1996;40:300A
organic acid disorders and the ketogenic diet (Demeritte et al) 1996;40:305A
Epilepsy, drug therapy
carbamazepine-responsive epileptic oral motor and oculomotor apraxia (Naqvi et al) 1996;40:302A
what happens to children with epilepsy who experience a seizure recurrence after withdrawal of antiepileptic drugs? (Shinnar et al) 1996;40:301A
Epilepsy, frontal lobe
fluorodeoxyglucose positron emission tomography in children and adolescents with frontal lobe epilepsy (Gaillard et al) 1996;40:305A
Epilepsy, myoclonic
familial adult myoclonus epilepsy: a new phenotype of autosomal dominant myoclonus epilepsy (Uyama et al) 1996;40:505A
Epilepsy, partial
benzodiazepine receptors in focal epilepsy with cortical dysgenesis: an ^{11}C-flumazenil PET study (Richardson et al) 1996;40:188
Epilepsy, pathology
hemifacial seizures and cerebellar ganglioglioma: an epilepsy syndrome of infancy with seizures of cerebellar origin (Harvey et al) 1996;40:91
relationship between neuropathology and surgical outcome in children with intractable epilepsy from extratemporal lobes (Chen et al) 1996;40:306A
value of single-photon emission computed tomography in evaluating occipital lobe epilepsy (Azhar et al) 1996;40:307A
Epilepsy, physiopathology
cerebral vasoreactivity in patients with epilepsy (DeCarli et al) 1996;40:505A
epilepsy in children with brain injuries: impact on sleep (Gupta et al) 1996;40:304A
language cortex representation: effects of developmental versus acquired pathology (Duchowny et al) 1996;40:31
Epilepsy, surgery
epilepsy surgery in patients under age 3 years (Duchowny et al) 1996;40:286A
relationship between neuropathology and surgical outcome in children with intractable epilepsy from extratemporal lobes (Chen et al) 1996;40:306A
Epilepsy, temporal lobe
clinical features of neocortical temporal lobe epilepsy (Pacia et al) 1996;40:724
familial temporal lobe epilepsy: a common disorder identified in twins (Berkovic et al) 1996;40:227
normalization of contralateral metabolic function following temporal lobectomy demonstrated by ^{1}H magnetic resonance spectroscopic imaging (Hugg et al) 1996;40:236
repetitive transcranial magnetic stimulation of the dominant hemisphere can disrupt visual naming as well as speech in temporal lobe epilepsy patients (Wassermann et al) 1996;40:525A
sequential treatment with FGF-2 and BDNF permits the production of new neurons by precursors derived from the adult human epileptic temporal lobe (Pincus et al) 1996;40:550A
Epilepsy, therapy
left vagal nerve stimulation to control refractory epilepsy (Murphy et al) 1996;40:303A
Epithelial cells
expression of markers for both neuronal and glial cells in human amniotic epithelial cells: possible multipotential neural stem cells for transplantation in human brain (Sakuragawa et al) 1996;40:296A
Epstein-Barr virus
acute palsy of the recurrent laryngeal nerve and Epstein-Barr virus infection (Trifiletti et al) 1996;40:326A
Epstein-Barr virus genome is absent in myasthenic thymic tissue (Woolfenden et al) 1996;40:540A
Epstein-Barr virus transformation induces expression of *trk b* messenger RNA in human B lymphocytes (Eggers et al) 1996;40:518A
Epstein-Barr virus–associated acute autonomic neuropathy (Bennett et al) 1996;40:453
Esophagus
esophageal dysfunction in oculopharyngeal muscular dystrophy (Tiomni et al) 1996;40:512A
Estrogen
effects of estrogen on cognitive function in nondemented postmenopausal women (Jacobs et al) 1996;40:502A
Ethanol; *see* **Alcohol, ethyl**
Etoposide
is early complete response in recurrent malignant gliomas treated with cisplatin, VP-16, and vincristine related to anticonvulsants? (Phuphanich et al) 1996;40:490A
recurrent supratentorial gliomas: salvage therapy with oral etoposide (Chamberlain) 1996;40:335A
Evoked potentials, auditory
childhood idiopathic language deterioration: positive treatment responses associated with improved steady state auditory evoked potentials (Stefanatos et al) 1996;40:301A
relationship between electroencephalographic abnormalities and cortical auditory evoked potentials in children with severe language deficits (Mott and Weiss) 1996;40:332A
Exercise
exercise fuel mobilization in mitochondrial myopathy: a metabolic dilemma (Vissing et al) 1996;40:655
oral branched-chain amino acids do not improve exercise capacity in McArdle's disease (Haller et al) 1996;40:541A
Exercise test
ischemic exercise test in pediatric patients (Bruno et al) 1996;40:329A
Exons
congenital myasthenic syndrome with a single nucleotide deletion at the intron/exon boundary in exon 12 of the gene encoding the acetylcholine receptor ϵ subunit (Croxen et al) 1996;40:513A

Experimental allergic encephalomyelitis; *see* **Encephalomyelitis, allergic**
Experimental autoimmune encephalomyelitis; *see* **Encephalomyelitis, autoimmune**
Extracorporeal membrane oxygenation
survivors of neonatal ECMO at early school age: evidence of right cerebral dysfunction (Stanley et al) 1996;40:319A
Eye
topical transconjunctival therapy for typical face pain (Casey) 1996;40:507A
Eye movements
bilateral ptosis and upgaze palsy with right hemispheric lesions (Averbuch-Heller et al) 1996;40:465
"round the houses" sign in progressive supranuclear palsy (Quinn) (Letter); (Leigh) (Reply) 1996;40:951
Eyelids
bilateral ptosis and upgaze palsy with right hemispheric lesions (Averbuch-Heller et al) 1996;40:465

Fabry's disease
cerebrovascular complications of Fabry's disease (Mitsias and Levine) 1996;40:8 (Neurological progress)
Facial expression
discrimination of facial expression in vegetative state. mismatch negativity of visual event-related potential study (Kaga et al) 1996;40:316A
Facial nerve diseases
facial nerve palsy in Kawasaki disease (Bushara et al) 1996;40:329A
Facial pain
topical transconjunctival therapy for typical face pain (Casey) 1996;40:507A
Facial paralysis
Lyme disease presenting as isolated unilateral facial palsy (Cadavid et al) 1996;40:521A
Fasciculation
episodic ataxia and myokymia syndrome: a new mutation of potassium channel gene Kv1.1 (Çomu et al) 1996;40:684
Fatigue
motor unit alterations may contribute to excessive fatigue in patients with amyotrophic lateral sclerosis (Sharma and Miller) 1996;40:514A
Fatty acids
trifunctional enzyme deficiency: adult presentation of a usually fatal β-oxidation defect (Schaefer et al) 1996;40:597
Febrile seizures; *see* **Convulsions, febrile**
Fetal growth retardation
phentolamine pretreatment prevents a component of growth retardation and of inattention induced by prenatal cocaine exposure (Kosofsky et al) 1996;40:315A
three-year follow-up of children with intrauterine growth retardation (Fattal-Valevski et al) 1996;40:322A
Fetus
amniocentesis and fetal brain injury (Squier et al) 1996;40:320A
fetal cocaine exposure and neurological outcome in school-aged children (Chiriboga et al) 1996;40:323A
magnetic resonance imaging findings in an infant with in utero carbon monoxide poisoning (Sum and Hahn) 1996;40:311A
Fibrinogen
fibrinogen is associated with high-grade carotid stenosis and vascular events (Vieira et al) 1996;40:529A
Fibroblast growth factor, basic
sequential treatment with FGF-2 and BDNF permits the production of new neurons by precursors derived from the adult human epileptic temporal lobe (Pincus et al) 1996;40:550A
Fingers
recovery of sympathetic skin responses after digit-to-digit replantation and toe-to-digit transplantation in humans (Chu) 1996;40:67
5-HTP receptors; *see* **Receptors, serotonin**
FK-506
immunosuppressants, immunophilins, and the nervous system (Dawson) 1996;40:559 (Editorial)
immunosuppression-induced leukoencephalopathy from tacrolimus (FK506) (Small et al) 1996;40:575
Flumazenil
benzodiazepine receptors in focal epilepsy with cortical dysgenesis: an ^{11}C-flumazenil PET study (Richardson et al) 1996;40:188
Fluorescence
detection of numerical chromosomal aberrations by fluorescence in situ hybridization in cells from cerebrospinal fluid (van Oostenbrugge et al) 1996;40:492A
Fluorodeoxyglucose
clinical application of thallium 201 single-photon emission-computed tomography and fluorodeoxyglucose-positron emission tomography in childhood brain tumors (Smietana et al) 1996;40:333A
fluorodeoxyglucose positron emission tomography in children and adolescents with frontal lobe epilepsy (Gaillard et al) 1996;40:305A
fluorodeoxyglucose positron emission tomography in pediatric patients with neurofibromatosis type 1 (Molloy et al) 1996;40:325A
usefulness of 18-fluorodeoxyglucose positron emission tomography in pediatric neurology patients (Molloy et al) 1996;40:313A
Focal adhesion kinase; *see* **Kinases**
Focal dystonia; *see* **Dystonia**
Focal epilepsy; *see* **Epilepsy, partial**
Folinic acid; *see* **Leucovorin**
Forebrain; *see* **Prosencephalon**
Free radicals
CNS distribution of free-radical inactivating enzymes in amyotrophic lateral sclerosis (Mitchell et al) (Letter); (Przedborski and Donaldson) (Reply) 1996;40:689
increased brain hydroxyl radical production during reversible focal cerebral ischemia (Solenski et al) 1996;40:526A
Friedreich's ataxia
evidence of genetic heterogeneity within the Friedreich's ataxia phenotype (Christodoulou et al) 1996;40:548A
Friedreich's ataxia mutation does not always result in ataxia (Subramony et al) 1996;40:542A
Frontal lobe epilepsy; *see* **Epilepsy, frontal lobe**

GABA
cerebral glutamate and γ-aminobutyric acid in pediatric epilepsy (Novotny and Rothman) 1996;40:285A
low brain GABA level is associated with poor seizure control (Petroff et al) 1996;40:908
low brain GABA levels remote from the seizure focus are associated with poor seizure control in patients with complex partial epilepsy (Petroff et al) 1996;40:506A
GABA receptors; *see* **Receptors, GABA-benzodiazepine**
Gabapentin
multicenter, randomized, double-blind, comparative dose-

initiation study of gabapentin (CI-945) in adolescents (Pellock et al) 1996;40:287A
outcome of children treated with gabapentin (Hammer and Stack) 1996;40:304A
Galactosylceramides
late-onset Krabbe disease in galactosylceramide β-galactosidase compound heterozygotes (Bernardini et al) 1996;40:300A
multiple mutations in the GALC gene in a patient with adult-onset Krabbe disease (Luzi et al) 1996;40:116
Gamma-aminobutyric acid; *see* **GABA**
Gamma-butyrolactone; *see* **4-Butyrolactone**
Ganciclovir
glioblastoma gene therapy: strategies for optimizing clinical application of the TK/GCV system (Sturtz et al) 1996;40:489A
Ganglia, spinal
HIV infection of dorsal root ganglion neurons detected by polymerase chain reaction–amplified in situ hybridization (Brannagan et al) 1996;40:510A
Ganglioglioma; *see* **Glioma**
Gangliosides
close association of Guillain-Barré syndrome with antibodies to minor monosialogangliosides GM_{1b} and $GM_{1\alpha}$ (Tagawa et al) 1996;40:554A
sensitization with GB_{1b} ganglioside induced ataxic sensory neuropathy in rabbits (Kusunoki et al) 1996;40:551A
Gastrointestinal diseases
mitochondrial neurogastrointestinal encephalomyopathy with multiple deletions of mitochondrial DNA (Collier et al) 1996;40:545A
Gelatinase
interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis (Leppert et al) 1996;40:846
Gender factors
effects of estrogen on cognitive function in nondemented postmenopausal women (Jacobs et al) 1996;40:502A
risk factors for Alzheimer's disease in women (Duara et al) 1996;40:500A
Gene deletion; *see* **Chromosome deletion**
Gene products, Tat
mechanisms of neurotoxicity of the human immunodeficiency virus-1 protein Tat in perinatal rat brain (Wang et al) 1996;40:292A
Gene therapy
interferons are major determinants in efficacy of gene therapy in the neuromuscular system by adenoviral vectors (Acsadi et al) 1996;40:294A
Gene transfer; *see* **Transfection**
Genes
decreased expression of the apoptosis inhibitor Bcl-2 in T cells in the central nervous system in experimental autoimmune encephalomyelitis (Pender et al) 1996;40:552A
exploiting up-regulation of *bcl-2* in the development of targeted strategies for treatment of neural crest cancers: turning adversity into advantage (Schor and Cortazzo) 1996;40:290A
Genes, pX
human T-lymphotropic virus type I–associated myelopathy and tax gene expression in $CD4^+$ T lymphocytes (Moritoyo et al) 1996;40:84
Genetics, biochemical
clinical and molecular genetic features of congenital spinal muscular atrophy (Devriendt et al) 1996;40:731
molecular genetic defect in muscle AMP deaminase deficiency: relationship to phenotype (Sahenk et al) 1996;40:512A
Genomes
autosomal dominant chronic progressive external ophthalmoplegia: a tale of two genomes (Shoubridge) 1996;40:693 (Editorial)
clonal expansion of mitochondrial DNA with multiple deletions in autosomal dominant progressive external ophthalmoplegia (Moslemi et al) 1996;40:707
Genotype
apolipoprotein E genotype in elderly nondemented subjects without senile changes in the brain (Yamada et al) 1996;40:243
cerebral adrenoleukodystrophy (ALD) in only one of monozygotic twins with an identical ALD genotype (Korenke et al) 1996;40:254
Gigantism
neuroimaging features of Sotos syndrome (Schaefer et al) 1996;40:312A
Glial cells; *see* **Neuroglia**
Glioblastoma
glioblastoma gene therapy: strategies for optimizing clinical application of the TK/GCV system (Sturtz et al) 1996;40:489A
Glioma
abducens palsy predicts pathology and outcome in brainstem gliomas (Fisher et al) 1996;40:335A
adjuvant chemotherapy for malignant gliomas: who benefits? (DeAngelis et al) 1996;40:491A
bone metastases with meningeal gliomatosis as a progression from hypothalamic low-grade astrocytoma and complete response by chemotherapy (Johnston et al) 1996;40:489A
diagnosis of glioma with C-11-methionine positron emission tomography (Herholz et al) 1996;40:490A
factors predicting disease control in children with progressive low-grade gliomas treated with carboplatin and vincristine chemotherapy (Packer et al) 1996;40:292A
hemifacial seizures and cerebellar ganglioglioma: an epilepsy syndrome of infancy with seizures of cerebellar origin (Harvey et al) 1996;40:91
is early complete response in recurrent malignant gliomas treated with cisplatin, VP-16, and vincristine related to anticonvulsants? (Phuphanich et al) 1996;40:490A
malignant transformation of cerebral low-grade gliomas in adults: an analysis of risk factors (Dropcho) 1996;40:489A
preoperative localization of speech-related brain areas in glioma patients (Herholz et al) 1996;40:489A
recurrent supratentorial gliomas: salvage therapy with oral etoposide (Chamberlain) 1996;40:335A
scatter factor enhances glioma malignancy (Laterra et al) 1996;40:492A
treatment of diencephalic syndrome with chemotherapy—growth, tumor response, and long-term control (Gropman et al) 1996;40:293A
Globus pallidus
high-frequency pallidal stimulation in Parkinson's disease (Pahwa et al) 1996;40:533A
unilateral stimulation of the globus pallidus internus in Parkinson's disease: bilateral improvement of major symptoms (van der Linden et al) 1996;40:538A
Globus pallidus, surgery
does bradykinesia improve after pallidotomy? (Overby et al) 1996;40:535A

Globus pallidus, surgery (*continued*)
GPi pallidotomy—have we made a dent in Parkinson's disease? (Olanow) 1996;40:341 (Editorial)
levodopa-induced dyskinesias are the main features improved by contralateral pallidotomy in Parkinson's disease: 2-year follow-up (Rabey et al) 1996;40:535A
pallidotomy for medically intractable Parkinson's disease: 2-year follow-up (Vitek et al) 1996;40:488A
posteroventral-medial pallidotomy for late-stage Parkinson's disease: a 2-year follow-up (Lang et al) 1996;40: 538A
postural control in patients with Parkinson's disease after pallidotomy (Roberts-Warrior et al) 1996;40:534A
stereotactic radiosurgical thalamotomy and pallidotomy for treatment of movement disorders (Young et al) 1996;40:537A
treatment of advanced Parkinson's disease by posterior GPi pallidotomy: 1-year results of a pilot study (Baron et al) 1996;40:355 (Expedited publication)
treatment of advanced Parkinson's disease with microelectrode-guided pallidotomy (Lai et al) 1996;40:534A
Glucose
alternating hemiplegia of childhood: clinical findings, brain glucose metabolism, and glucose transport studies (da Silva et al) 1996;40:314A
effects of healthy aging on regional cerebral metabolic rates of glucose: assessment with positron emission tomography and statistical parametric mapping (Petit-Taboué et al) 1996;40:501A
infantile autism: brain glucose metabolism abnormalities (da Silva et al) 1996;40:313A
insulin-like growth factor-I prevents glucotoxicity in Schwann cells (Feldman et al) 1996;40:510A
insulin-like growth factor-I protects sensory neurons from glucotoxicity (Russell and Feldman) 1996;40: 510A
pattern of resting brain glucose utilization (rCMRGlc) in cognitively uncomplicated Parkinson's disease: focusing on cortico-subcortical circuits (Marié et al) 1996;40: 536A
Glutamates
abnormal mRNA leads to downregulation of glutamate transporter EAAT2 (GLT-1) expression in familial amyotrophic lateral sclerosis (Lin et al) 1996;40:540A
aurintricarboxylic acid prevents hypoxia-induced apoptosis: evidence for a mechanism other than interfering with overactivation of the glutamate receptor (Rosenbaum et al) 1996;40:499A
cerebral glutamate and γ-aminobutyric acid in pediatric epilepsy (Novotny and Rothman) 1996;40:285A
deficient glutamate transport is associated with neurodegeneration in Alzheimer's disease (Masliah et al) 1996; 40:759
glial glutamate transporter complementary DNA in patients with amyotrophic lateral sclerosis (Meyer et al) 1996;40:456
nitration of glutamate transporters in transgenic mice with a familial amyotrophic lateral sclerosis-linked SOD1 mutation (Nagano et al) 1996;40:542A
selective inhibitor of monoamine oxidase B (MAO-B) rescues nerve in vivo and protects from glutamate-induced death in vitro (Schwartz and Yoles) 1996;40:495A
Glycogen storage disease type IV
evidence of clinical overlap between Andersen's syndrome and typical long QT syndrome: analysis of 10 patients (Sansone et al) 1996;40:544A
Glycogen storage disease type V
oral branched-chain amino acids do not improve exercise capacity in McArdle's disease (Haller et al) 1996;40: 541A
Glycoproteins
copolymer-1 suppresses the T-cell proliferative response to myelin oligodendrocyte glycoprotein (Milo et al) 1996; 40:551A
muscular dystrophy associated with β-dystroglycan deficiency (Salih et al) 1996;40:925
G(M2) ganglioside
molecular mimicry between cytomegalovirus and GM_2 ganglioside: pathogenesis of Guillain-Barré syndrome (Yuki et al) 1996;40:519A
GPi pallidotomy; *see* **Globus pallidus, surgery**
Growth substances
therapeutic potential of neurotrophic factors for neurological disorders (Yuen and Mobley) 1996;40:346 (Neurological progress)
GTP cyclohydrolase
mutant GTP cyclohydrolase I mRNA levels contribute to dopa-responsive dystonia onset (Hirano et al) 1996;40: 796
three novel mutations in the GTP cyclohydrolase I gene in 3 Japanese families with dopa-responsive dystonia (Ueno et al) 1996;40:537A
Guamanian amyotrophic lateral sclerosis; *see* **Amyotrophic lateral sclerosis**
Guillain-Barré syndrome; *see* **Polyradiculoneuritis**

Hamartoma
ictal single-photon emission computed tomography findings in gelastic seizures secondary to hypothalamic hamartoma (Bebin et al) 1996;40:307A
large kindred with dominantly inherited hypothalamic hamartoma and polydactyly (Allen et al) 1996; 40:309A
Haplotypes
haplotype analysis indicates an independent origin of a Machado-Joseph disease allele in an African-American family (Chabrashvili et al) 1996;40:532A
Head, abnormalities
neurofibromatosis type 1: corpus callosum enlarged beyond megencephaly (Mott et al) 1996;40:325A
value of head ultrasound in infants with macrocephaly (Smith and Maytal) 1996;40:312A
Head injuries
early posttraumatic seizures are more common after nonaccidental head injury than other types of head injury (Gilles) 1996;40:316A
recurrent vomiting following mild head injury is related to migraine (Jan et al) 1996;40:337A
Headache
acetazolamide challenge confirms vascular versus tension headaches (Meyer et al) 1996;40:507A
acetazolamide responsiveness in familial hemiplegic migraine (Athwal and Lennox) (Letter); (Elliott et al) (Reply) 1996;40:820
headache in pediatric human immunodeficiency virus disease (Civitello) 1996;40:310A
orthostatic headaches and diffuse pachymeningeal gadolinium enhancement due to cerebrospinal fluid (CSF) leak but with normal CSF opening pressures (Mokri and Piepgras) 1996;40:506A
Heart defects, congenital
neurodevelopmental status of infants with congenital heart

defects prior to and following open heart surgery (Majnemer et al) 1996;40:289A
prospective clinical study of congenital heart disease in pediatric stroke (Cupido et al) 1996;40:338A
Heart surgery
cerebral near-infrared spectroscopy in children undergoing heart surgery (Wollert and Eckel) (Letter); (du Plessis et al) (Reply) 1996;40:818
prospective study of the effect of open heart surgery on cerebral and ventricular volume in children (Bodensteiner et al) 1996;40:338A
variation in stroke occurrence in cardiac surgical patients (McKhann et al) 1996;40:498A
Hemifacial seizures; *see* **Seizures**
Hemiplegia
acetazolamide responsiveness in familial hemiplegic migraine (Athwal and Lennox) (Letter); (Elliott et al) (Reply) 1996;40:820
alternating hemiplegia of childhood: clinical findings, brain glucose metabolism, and glucose transport studies (da Silva et al) 1996;40:314A
Hemispherectomy; *see* **Brain, surgery**
Hemorrhage
surgical management of superficial siderosis following cervical nerve root avulsion (Tapscott et al) 1996;40:936
Hereditary motor and sensory neuropathies; *see* **Neuropathies, hereditary motor and sensory**
Hereditary neuropathy with liability to pressure palsy; *see* **Neuropathy with pressure palsy, hereditary**
Herpes simplex
presence of herpes simplex DNA in surgical tissue from human epileptic seizure foci detected by polymerase chain reaction (Tourtellotte et al) 1996;40:505A
Heterogeneity
immunogenetics and heterogeneity in multiple sclerosis (Oksenberg) 1996;40:557 (Editorial)
Hippocampus
cyclothiazide-induced hippocampal injury in immature rat brain (Trescher) 1996;40:288A
mesial atrophy and outcome after amygdalohippocampectomy or temporal lobe removal (Arruda et al) 1996;40:446
small focal hippocampal magnetic resonance imaging hyperintensities (Pullicino et al) 1996;40:504A
volumetric magnetic resonance imaging measurements of the hippocampal formation and apolipoprotein E genotypes (Petersen et al) 1996;40:503A
Historical articles
early American professorships in neurology (Goetz and Pappert) 1996;40:258 (History of neurology)
HIV
headache in pediatric human immunodeficiency virus disease (Civitello) 1996;40:310A
HIV infection of dorsal root ganglion neurons detected by polymerase chain reaction–amplified in situ hybridization (Brannagan et al) 1996;40:510A
inducible nitric oxide synthase (iNOS)-like immunoreactivity in human immunodeficiency virus-associated central nervous system disease in children: differential cellular distribution and putative role in HIV-associated neuronopathy (Katsetos et al) 1996;40:310A
psychiatric disorders and cognitive dysfunction in human immunodeficiency virus–infected individuals (Schifitto et al) 1996;40:506A
HIV-1
fragmentation of neocortical neurites in pediatric human immunodeficiency virus-1-associated central nervous system disease: an immunoperoxidase study of tubulin epitopes in postmortem brains (Katsetos et al) 1996;40:309A
HIV-1 DNA in brains in AIDS and pre-AIDS: correlation with the stage of disease (An et al) 1996;40:611
human immunodeficiency virus-1 strain–associated variability in infection of primary neuroglia (McCarthy et al) 1996;40:488A
mechanisms of neurotoxicity of the human immunodeficiency virus-1 protein Tat in perinatal rat brain (Wang et al) 1996;40:292A
visuoconstructive and motor skills in children with vertical human immunodeficiency-1 infection (Preston et al) 1996;40:309A
HLA antigens
differential distribution of HLA alleles in two forms of Guillain-Barré syndrome (Monos et al) 1996;40:521A
Homeostasis
cerebral autoregulation is exhausted in limb-shaking transient ischemic attacks (Baumgartner and Baumgartner) 1996;40:527A
HTLV-I associated myelopathy; *see* **Paraparesis, tropical spastic**
HTLV-II
human T-cell lymphotropic virus type II–associated myelopathy: clinical and immunologic profiles (Lehky et al) 1996;40:714
Human immunodeficiency virus; *see* **HIV**
Human immunodeficiency virus-1; *see* **HIV-1**
Human T-cell lymphotropic virus type II; *see* **HTLV-II**
Huntington's chorea
brain energy metabolism in Huntington's disease measured with in vivo proton magnetic resonance spectroscopy (Martin et al) 1996;40:538A
mapping afferents of rabbit neostriatum: serotonin (anatomical evaluation of rabbit as a potential model of Huntington's disease) (Phelix and Russell) 1996;40:532A
striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease (Weeks et al) 1996;40:49
Hybridization
HIV infection of dorsal root ganglion neurons detected by polymerase chain reaction–amplified in situ hybridization (Brannagan et al) 1996;40:510A
Hydrocarbons
clinical and pathological features in hydrocarbon-induced parkinsonism (Pezzoli et al) 1996;40:922
Hydroxyl radicals; *see* **Free radicals**
Hypertension
maturation increases cerebral nitric oxide synthase activity in spontaneously hypertensive rats by decreasing the K_m for L-arginine (Ashwal et al) 1996;40:317A
Hypertransfusion; *see* **Blood transfusion**
Hyperventilation
accuracy of hyperventilation in predicting the activity of absence seizures (Ahmed and Libenson) 1996;40:308A
Hypomagnesemia; *see* **Magnesium deficiency**
Hypomelanosis of Ito; *see* **Pigmentation disorders**
Hypomyelinating neuropathy, congenital
congenital hypomyelinating neuropathy in two children with long-term follow-up (Phillips et al) 1996;40:328A
Hypothalamic diseases
ictal single-photon emission computed tomography findings in gelastic seizures secondary to hypothalamic hamartoma (Bebin et al) 1996;40:307A
large kindred with dominantly inherited hypothalamic hamartoma and polydactyly (Allen et al) 1996;40:309A

Hypothalamic neoplasms
bone metastases with meningeal gliomatosis as a progression from hypothalamic low-grade astrocytoma and complete response by chemotherapy (Johnston et al) 1996;40:489A
Hypothalamus
chronic stress in infancy results in downregulation of corticotropin-releasing hormone gene expression in the hypothalamus (Gilles and Baram) 1996;40:322A
Hypoxia; *see* **Anoxia**

IgG
IgG subclasses of autoantibodies associated with human paraneoplastic neurological syndromes (Greenlee et al) 1996;40:492A
proteolytic activity in amyotrophic lateral sclerosis IgG preparations (Nyormoi) 1996;40:701
IgM
controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy (Dalakas et al) 1996;40:792
sarcolemmal complement and IgM deposits in immune-mediated myopathies (Spuler and Engel) 1996;40:511A
Immunoassays
immunoassays fail to detect antibodies against neuronal calcium channels in amyotrophic lateral sclerosis serum (Arsac et al) 1996;40:695
Immunoenzyme techniques
fragmentation of neocortical neurites in pediatric human immunodeficiency virus-1-associated central nervous system disease: an immunoperoxidase study of tubulin epitopes in postmortem brains (Katsetos et al) 1996;40:309A
Immunogenetics
immunogenetics and heterogeneity in multiple sclerosis (Oksenberg) 1996;40:557 (Editorial)
Western versus Asian types of multiple sclerosis: immunogenetically and clinically distinct disorders (Kira et al) 1996;40:569
Immunoglobulins
α/β T cells and immunoglobulins protect mice from Theiler's virus–induced encephalitis whereas Class I MHC/$CD8^+$ T cells protect against demyelination (Drescher et al) 1996;40:517A
Lambert-Eaton myasthenic syndrome immunoglobulins react with multiple types of calcium channels in small-cell lung carcinoma (Meriney et al) 1996;40:739
Immunoglobulins, intravenous
comparison of plasma exchange, intravenous immunoglobulin, and plasma exchange followed by intravenous immunoglobulin in the treatment of Guillain-Barré syndrome (Hughes and Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group) 1996;40:551A
controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy (Dalakas et al) 1996;40:792
intravenous immunoglobulin as therapy for pediatric Guillain-Barré syndrome (Abd-Allah et al) 1996;40:330A
lack of efficacy after treatment with intravenous immunoglobulin in pediatric Guillain-Barré syndrome (Smith et al) 1996;40:327A
maintenance immune globulin therapy for multifocal motor neuropathy: results of long-term follow-up (Chaudhry et al) 1996;40:513A
predictors of outcome of the Guillain-Barré syndrome after treatment with high-dose intravenous immune globulins or plasma exchange (Visser et al) 1996;40:511A
Immunophilins
immunosuppressants, immunophilins, and the nervous system (Dawson) 1996;40:559 (Editorial)
Immunosuppression
immunosuppressants, immunophilins, and the nervous system (Dawson) 1996;40:559 (Editorial)
immunosuppression-induced leukoencephalopathy from tacrolimus (FK506) (Small et al) 1996;40:575
progressive encephalomyelitis with rigidity responsive to plasmapheresis and immunosuppression (Fogan) 1996;40:451
Immunotoxins
skeletal muscle–specific immunotoxin for the treatment of focal muscle spasm (Hott et al) 1996;40:539A
In situ hybridization; *see* **Hybridization**
Inattention; *see* **Attention**
Inclusion bodies; *see* **Cellular inclusions**
Indoacetates
indoacetate-induced muscle contracture results from elevated intracellular calcium and increased myofibrillar calcium sensitivity (Ruff and Corsillo) 1996;40:508A
Infant, newborn
acquired brachial plexopathy in neonates: an early sign of osteomyelitis (Sadlier and Connolly) 1996;40:320A
cerebrospinal fluid nitrite/nitrate in normal neonates and those with intraventricular hemorrhage (Filipov et al) 1996;40:324A
cerebrospinal fluid protein tyrosine nitration in neonates: marker of brain NO production (Hills et al) 1996;40:324A
diffusion-weighted magnetic resonance imaging findings in acute neonatal hyperbilirubin encephalopathy (Hahn et al) 1996;40:322A
evolving trends in neonatal intraventricular hemorrhage: a 10-year perspective (Sheth et al) 1996;40:295A
folinic acid-responsive intractable neonatal seizures associated with an unidentified cerebrospinal fluid compound (Torres et al) 1996;40:319A
motor function is preserved after neonatal hemispherectomy by maintenance of primitive bilateral corticospinal projections (Bicknese et al) 1996;40:286A
outcome of neonatal seizures associated with neonatal strokes in term infants (Wong and DeGrauw) 1996;40:287A
short-duration treatment of neonatal seizures: retrospective review of management and outcome (Bergin and Ichord) 1996;40:307A
study of brain adaptation from neonatal to infancy periods using spectral electroencephalographic-sleep analyses (Scher et al) 1996;40:320A
survivors of neonatal ECMO at early school age: evidence of right cerebral dysfunction (Stanley et al) 1996;40:319A
Infant, premature
analysis of variables associated with preterm birth and their predictive value in periventricular leukomalacia (FineSmith et al) 1996;40:322A
dysmaturity index derived from electroencephalographic sleep analyses to document brain adaptation to conditions of prematurity (Scher et al) 1996;40:320A
elevated uric acid levels in the first postnatal day are associated with periventricular hemorrhage and cystic peri-

ventricular leukomalacia in premature infants (Perlman and Risser) 1996;40:321A
Infantile autism; *see* **Autism, infantile**
Infantile spasms; *see* **Spasms, infantile**
Inflammation
circulating soluble CD8 and interleukin-2 receptor levels are measures of disease activity in idiopathic inflammatory myopathies (Okada et al) 1996;40:516A
congenital muscular dystrophy with primary laminin α2 (merosin) deficiency presenting as inflammatory myopathy (Pegoraro et al) 1996;40:782
Inhibitory transcription factor Sp3; *see* **Transcription factor, Sp3**
Injections, spinal
anterior radiculopathy and motor neuron dysfunction after intrathecal methotrexate (Koh et al) 1996;40:334A
Insulin-like growth factor I
early insulin-like growth factor-I treatment reduces clinical deficits and lesion severity in relapses of chronic experimental autoimmune encephalomyelitis (Li et al) 1996;40:514A
insulin-like growth factor-I prevents glucotoxicity in Schwann cells (Feldman et al) 1996;40:510A
insulin-like growth factor-I protects sensory neurons from glucotoxicity (Russell and Feldman) 1996;40:510A
insulin-like growth factor-I stimulates the tyrosine phosphorylation of paxillin and focal adhesion kinase (Leventhal and Feldman) 1996;40:509A
insulin-like growth factor-I stimulates tyrosine phosphorylation of MAP kinases and neurite outgrowth in human neuroblastoma cells (Kim et al) 1996;40:510A
Intensive care
acute myopathy of intensive care: clinical, electromyographic, and pathologic aspects (Lacomis et al) 1996;40:645
Intercellular adhesion molecule-1; *see* **Cell adhesion molecules**
Interferon-alpha
changes induced in interferon-γ–secreting cell number and production by class I interferons (Dayal et al) 1996;40:520A
Interferon-beta
activation/adhesion molecule expression in multiple sclerosis: effect of interferon beta-1b treatment (McRae et al) 1996;40:519A
cerebrospinal fluid abnormalities in a Phase III trial interferon beta-1a (Avonex) for relapsing multiple sclerosis (Rudick et al) 1996;40:516A
changes induced in interferon-γ–secreting cell number and production by class I interferons (Dayal et al) 1996;40:520A
downregulation of VLA-4 on peripheral blood lymphocytes from multiple sclerosis patients treated with interferon beta-1B (Calabresi et al) 1996;40:553A
interferon-β-1b decreases induced nitric oxide production by a human astrocytoma cell line (Mattson and Guthikonda) 1996;40:515A
interferon beta-1a (Avonex) increases cerebrospinal fluid interleukin-10 (Rudick et al) 1996;40:553A
interferon β-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9 (Stüve et al) 1996;40:853
interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis (Leppert et al) 1996;40:846
interferon beta induced interleukin-10 expression: relevance to multiple sclerosis (Rudick et al) 1996;40:618
intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis (Paty and Li) (Letter); (Simon et al) (Reply) 1996;40:951
lack of interferon-β gene expression in virus-infected neuronal cells: implications on virus persistence (Dhib-Jalbut and Xia) 1996;40:494A
multiple sclerosis: effect of clinical disease activity, disability status, and interferon beta-1b treatment on blood and CSF-ICAM-1, tumor necrosis factor receptor, and other immunological parameters (Baumhefner et al) 1996;40:552A
quality of life in low-disability multiple sclerosis patients participating in a Phase III trial of interferon beta-1a for relapsing multiple sclerosis (Cookfair et al) 1996;40:550A
targets for the therapeutic action of interferon-β in multiple sclerosis (Hartung and Kieseier) 1996;40:825 (Editorial)
Interferon-gamma
changes induced in interferon-γ–secreting cell number and production by class I interferons (Dayal et al) 1996;40:520A
Interferons
interferons are major determinants in efficacy of gene therapy in the neuromuscular system by adenoviral vectors (Acsadi et al) 1996;40:294A
Interleukin-2
circulating soluble CD8 and interleukin-2 receptor levels are measures of disease activity in idiopathic inflammatory myopathies (Okada et al) 1996;40:516A
production of and response to interleukin-2 by cultured lymphocytes from patients with Guillain-Barré syndrome (Yoshii et al) 1996;40:541A
Interleukin-10
interferon beta-1a (Avonex) increases cerebrospinal fluid interleukin-10 (Rudick et al) 1996;40:553A
interferon beta induced interleukin-10 expression: relevance to multiple sclerosis (Rudick et al) 1996;40:618
Intermediate filaments
neurofilament gene expression in experimental diabetes (Scott et al) 1996;40:514A
Internal carotid artery diseases; *see* **Carotid artery diseases**
Interobserver variation; *see* **Observer variation**
Intracerebral hemorrhage; *see* **Cerebral hemorrhage**
Intrathecal injections; *see* **Injections, spinal**
Intrauterine growth retardation; *see* **Fetal growth retardation**
Intravascular pressure; *see* **Blood pressure**
Intravenous immunoglobulins; *see* **Immunoglobulins, intravenous**
Intraventricular hemorrhage; *see* **Cerebral hemorrhage**
Ischemia
ischemic exercise test in pediatric patients (Bruno et al) 1996;40:329A
neuroprotection by rasagiline mesylate (TVP-1012) in experimental models of hypoxia and ischemia (Speiser et al) 1996;40:495A
peroxynitrite-mediated oxidative injury in optic nerve ischemia (Guy et al) 1996;40:496A
propentofylline protects rat brain from complete ischemia without adenosine receptor function (Haida et al) 1996;40:493A
spontaneous neurological recovery after stroke and the fate of the ischemic penumbra (Furlan et al) 1996;40:216-26
Ischemic stroke; *see* **Cerebrovascular disorders**

Japan
clinical phenotype of two missense mutations in the presenilin I gene in Japanese patients (Ikeda et al) 1996; 40:912
Jaundice, neonatal
diffusion-weighted magnetic resonance imaging findings in acute neonatal hyperbilirubin encephalopathy (Hahn et al) 1996;40:322A
Joubert syndrome
"Joubert syndrome": a rhombencephalic segmentation anomaly (Maria et al) 1996;40:297A
Juvenile diabetes mellitus; *see* **Diabetes mellitus, insulin-dependent**

Kainic acid
neuroprotective effects of adrenalectomy in the kainic acid model of limbic status epilepticus in adult rat (Dure et al) 1996;40:287A
Kawasaki disease; *see* **Mucocutaneous lymph node syndrome**
Kernicterus
diffusion-weighted magnetic resonance imaging findings in acute neonatal hyperbilirubin encephalopathy (Hahn et al) 1996;40:322A
Ketone bodies
observation of cerebral ketone bodies by proton nuclear magnetic resonance spectroscopy (Novotny and Rothman) 1996;40:285A
Ketones
complications of the ketogenic diet (Ballaban-Gil et al) 1996;40:307A
electroencephalographic analysis in the ketogenic diet (Demeritte et al) 1996;40:305A
ketogenic diet in children with medically resistant epilepsy (Resnick et al) 1996;40:302A
multi-center study of the efficacy of the ketogenic diet (The Johns Hopkins Medical Institutions et al) 1996; 40:300A
organic acid disorders and the ketogenic diet (Demeritte et al) 1996;40:305A
Kinases
aberrant expression of cyclin-dependent kinases in myofibrillary myopathy with abnormal foci of desmin positivity: analysis of 8 cases (Nakano et al) 1996;40:508A
insulin-like growth factor-I stimulates the tyrosine phosphorylation of paxillin and focal adhesion kinase (Leventhal and Feldman) 1996;40:509A
insulin-like growth factor-I stimulates tyrosine phosphorylation of MAP kinases and neurite outgrowth in human neuroblastoma cells (Kim et al) 1996;40:510A
Krabbe disease; *see* **Leukodystrophy, globoid cell**
Kuru
prion-containing Kuru-like plaques in familial Alzheimer-like disease with concomitant β/A4 amyloid–containing plaques and a single mutation in the presenilin 1 gene (Kuljis et al) 1996;40:503A

Lactams
γ-butyrolactones and lactams: a new class of anticonvulsants (Rothman et al) 1996;40:286A
Lactates
proton magnetic resonance spectroscopy-determined cerebral lactate is associated with poor neurologic outcomes in children with central nervous system disease (Ashwal et al) 1996;40:314A
Lambert-Eaton myasthenic syndrome
factors leading to diagnostic delay of the Lambert-Eaton myasthenic syndrome (Jones et al) 1996;40:542A
Lambert-Eaton myasthenic syndrome immunoglobulins react with multiple types of calcium channels in small-cell lung carcinoma (Meriney et al) 1996;40:739
Laminin
congenital muscular dystrophy with primary laminin α2 (merosin) deficiency presenting as inflammatory myopathy (Pegoraro et al) 1996;40:782
Lamotrigine
outcome of children treated with lamotrigine (Hammer and Stack) 1996;40:304A
Landau-Kleffner syndrome; *see* **Aphasia**
Language; *see also* **Speech**
language cortex representation: effects of developmental versus acquired pathology (Duchowny et al) 1996;40:31
language processing in the dominant cerebral hemisphere inhibits transcallosal activity (Karbe et al) 1996;40: 525A
Language disorders
childhood idiopathic language deterioration: positive treatment responses associated with improved steady state auditory evoked potentials (Stefanatos et al) 1996;40: 301A
comorbidity of developmental language disorders and cognitive dysfunction (Gross-Tsur et al) 1996;40:338A
interobserver variability of single-photon emission computed tomography scan interpretation in children with language regression (Yaylali et al) 1996;40:311A
prolonged electroencephalographic monitoring findings in children with pervasive developmental disorder and regression (Villalobos et al) 1996;40:300A
relationship between electroencephalographic abnormalities and cortical auditory evoked potentials in children with severe language deficits (Mott and Weiss) 1996; 40:332A
sleep and amitriptyline enhance the sensitivity of electroencephalograms in children with a pervasive developmental disorder and language regression (Kollros et al) 1996;40:303A
speech and language disabilities in association with parietotemporal white matter abnormalities in hypomelanosis of Ito: an anatomical substrate for a behavioral phenotype? (Ruggieri et al) 1996;40:312A
Laryngeal nerves
acute palsy of the recurrent laryngeal nerve and Epstein-Barr virus infection (Trifiletti et al) 1996;40:326A
Lazabemide
effect of lazabemide on the progression of disability in early Parkinson's disease (The Parkinson Study Group) 1996;40:99
Learning disorders
magnetic resonance imaging morphometric indices as predictive markers for learning disabilities in children with neurofibromatosis-1 (Said et al) 1996;40:324A
Leber optic neuropathy; *see* **Optic atrophy, hereditary**
Leigh disease
deficiency of respiratory chain complex I is a common cause of Leigh disease (Morris et al) 1996;40:25
genetic heterogeneity in Leigh syndrome (DiMauro and De Vivo) 1996;40:5 (Editorial)
Leksell gamma knife; *see* **Radiosurgery**
Lennox-Gastaut syndrome
efficacy of toprimate in Lennox-Gastaut syndrome (Kugler et al) 1996;40:303A

epidemiology of Lennox-Gastaut syndrome and multiple seizure types in Atlanta children (Trevathan et al) 1996; 40:301A

Leprosy
leprous neuropathy—clinical, histopathological, and electrophysiological correlation in 40 patients (Anand et al) 1996;40:543A

Leptomeninges; *see* **Arachnoid**

Leucovorin
folinic acid-responsive intractable neonatal seizures associated with an unidentified cerebrospinal fluid compound (Torres et al) 1996;40:319A

Leukocytes, mononuclear
deficient expression in multiple sclerosis of the inhibitory transcription factor Sp3 in mononuclear blood cells (Grekova et al) 1996;40:108

Leukodystrophy, globoid cell
Krabbe disease: proton magnetic resonance spectroscopy findings (Moore et al) 1996;40:299A
late-onset Krabbe disease in galactosylceramide β-galactosidase compound heterozygotes (Bernardini et al) 1996; 40:300A
multiple mutations in the GALC gene in a patient with adult-onset Krabbe disease (Luzi et al) 1996;40:116

Leukoencephalopathy
cerebral autosomal dominant arteriopathy with subcortical infarctions and leukoencephalopathy in context: data from two Scottish pedigrees (de Silva et al) 1996;40: 531A
immunosuppression-induced leukoencephalopathy from tacrolimus (FK506) (Small et al) 1996;40:575

Leukomalacia, periventricular
analysis of variables associated with preterm birth and their predictive value in periventricular leukomalacia (FineSmith et al) 1996;40:322A
elevated uric acid levels in the first postnatal day are associated with periventricular hemorrhage and cystic periventricular leukomalacia in premature infants (Perlman and Risser) 1996;40:321A
placental abnormalities: insights into pathogenesis of cystic periventricular leukomalacia (Roland et al) 1996;40: 321A

Levodopa
deprenyl and levodopa and Parkinson's disease progression (Fowler et al) 1996;40:267 (Letter)
levodopa-induced dyskinesias are the main features improved by contralateral pallidotomy in Parkinson's disease: 2-year follow-up (Rabey et al) 1996;40:535A
long-term follow-up of levodopa responsiveness in generalized dystonia (Dewey et al) 1996;40:537A
mutant GTP cyclohydrolase I mRNA levels contribute to dopa-responsive dystonia onset (Hirano et al) 1996;40: 796
three novel mutations in the GTP cyclohydrolase I gene in 3 Japanese families with dopa-responsive dystonia (Ueno et al) 1996;40:537A

Lewy body disease; *see* **Parkinson's disease**

Limb-shaking; *see* **Movement disorders**

Linkage
confirmation of linkage of oculopharyngeal muscular dystrophy to chromosome 14q11.2-q13 (Stajich et al) 1996;40:801

Linkage mapping; *see* **Chromosome mapping**

Lipodystrophy, intestinal
diagnostic guidelines in central nervous system Whipple's disease (Louis et al) 1996;40:537A, 1996;40:561 (Neurological progress)
polymerase chain reaction–based detection of *Tropheryma whippelii* in central nervous system Whipple's disease (Lynch et al) 1996;40:535A

Lipoproteins, VLDL
lack of association of very low density lipoprotein receptor gene polymorphism with caucasian Alzheimer's disease (Okuizumi et al) 1996;40:251

Lipoxygenase
long-term elevation of cyclooxygenase-2, but not lipoxygenase, in regions synaptically distant from spreading depression (Caggiano et al) 1996;40:547A

Lissencephaly; *see* **Brain, abnormalities**

Liver transplantation
acute neuromuscular disease following liver transplantation: a prospective study (Campellone et al) 1996;40: 509A
causes and outcome of seizures in liver transplant recipients (Wijdicks et al) 1996;40:505A

Long QT syndrome
evidence of clinical overlap between Andersen's syndrome and typical long QT syndrome: analysis of 10 patients (Sansone et al) 1996;40:544A

Lung neoplasms
motor neuron disease: a paraneoplastic process associated with anti-Hu antibody and small-cell lung carcinoma (Verma et al) 1996;40:112

Lupus erythematosus, systemic
extrapyramidal parkinsonism syndrome complicating systemic lupus erythematosus (Shahar et al) 1996;40:336A

Lyme disease
cerebrospinal fluid culture positive for North American Lyme meningitis (Coyle et al) 1996;40:494A
Lyme disease presenting as isolated unilateral facial palsy (Cadavid et al) 1996;40:521A

Lymphocytes
downregulation of VLA-4 on peripheral blood lymphocytes from multiple sclerosis patients treated with interferon beta-1B (Calabresi et al) 1996;40:553A
production of and response to interleukin-2 by cultured lymphocytes from patients with Guillain-Barré syndrome (Yoshii et al) 1996;40:541A

Lymphocytic choriomeningitis virus
congenital lymphocytic choriomeningitis virus infection: a disorder closely mimicking congenital toxoplasmosis and cytomegalovirus infection (Wright et al) 1996;40: 319A

Lymphoma
long-term survival in primary central nervous system lymphoma (Abrey et al) 1996;40:491A

Lymphoma, non-Hodgkin's
reversible magnetic resonance imaging lesions due to pegapargase treatment of non-Hodgkin's lymphoma (Bushara and Rust) 1996;40:317A

Lymphoproliferative disorders
lymphoproliferative disorders and motor neuron disease (Gordon et al) 1996;40:544A

Machado-Joseph disease; *see* **Spinocerebellar degeneration**

Macrocephaly; *see* **Head, abnormalities**

Magnesium deficiency
familial hypomagnesemia with seizures, migraine, and stroke-like events (Selcen et al) 1996;40:336A

Magnetic resonance imaging
clinical utility of diffusion-weighted magnetic resonance imaging in pediatric population (Kothare et al) 1996; 40:295A

Magnetic resonance imaging (*continued*)
cognitive and brain magnetic resonance imaging findings in adrenomyeloneuropathy (Edwin et al) 1996;40:675
diffusion-weighted magnetic resonance imaging findings in acute neonatal hyperbilirubin encephalopathy (Hahn et al) 1996;40:322A
effect of copolymer 1 on serial gadolinium-enhanced magnetic resonance scans in relapsing multiple sclerosis (Mancardi et al) 1996;40:521A
functional magnetic resonance imaging of the brain without magnetic susceptibility artifact (Edelman et al) 1996;40:524A
functional MRI of lateral occipitotemporal cortex during pursuit and motion perception (Barton et al) 1996;40:387
high-resolution three-dimensional T_1-weighted gradient echo sequence improves the detection of disease activity in multiple sclerosis (Filippi et al) 1996;40:901
magnetic resonance evaluation in children with new onset of seizure (Klug et al) 1996;40:304A
magnetic resonance imaging findings in an infant with in utero carbon monoxide poisoning (Sum and Hahn) 1996;40:311A
magnetic resonance imaging morphometric indices as predictive markers for learning disabilities in children with neurofibromatosis-1 (Said et al) 1996;40:324A
magnetic source imaging and the neural basis of dyslexia (Poeppel and Rowley) 1996;40:137 (Editorial)
misleading magnetic resonance angiography in patients with posterior circulation occlusive disease (Belden et al) 1996;40:498A
orthostatic headaches and diffuse pachymeningeal gadolinium enhancement due to cerebrospinal fluid (CSF) leak but with normal CSF opening pressures (Mokri and Piepgras) 1996;40:506A
pediatric presentation of congenital bilateral perisylvian syndrome: clinical and magnetic resonance imaging findings (Gropman et al) 1996;40:337A
perivascular spaces in pediatric brain magnetic resonance imaging: frequency, variation, clinical significance (Richards and Morse) 1996;40:336A
reduction of lesion volume in human stroke by citicoline detected by diffusion weighted magnetic resonance imaging: a pilot study (Warach et al) 1996;40:527A
reversible magnetic resonance imaging lesions due to pegapargase treatment of non-Hodgkin's lymphoma (Bushara and Rust) 1996;40:317A
role of magnetic resonance imaging in the evaluation of unexplained mononeuropathy in children and adolescents (Weig and McAvoy) 1996;40:326A
small focal hippocampal magnetic resonance imaging hyperintensities (Pullicino et al) 1996;40:504A
volumetric magnetic resonance imaging measurements of the hippocampal formation and apolipoprotein E genotypes (Petersen et al) 1996;40:503A
X-linked spastic paraplegia: clinical features, magnetic resonance imaging, and molecular studies (Morse and Carrier) 1996;40:313A

Magnetic stimulation
decreased excitability of human motor cortex induced by transcranial magnetic stimulation at 0.9 Hz (Cohen et al) 1996;40:524A
effects of antiepileptic drugs on motor cortex excitability in humans: a transcranial magnetic stimulation study (Ziemann et al) 1996;40:367
repetitive transcranial magnetic stimulation of the dominant hemisphere can disrupt visual naming as well as speech in temporal lobe epilepsy patients (Wassermann et al) 1996;40:525A
speech-induced changes in corticospinal excitability (Tokimura et al) 1996;40:628
transcranial magnetic stimulation: a useful tool for clinical neurophysiology (Hallett) 1996;40:344 (Editorial)

Magnetoencephalography
impaired visual word processing in dyslexia revealed with magnetoencephalography (Salmelin et al) 1996;40:157
magnetic source imaging and the neural basis of dyslexia (Poeppel and Rowley) 1996;40:137 (Editorial)

Major histocompatibility complex
α/β T cells and immunoglobulins protect mice from Theiler's virus–induced encephalitis whereas Class I MHC/$CD8^+$ T cells protect against demyelination (Drescher et al) 1996;40:517A
Class I MHC and/or $CD8^+$ T cells are necessary for clinical deficits in a mouse model of multiple sclerosis (Rivera-Quinones et al) 1996;40:517A

MAP kinase; *see* **Kinases**

Marburg multiple sclerosis; *see* **Multiple sclerosis**

Marchiafava-Bignami disease
new insights into the pathophysiology of Marchiafava-Bignami disease using proton magnetic resonance spectroscopy (Nicoli et al) 1996;40:524A

Mass screening
toward a "7-minute" screening battery sensitive to Alzheimer's disease (Solomon et al) 1996;40:502A

Maturation; *see* **Age factors**

McArdle's disease; *see* **Glycogen storage disease type V**

Medulloblastoma
neurotrophin-3 receptor activation induces apoptosis of a medulloblastoma cell line (Sutton et al) 1996;40:291A
what constitutes standard treatment for children older than 3 years of age with nondisseminated medulloblastoma? (Packer et al) 1996;40:291A

Megencephaly; *see* **Head, abnormalities**

Melanoma
leptomeningeal metastases due to melanoma: combined-modality therapy (Chamberlain and Kormanik) 1996;40:490A

MELAS syndrome
MELAS associated with a mutation in the valine transfer RNA gene of mitochondrial DNA (Taylor et al) 1996;40:459
mitochondrial DNA and RNA processing in MELAS (Kaufmann et al) 1996;40:172
mitochondrial encephalopathy with infantile onset and multiple symmetrical infarcts (Gingold et al) 1996;40:309A

Memory disorders; *see also specific disorders*
complex memory impairments in autism: evidence of cortical dysfunction (Minshew et al) 1996;40:333A
effect of methylphenidate in the postradiation attention and memory deficits in children (Torres et al) 1996;40:331A

Meningeal neoplasms
bone metastases with meningeal gliomatosis as a progression from hypothalamic low-grade astrocytoma and complete response by chemotherapy (Johnston et al) 1996;40:489A

Meningitis
carcinomatous meningitis secondary to breast cancer: combined-modality therapy (Chamberlain and Kormanik) 1996;40:490A

cerebrospinal fluid culture positive for North American Lyme meningitis (Coyle et al) 1996;40:494A
Mental disorders
psychiatric disorders and cognitive dysfunction in human immunodeficiency virus–infected individuals (Schifitto et al) 1996;40:506A
Mental status; *see* **Cognition**
Merosin
congenital muscular dystrophy with primary laminin α2 (merosin) deficiency presenting as inflammatory myopathy (Pegoraro et al) 1996;40:782
immunogold and freeze etch electron microscopic studies of merosin localization in basal lamina of human skeletal muscle fibers (Wakayama et al) 1996;40:511A
merosin-deficient congenital muscular dystrophy associated with normal central myelination and prolonged motor nerve conductions (Acsadi et al) 1996;40:330A
normal peripheral nerve myelination in merosin(-) congenital muscular dystrophy (Edgar et al) 1996;40:329A
Messenger RNA; *see* **RNA, messenger**
Metalloproteinases
interferon β-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9 (Stüve et al) 1996;40:853
matrix metalloprotease inhibitor is effective in treatment of chronic relapsing murine experimental allergic encephalomyelitis (Liedtke et al) 1996;40:515A
Methotrexate
anterior radiculopathy and motor neuron dysfunction after intrathecal methotrexate (Koh et al) 1996;40:334A
2-Methyl, 3-hydroxy butyric acid
case of 2-methyl, 3-hydroxy butyryl-CoA dehydrogenase deficiency (Sansaricq et al) 1996;40:318A
Methylglutaconic acid
3-methylglutaconic aciduria: a new etiology of cerebral palsy (Straussberg et al) 1996;40:298A
Methylphenidate
effect of methylphenidate in the postradiation attention and memory deficits in children (Torres et al) 1996;40:331A
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
progressive choreic and dystonic dyskinesias induced by a D1 agonist in nonprimed MPTP-treated primates (Papa et al) 1996;40:535A
Methylsalsolinol
dopaminergic neurotoxin, (*R*)-N-methylsalsolinol, increases in parkinsonian cerebrospinal fluid (Maruyama et al) 1996;40:119
Microelectrodes
treatment of advanced Parkinson's disease with microelectrode-guided pallidotomy (Lai et al) 1996;40:534A
Microglia
expression of the urokinase plasminogen activator in adult human CNS microglial cells (Dore-Duffy et al) 1996;40:516A
Microscopy, electron
immunogold and freeze etch electron microscopic studies of merosin localization in basal lamina of human skeletal muscle fibers (Wakayama et al) 1996;40:511A
Migraine
acetazolamide responsiveness in familial hemiplegic migraine (Athwal and Lennox) (Letter); (Elliott et al) (Reply) 1996;40:820
familial hypomagnesemia with seizures, migraine, and stroke-like events (Selcen et al) 1996;40:336A
recurrent vomiting following mild head injury is related to migraine (Jan et al) 1996;40:337A
summary of the efficacy of 311C90: a new acute treatment for migraine (Klein) 1996;40:506A
Miller-Dieker lissencephaly; *see* **Brain, abnormalities**
Mini-Mental State Examination
further studies validating the Severe Mini-Mental State Examination for use in severely impaired Alzheimer's patients (Harrell et al) 1996;40:500A
Missense mutation; *see* **Mutation**
Mitochondria
exercise fuel mobilization in mitochondrial myopathy: a metabolic dilemma (Vissing et al) 1996;40:655
mitochondria . . . 1989–1996 (Schapira) 1996;40:487A
mitochondrial encephalomyopathy in discordant triplets (Johns et al) 1996;40:532A
stroke in four girls with nosologically overlapping mitochondrial disease (Al-Yamani et al) 1996;40:338A
Mitochondrial DNA; *see* **DNA, mitochondrial**
Modafinil
new alternative in the pharmacological management of somnolence: a Phase III study of modafinil in narcolepsy (Fry) 1996;40:493A
Molecular genetics; *see* **Genetics, biochemical**
Monoamine oxidase inhibitors
effect of lazabemide on the progression of disability in early Parkinson's disease (The Parkinson Study Group) 1996;40:99
selective inhibitor of monoamine oxidase B (MAO-B) rescues nerve in vivo and protects from glutamate-induced death in vitro (Schwartz and Yoles) 1996;40:495A
Monoclonal gammopathies; *see* **Paraproteinemias**
Mononeuropathy; *see* **Peripheral nerve diseases**
Mononuclear leukocytes; *see* **Leukocytes, mononuclear**
Monosialogangliosides; *see* **Gangliosides**
Mortality; *see* **Death**
Mosaicism
somatic mosaicism in the central nervous system in spinocerebellar ataxia type 1 and Machado-Joseph disease (Lopes-Cendes et al) 1996;40:199
Motion
functional MRI of lateral occipitotemporal cortex during pursuit and motion perception (Barton et al) 1996;40:387
Motor activity
motor function is preserved after neonatal hemispherectomy by maintenance of primitive bilateral corticospinal projections (Bicknese et al) 1996;40:286A
Motor cortex
decreased excitability of human motor cortex induced by transcranial magnetic stimulation at 0.9 Hz (Cohen et al) 1996;40:524A
detection of motor cortex activation in paralytic amyotrophic lateral sclerosis patients without apparent muscle contraction (Shinohara et al) 1996;40:547A
effects of antiepileptic drugs on motor cortex excitability in humans: a transcranial magnetic stimulation study (Ziemann et al) 1996;40:367
speech-induced changes in corticospinal excitability (Tokimura et al) 1996;40:628
transcranial magnetic stimulation: a useful tool for clinical neurophysiology (Hallett) 1996;40:344 (Editorial)
Motor neuron disease
computerized testing of cognitive function in motor neuron disease: evidence of attention deficit (Chari et al) 1996;40:525A
lymphoproliferative disorders and motor neuron disease (Gordon et al) 1996;40:544A

Motor neuron disease (*continued*)
motor neuron disease: a paraneoplastic process associated with anti-Hu antibody and small-cell lung carcinoma (Verma et al) 1996;40:112
Motor neurons
acute motor axonal neuropathy: an antibody-mediated attack on axolemma (Hafer-Macko et al) 1996;40:635
altered expression of *bcl-2* and *bax* mRNA in amyotrophic lateral sclerosis spinal cord motor neurons (Mu et al) 1996;40:379
biopsy findings link multifocal motor neuropathy to chronic inflammatory demyelinating polyneuropathy (Krendel) (Letter); (Corse et al) (Reply) 1996;40:948
selective resistance of extraocular motoneuron terminals to effects of sera from patients with amyotrophic lateral sclerosis (Mosier et al) 1996;40:532A
sequence variants in human neurofilament proteins: absence of linkage to familial amyotrophic lateral sclerosis (Vechio et al) 1996;40:603
Motor skills
visuoconstructive and motor skills in children with vertical human immunodeficiency-1 infection (Preston et al) 1996;40:309A
Movement disorders; *see also specific disorders*
cerebral autoregulation is exhausted in limb-shaking transient ischemic attacks (Baumgartner and Baumgartner) 1996;40:527A
cortical myoclonus in Angelman syndrome (Guerrini et al) 1996;40:39
does bradykinesia improve after pallidotomy? (Overby et al) 1996;40:535A
levodopa-induced dyskinesias are the main features improved by contralateral pallidotomy in Parkinson's disease: 2-year follow-up (Rabey et al) 1996;40:535A
progressive choreic and dystonic dyskinesias induced by a D1 agonist in nonprimed MPTP-treated primates (Papa et al) 1996;40:535A
specific movement deficit due to focal lesion of the inferior cerebellar vermis in children (Bastian et al) 1996;40:317A
stereotactic radiosurgical thalamotomy and pallidotomy for treatment of movement disorders (Young et al) 1996;40:537A
MPTP; *see* **1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine**
Mucocutaneous lymph node syndrome
facial nerve palsy in Kawasaki disease (Bushara et al) 1996;40:329A
Multifocal motor neuropathy
maintenance immune globulin therapy for multifocal motor neuropathy: results of long-term follow-up (Chaudhry et al) 1996;40:513A
Multiple sclerosis, analysis
acute multiple sclerosis (Marburg type) is associated with developmentally immature myelin basic protein (Wood et al) 1996;40:18
possible role for altered myelin basic protein in multiple sclerosis (Whitaker and Mitchell) 1996;40:3 (Editorial)
sequence of mitochondrial DNA in patients with multiple sclerosis (Chalmers et al) 1996;40:239
urinary myelin basic protein-like material as a correlate of the progression of multiple sclerosis (Giovannoni et al) (Letter); (Whitaker et al) (Reply) 1996;40:128
Multiple sclerosis, cerebrospinal fluid
cerebrospinal fluid abnormalities in a Phase III trial interferon beta-1a (Avonex) for relapsing multiple sclerosis (Rudick et al) 1996;40:516A
Multiple sclerosis, classification
worsening on DSS is not a useful entry criterion for multiple sclerosis clinical trials to prevent progression (Myers et al) 1996;40:552A
Multiple sclerosis, diagnosis
guidelines to avoid errors in the diagnosis of multiple sclerosis (Katzan and Rudick) 1996;40:554A
Multiple sclerosis, drug therapy
effect of copolymer 1 on serial gadolinium-enhanced magnetic resonance scans in relapsing multiple sclerosis (Mancardi et al) 1996;40:521A
humoral responses to copolymer 1 in multiple sclerosis patients: preferential production of IgG1 over IgG2 (Brenner et al) 1996;40:518A
safety profile of copolymer 1 in multiple sclerosis (Korczyn and Nisipeanu) 1996;40:517A
Multiple sclerosis, etiology
search for retrovirus in patients with multiple sclerosis (Hackett et al) 1996;40:805
Multiple sclerosis, genetics
deficient expression in multiple sclerosis of the inhibitory transcription factor Sp3 in mononuclear blood cells (Grekova et al) 1996;40:108
discordance of the myelin basic protein gene in familial multiple sclerosis (Rose et al) 1996;40:520A
immunogenetics and heterogeneity in multiple sclerosis (Oksenberg) 1996;40:557 (Editorial)
Western versus Asian types of multiple sclerosis: immunogenetically and clinically distinct disorders (Kira et al) 1996;40:569
Multiple sclerosis, immunology
Class I MHC and/or $CD8^+$ T cells are necessary for clinical deficits in a mouse model of multiple sclerosis (Rivera-Quinones et al) 1996;40:517A
downregulation of VLA-4 on peripheral blood lymphocytes from multiple sclerosis patients treated with interferon beta-1B (Calabresi et al) 1996;40:553A
multiple sclerosis: effect of clinical disease activity, disability status, and interferon beta-1b treatment on blood and CSF-ICAM-1, tumor necrosis factor receptor, and other immunological parameters (Baumhefner et al) 1996;40:552A
T-cell reactivity to peptides of proteolipid protein and myelin basic protein in multiple sclerosis (Pender et al) 1996;40:552A
T-cell receptor (TCR) peptide immunization in multiple sclerosis boosts TCR-specific Th2 cells and suppresses MBP-specific Th1 cells: report of a double-blind, placebo-controlled pilot trial (Bourdette et al) 1996;40:518A
Multiple sclerosis, pathology
cerebral atrophy in multiple sclerosis: a neglected but important phenomenon (Losseff et al) 1996;40:531A
evidence of platelet activation in multiple sclerosis (Kolodny et al) 1996;40:520A
high-resolution three-dimensional T_1-weighted gradient echo sequence improves the detection of disease activity in multiple sclerosis (Filippi et al) 1996;40:901
mechanism of $\gamma\Delta$ T-cell cytotoxicity in multiple sclerosis (Zeine et al) 1996;40:555A
oligodendrocyte loss and preservation in early multiple sclerosis (Lucchinetti et al) 1996;40:522A
Western versus Asian types of multiple sclerosis: immunogenetically and clinically distinct disorders (Kira et al) 1996;40:569

Multiple sclerosis, physiopathology
diversity and plasticity of self-determinant recognition during the early development of multiple sclerosis (Tuohy et al) 1996;40:519A
quality of life in low-disability multiple sclerosis patients participating in a Phase III trial of interferon beta-1a for relapsing multiple sclerosis (Cookfair et al) 1996; 40:550A
Multiple sclerosis, therapy
activation/adhesion molecule expression in multiple sclerosis: effect of interferon beta-1b treatment (McRae et al) 1996;40:519A
clinical outcomes assessment in multiple sclerosis (Rudick et al) 1996;40:469 (Special report)
interferon beta-1a (Avonex) increases cerebrospinal fluid interleukin-10 (Rudick et al) 1996;40:553A
interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis (Leppert et al) 1996;40:846
interferon beta induced interleukin-10 expression: relevance to multiple sclerosis (Rudick et al) 1996;40:618
intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis (Paty and Li) (Letter); (Simon et al) (Reply) 1996;40:951
targets for the therapeutic action of interferon-β in multiple sclerosis (Hartung and Kieseier) 1996;40:825 (Editorial)
Multiple seizure types; *see* **Seizures**
Multiple system atrophy
decreased striatal monoaminergic terminals in olivopontocerebellar atrophy and multiple system atrophy demonstrated with positron emission tomography (Gilman et al) 1996;40:885
differences between multiple system atrophy and olivopontocerebellar atrophy (Quinn and Daniel) (Letter); (Sima and Lynch) (Reply) 1996;40:945
Muscle, analysis
diagnostic utility of the nerve-muscle-skin biopsy in pediatric neurology practice (Miller et al) 1996;40:328A
Muscle, injuries
subnecrotic doses of calcium ionophore injury induce apoptosis of differentiated skeletal muscle (Abu-Shakra et al) 1996;40:495A
Muscle contraction
indoacetate-induced muscle contracture results from elevated intracellular calcium and increased myofibrillary calcium sensitivity (Ruff and Corsillo) 1996;40:508A
Muscle fiber
impact of changes in muscle fiber length on membrane excitability near and away from the end-plate (Ruff) 1996;40:509A
Muscle rigidity
progressive encephalomyelitis with rigidity responsive to plasmapheresis and immunosuppression (Fogan) 1996; 40:451
Muscle spasticity
botulinum toxin is a safe and effective treatment for children with dystonias and spasticity and in some cases obviates the need for surgical intervention (Latimer and Jabbari) 1996;40:331A
clinical outcomes of botulinum toxin use in children with spasticity (Tilton et al) 1996;40:315A
skeletal muscle–specific immunotoxin for the treatment of focal muscle spasm (Hott et al) 1996;40:539A
Muscular atrophy, spinal
clinical and molecular genetic features of congenital spinal muscular atrophy (Devriendt et al) 1996;40:731
linkage of scapuloperoneal spinal muscular atrophy to chromosome 12q24.1-q24.31 (Isozumi et al) 1996;40: 541A
molecular basis of phenotypic heterogeneity in siblings with spinal muscular atrophy (Parano et al) 1996;40: 247
molecular characterization of gene deletions in families with spinal muscular atrophy and intrafamilial phenotypic variations (Wang et al) 1996;40:293A
polymerase chain reaction assay for detection of spinal muscular atrophy heterozygotes (Berry-Kravis et al) 1996;40:294A
Muscular diseases; *see also specific diseases*
acute myopathy of intensive care: clinical, electromyographic, and pathologic aspects (Lacomis et al) 1996; 40:645
apolipoprotein E alleles in sporadic inclusion-body myositis and hereditary inclusion-body myopathy (Askanas et al) (Letter); (Garlepp and Mastaglia) (Reply) 1996;40: 264
apolipoprotein E and apolipoprotein E messenger RNA in muscle of inclusion body myositis and myopathies (Mirabella et al) 1996;40:864
apolipoprotein E and inclusion body myositis (Garlepp and Mastaglia) 1996;40:826 (Editorial)
congenital muscular dystrophy with primary laminin α2 (merosin) deficiency presenting as inflammatory myopathy (Pegoraro et al) 1996;40:782
exercise fuel mobilization in mitochondrial myopathy: a metabolic dilemma (Vissing et al) 1996;40:655
is hereditary inclusion body myopathy a "familial prion disease"? (Cervenáková et al) 1996;40:128 (Letter)
ischemic exercise test in pediatric patients (Bruno et al) 1996;40:329A
novel mitochondrial DNA G8313A mutation associated with severe childhood encephalomyopathy (Verma et al) 1996;40:542A
sarcolemmal complement and IgM deposits in immune-mediated myopathies (Spuler and Engel) 1996;40:511A
Muscular dystrophy
confirmation of linkage of oculopharyngeal muscular dystrophy to chromosome 14q11.2-q13 (Stajich et al) 1996;40:801
congenital muscular dystrophy with primary laminin α2 (merosin) deficiency presenting as inflammatory myopathy (Pegoraro et al) 1996;40:782
esophageal dysfunction in oculopharyngeal muscular dystrophy (Tiomni et al) 1996;40:512A
merosin-deficient congenital muscular dystrophy associated with normal central myelination and prolonged motor nerve conductions (Acsadi et al) 1996;40:330A
muscular dystrophy associated with β-dystroglycan deficiency (Salih et al) 1996;40:925
normal peripheral nerve myelination in merosin(-) congenital muscular dystrophy (Edgar et al) 1996; 40:329A
prednisone therapy in Becker's muscular dystrophy (Johnsen and Johnson) 1996;40:328A
similar telomere lengths in normal and dystrophic muscle indicate that replicative aging is not the cause of progression in Duchenne muscular dystrophy (Oexle et al) 1996;40:294A

Mutation
clinical and molecular analysis of pyruvate dehydrogenase deficiency (Alvarez et al) 1996;40:289A
clinical genetic analysis of Parkinson's disease in the Contursi kindred (Golbe et al) 1996;40:767
clinical phenotype of two missense mutations in the presenilin I gene in Japanese patients (Ikeda et al) 1996; 40:912
clinically distinct codon 69 mutations in major myelin protein zero in demyelinating neuropathies (Meijerink et al) 1996;40:672
end-plate acetylcholine receptor deficiency due to nonsense mutations in the ϵ subunit (Engel et al) 1996;40: 810 (Expedited publication)
episodic ataxia and myokymia syndrome: a new mutation of potassium channel gene Kv1.1 (Çomu et al) 1996; 40:684
Friedreich's ataxia mutation does not always result in ataxia (Subramony et al) 1996;40:542A
inherited prion disease linked with a missense mutation at codon 105 in the prion protein gene (Yamada et al) 1996;40:500A
MELAS associated with a mutation in the valine transfer RNA gene of mitochondrial DNA (Taylor et al) 1996; 40:459
missense mutations of the *PS-1/S182* gene in German early-onset Alzheimer's disease patients (Sandbrink et al) 1996;40:265 (Letter)
molecular analysis of gene mutation in Batten disease (Zhong et al) 1996;40:298A
multiple mutations in the GALC gene in a patient with adult-onset Krabbe disease (Luzi et al) 1996;40:116
mutant GTP cyclohydrolase I mRNA levels contribute to dopa-responsive dystonia onset (Hirano et al) 1996;40: 796
mutations in the muscle acetylcholine receptor α subunit gene in slow-channel congenital myasthenic syndrome (Beeson et al) 1996;40:487A
nitration of glutamate transporters in transgenic mice with a familial amyotrophic lateral sclerosis-linked SOD1 mutation (Nagano et al) 1996;40:542A
novel mitochondrial DNA G8313A mutation associated with severe childhood encephalomyopathy (Verma et al) 1996;40:542A
parental origin of new mutation in neurofibromatosis 2 (MacCollin et al) 1996;40:288A
point mutation associated with a severe phenotype of neurofibromatosis 2 (MacCollin et al) 1996;40:440
prion-containing Kuru-like plaques in familial Alzheimer-like disease with concomitant β/A4 amyloid–containing plaques and a single mutation in the presenilin 1 gene (Kuljis et al) 1996;40:503A
X-linked dominant Charcot-Marie-Tooth disease: novel connexin 32 mutations and their relationship to clinical and pathological disease (Tan et al) 1996;40:545A
Myasthenia gravis
action potential thresholds are elevated near the end-plate but not elsewhere in myasthenia gravis and passive transfer experimental myasthenia gravis (Ruff) 1996;40: 507A
congenital myasthenic syndrome with a single nucleotide deletion at the intron/exon boundary in exon 12 of the gene encoding the acetylcholine receptor ϵ subunit (Croxen et al) 1996;40:513A
end-plate acetylcholine receptor deficiency due to nonsense mutations in the ϵ subunit (Engel et al) 1996;40: 810 (Expedited publication)
Epstein-Barr virus genome is absent in myasthenic thymic tissue (Woolfenden et al) 1996;40:540A
incidence of myasthenic crises in pediatric myasthenia gravis after thymectomy (Sivak et al) 1996;40:327A
mutations in the muscle acetylcholine receptor α subunit gene in slow-channel congenital myasthenic syndrome (Beeson et al) 1996;40:487A
Mycoplasma pneumoniae
role of *Mycoplasma pneumoniae* in acute childhood encephalitis (Kolski et al) 1996;40:310A
Myelin
abnormal myelination in isolated dihydroxyacetonephosphate acyltransferase deficiency (Sztriha et al) 1996;40: 298A
normal peripheral nerve myelination in merosin(-) congenital muscular dystrophy (Edgar et al) 1996;40:329A
Myelin basic protein; *see* **Encephalitogenic basic proteins**
Myelin proteins
clinically distinct codon 69 mutations in major myelin protein zero in demyelinating neuropathies (Meijerink et al) 1996;40:672
Myelin sheath
oligodendroglial and astroglial differentiation during development and remyelination (Mabie et al) 1996;40: 546A
remyelinating peripheral nerves of Po knockout mice with a Po expressing adenovirus (Shy et al) 1996;40: 545A
Myelopathy; *see* **Spinal cord diseases**
Myoadenylate deaminase
family with myoadenylate deaminase deficiency (Koo and Sabina) 1996;40:328A
Myoclonic epilepsy; *see* **Epilepsy, myoclonic**
Myoclonus
cortical myoclonus in Angelman syndrome (Guerrini et al) 1996;40:39
5-HTP–induced myoclonus is specifically mediated through the 5-HT_1 subsystem: implications for new drug development (Pappert et al) 1996;40:534A
treatment of childhood myoclonus with botulinum toxin type-A (Awaad et al) 1996;40:308A
Myofibrils
aberrant expression of cyclin-dependent kinases in myofibrillary myopathy with abnormal foci of desmin positivity: analysis of 8 cases (Nakano et al) 1996;40: 508A
indoacetate-induced muscle contracture results from elevated intracellular calcium and increased myofibrillar calcium sensitivity (Ruff and Corsillo) 1996;40:508A
Myokymia; *see* **Fasciculation**
Myositis
apolipoprotein E alleles in sporadic inclusion-body myositis and hereditary inclusion-body myopathy (Askanas et al) (Letter); (Garlepp and Mastaglia) (Reply) 1996;40: 264
inclusion body myositis: clinical and pathological boundaries (Amato et al) 1996;40:581
Myotonia
cerebrospinal fluid and serum from acquired neuromyotonia patients seropositive for anti–potassium channel antibodies label dentate nucleus neurons (Hart et al) 1996;40:554A
Myotonia atrophica
impaired central respiratory drive in myotonic dystrophy (Zifko et al) 1996;40:511A
isolation of RNA (CUG repeat) binding proteins from

human muscle and brain: implications for myotonic dystrophy (Bhagwati and Ghatpande) 1996;40:543A
lack of correlation between CTG repeat size and skeletal myopathology in myotonic dystrophy (Shaibani et al) 1996;40:543A

***N*-acetylaspartate**
regional *N*-acetylaspartate level as an index for neuronal viability in experimental ischemic/postischemic injury (Nakano et al) 1996;40:528A
***N*-methylaspartate**
increased hypoxic tolerance by systemic pretreatment of experimental animals with 3-nitropropionic acid is reversed by APV, an NMDA antagonist (Riepe et al) 1996;40:548A
Narcolepsy
new alternative in the pharmacological management of somnolence: a Phase III study of modafinil in narcolepsy (Fry) 1996;40:493A
Near-infrared spectroscopy; *see* **Spectroscopy**
Neocortex; *see* **Cerebral cortex**
Neonatal hyperbilirubinemia; *see* **Jaundice, neonatal**
Neonate; *see* **Infant, newborn**
Neoplasm metastasis
bone metastases with meningeal gliomatosis as a progression from hypothalamic low-grade astrocytoma and complete response by chemotherapy (Johnston et al) 1996;40:489A
carcinomatous meningitis secondary to breast cancer: combined-modality therapy (Chamberlain and Kormanik) 1996;40:490A
leptomeningeal metastases due to melanoma: combined-modality therapy (Chamberlain and Kormanik) 1996;40:490A
Neoplasms; *see also specific neoplasms*
microvascular endothelial cell activation in the central nervous system is associated with cancer and cerebral thromboembolism (Rogers et al) 1996;40:492A
Neostriatum; *see* **Corpus striatum**
Nephropathic cystinosis; *see* **Cystinosis**
Nerve compression syndromes
reflex sympathetic dystrophy associated with deep peroneal nerve entrapment (Parano and Trifiletti) 1996;40:315A
Nerve degeneration
deficient glutamate transport is associated with neurodegeneration in Alzheimer's disease (Masliah et al) 1996;40:759
Guamanian neurodegenerative disease: ultrastructural studies of skin (Ono et al) 1996;40:530A
neurodegenerative disorders with extensive tau pathology: a comparative study and review (Feany and Dickson) 1996;40:139 (Neurological progress)
Nerve growth factors
excess nerve growth factor inhibits axonal growth and induces apoptosis in sensory neurons (Conti and Windebank) 1996;40:531A
interference with p75 binding of nerve growth factor as a means of overcoming chemotherapeutic resistance of neural crest tumors (Schor et al) 1996;40:291A
results of a double-blind, placebo-controlled trial of recombinant human nerve growth factor in diabetic polyneuropathy (Apfel et al) 1996;40:540A
Nerve regeneration
changes in neuropeptide content of regenerated cutaneous nerves after peripheral nerve division in humans: a quantitative analysis using indirect immunofluorescence histochemistry (McAllister et al) 1996;40:523A
Nerves, analysis
diagnostic utility of the nerve-muscle-skin biopsy in pediatric neurology practice (Miller et al) 1996;40:328A
Neural crest
exploiting up-regulation of *bcl-2* in the development of targeted strategies for treatment of neural crest cancers: turning adversity into advantage (Schor and Cortazzo) 1996;40:290A
interference with p75 binding of nerve growth factor as a means of overcoming chemotherapeutic resistance of neural crest tumors (Schor et al) 1996;40:291A
Neural progenitor cells; *see* **Stem cells**
Neurites
fragmentation of neocortical neurites in pediatric human immunodeficiency virus-1-associated central nervous system disease: an immunoperoxidase study of tubulin epitopes in postmortem brains (Katsetos et al) 1996;40:309A
insulin-like growth factor-I stimulates tyrosine phosphorylation of MAP kinases and neurite outgrowth in human neuroblastoma cells (Kim et al) 1996;40:510A
Neuritis
bilateral brachial plexus neuritis following parvovirus B19 and cytomegalovirus infection (Maas et al) 1996;40:928
Neuroblastoma
insulin-like growth factor-I stimulates tyrosine phosphorylation of MAP kinases and neurite outgrowth in human neuroblastoma cells (Kim et al) 1996;40:510A
Neurofibrillary tangles
Alzheimer's disease without neocortical tangles: a second look (Sabbagh et al) 1996;40:500A
neuronal activity and early neurofibrillary tangles in Alzheimer's disease (Hatanpää et al) 1996;40:411
Neurofibromatosis 1
brain morphometric analysis in neurofibromatosis type-1 (DiMario et al) 1996;40:325A
computed tomographic imaging in neurofibromatosis (Tonsgard et al) 1996;40:311A
fluorodeoxyglucose positron emission tomography in pediatric patients with neurofibromatosis type 1 (Molloy et al) 1996;40:325A
magnetic resonance imaging morphometric indices as predictive markers for learning disabilities in children with neurofibromatosis-1 (Said et al) 1996;40:324A
neurofibromatosis type 1: corpus callosum enlarged beyond megencephaly (Mott et al) 1996;40:325A
vascular complications of neurofibromatosis-1 (Weinstock et al) 1996;40:324A
Neurofibromatosis 2
parental origin of new mutation in neurofibromatosis 2 (MacCollin et al) 1996;40:288A
point mutation associated with a severe phenotype of neurofibromatosis 2 (MacCollin et al) 1996;40:440
Neurofilament proteins
sequence variants in human neurofilament proteins: absence of linkage to familial amyotrophic lateral sclerosis (Vechio et al) 1996;40:603
Neurofilaments; *see* **Intermediate filaments**
Neurogastrointestinal diseases; *see* **Gastrointestinal diseases**
Neuroglia
differences between multiple system atrophy and olivopontocerebellar atrophy (Quinn and Daniel) (Letter); (Sima and Lynch) (Reply) 1996;40:945
different cytokine families regulate neuronal and glial differentiation from neural progenitor cells (Mehler et al) 1996;40:546A

Neuroglia (*continued*)
expression of markers for both neuronal and glial cells in human amniotic epithelial cells: possible multipotential neural stem cells for transplantation in human brain (Sakuragawa et al) 1996;40:296A
glial and neuronal cytoplasmic inclusions in familial olivopontocerebellar atrophy (Berciano and Ferrer) (Letter); (Gilman et al) (Reply) 1996;40:819
glial cell line–derived neurotrophic factor reduces motor dysfunction in Wobbler mice (Klinkosz et al) 1996;40:540A
glial cell line–derived neurotrophic factor regulates neuropeptides in sensory neurons (Adler) 1996;40:549A
glial glutamate transporter complementary DNA in patients with amyotrophic lateral sclerosis (Meyer et al) 1996;40:456
human immunodeficiency virus-1 strain–associated variability in infection of primary neuroglia (McCarthy et al) 1996;40:488A
normal radial glia in two Miller-Dieker lissencephaly fetal brains (Clark et al) 1996;40:297A
Neuroleptic malignant syndrome
cocaine delirium and sudden death: a possible cocaine variant of neuroleptic malignant syndrome? (Mash et al) 1996;40:523A
Neuromuscular junction
nitric oxide synthase is concentrated at the muscle endplate (Kaminski and Kusner) 1996;40:547A
Neuromyotonia; *see* **Myotonia**
Neuronal adhesion molecules; *see* **Cell adhesion molecules, neuronal**
Neuronal ceroid-lipofuscinosis
clinicopathologic and molecular characteristics of atypical CLN3 cases (Wisniewski et al) 1996;40:330A
molecular analysis of gene mutation in Batten disease (Zhong et al) 1996;40:298A
Neurons
expression of markers for both neuronal and glial cells in human amniotic epithelial cells: possible multipotential neural stem cells for transplantation in human brain (Sakuragawa et al) 1996;40:296A
neuronal activity and early neurofibrillary tangles in Alzheimer's disease (Hatanpää et al) 1996;40:411
Neurons, afferent
excess nerve growth factor inhibits axonal growth and induces apoptosis in sensory neurons (Conti and Windebank) 1996;40:531A
insulin-like growth factor-I protects sensory neurons from glucotoxicity (Russell and Feldman) 1996;40:510A
Neurons, injuries
thiazides promote ischemic neuronal injury in vivo (Yamada et al) 1996;40:314A
Neurons, metabolism
multitude of biotinylated proteins in neural cells: alteration by oxidative stress (Nguyen et al) 1996;40:299A
Neurons, pathology
deficient glutamate transport is associated with neurodegeneration in Alzheimer's disease (Masliah et al) 1996;40:759
multifocal neuronal migration disorder as a probable result of a well-documented ischemic event at 18 weeks' gestation (Shafrir et al) 1996;40:296A
Neuropathies, hereditary motor and sensory
Adie-Holmes pupils, motor and sensory neuropathy, pyramidal tract involvement and autosomic dysfunction in a family (Haenggeli and De Vivo) 1996;40:329A
hereditary motor and sensory neuropathy (HMSN) type IIC is genetically distinct from HMSN IIB (Nagamatsu et al) 1996;40:509A
Neuropathy with pressure palsy, hereditary
childhood hereditary neuropathy with liability to pressure palsy (Poulin et al) 1996;40:327A
Neuropeptides
changes in neuropeptide content of regenerated cutaneous nerves after peripheral nerve division in humans: a quantitative analysis using indirect immunofluorescence histochemistry (McAllister et al) 1996;40:523A
glial cell line–derived neurotrophic factor regulates neuropeptides in sensory neurons (Adler) 1996;40:549A
Neurosteroids; *see* **Steroids**
Neurotoxins
dopaminergic neurotoxin, (*R*)-N-methylsalsolinol, increases in parkinsonian cerebrospinal fluid (Maruyama et al) 1996;40:119
humoral neurotoxic factor in sera of patients with critical illness polyneuropathy (Hund et al) 1996;40:539A
in vitro model system for predicting neurotoxicity of new chemotherapeutic agents (Windebank et al) 1996;40:491A
mechanisms of neurotoxicity of the human immunodeficiency virus-1 protein Tat in perinatal rat brain (Wang et al) 1996;40:292A
neuronal protection from excitotoxic injury by depolymerization of actin may also be due to a concomitant induction of reactive astrocytes (Kunkler et al) 1996;40:496A
Neurotrophic factors
early brain-derived neurotrophic factor and neurotrophin-3 signaling events (Yuen et al) 1996;40:548A
glial cell line–derived neurotrophic factor reduces motor dysfunction in Wobbler mice (Klinkosz et al) 1996;40:540A
glial cell line–derived neurotrophic factor regulates neuropeptides in sensory neurons (Adler) 1996;40:549A
sequential treatment with FGF-2 and BDNF permits the production of new neurons by precursors derived from the adult human epileptic temporal lobe (Pincus et al) 1996;40:550A
therapeutic potential of neurotrophic factors for neurological disorders (Yuen and Mobley) 1996;40:346 (Neurological progress)
Neurotrophins
early brain-derived neurotrophic factor and neurotrophin-3 signaling events (Yuen et al) 1996;40:548A
neurotrophin-3 receptor activation induces apoptosis of a medulloblastoma cell line (Sutton et al) 1996;40:291A
Neutrophils
neutrophil infiltration and neurological disease in transgenic mice expressing the chemokine KC in oligodendrocytes (Tani et al) 1996;40:554A
Nitric oxide
cerebrospinal fluid nitrite/nitrate in normal neonates and those with intraventricular hemorrhage (Filipov et al) 1996;40:324A
cerebrospinal fluid protein tyrosine nitration in neonates: marker of brain NO production (Hills et al) 1996;40:324A
inducible nitric oxide synthase (iNOS)-like immunoreactivity in human immunodeficiency virus-associated central nervous system disease in children: differential cellular distribution and putative role in HIV-associated neuronopathy (Katsetos et al) 1996;40:310A

interferon-β-1b decreases induced nitric oxide production by a human astrocytoma cell line (Mattson and Guthikonda) 1996;40:515A
maturation increases cerebral nitric oxide synthase activity in spontaneously hypertensive rats by decreasing the K_m for L-arginine (Ashwal et al) 1996;40:317A
nitric oxide and superoxide anion interactions in neurologic disease (Dawson) 1996;40:487A
nitric oxide synthase is concentrated at the muscle endplate (Kaminski and Kusner) 1996;40:547A
nitric oxide–induced programmed cell death: a rapid, dynamic molecular process that is reversible by peptide growth factors (Maiese et al) 1996;40:547A

Nitropropionic acid
increased hypoxic tolerance by systemic pretreatment of experimental animals with 3-nitropropionic acid is reversed by APV, an NMDA antagonist (Riepe et al) 1996;40:548A

Nitrotyrosine
detection of nitrotyrosine immunoreactivity in experimental autoimmune encephalomyelitis–affected CNS tissues: evidence for the presence of peroxynitrite in inflammatory CNS demyelination (Cross et al) 1996;40:520A

Non-Hodgkin's lymphoma; *see* **Lymphoma, non-Hodgkin's**

Nuclear magnetic resonance
brain energy metabolism in Huntington's disease measured with in vivo proton magnetic resonance spectroscopy (Martin et al) 1996;40:538A
Krabbe disease: proton magnetic resonance spectroscopy findings (Moore et al) 1996;40:299A
new insights into the pathophysiology of Marchiafava-Bignami disease using proton magnetic resonance spectroscopy (Nicoli et al) 1996;40:524A
normalization of contralateral metabolic function following temporal lobectomy demonstrated by ^1H magnetic resonance spectroscopic imaging (Hugg et al) 1996;40:236
observation of cerebral ketone bodies by proton nuclear magnetic resonance spectroscopy (Novotny and Rothman) 1996;40:285A
predictive value of proton magnetic resonance spectroscopy in perinatal central nervous system insults (Shu et al) 1996;40:293A
proton magnetic resonance spectroscopy-determined cerebral lactate is associated with poor neurologic outcomes in children with central nervous system disease (Ashwal et al) 1996;40:314A
proton magnetic resonance spectroscopy in children with acute brain injury: outcome prediction for different ages (Holshouser et al) 1996;40:316A
proton magnetic resonance spectroscopy in children with Sturge-Weber syndrome (Moore et al) 1996;40:313A
quantification of brainstem neuronal loss in amyotrophic lateral sclerosis with in vivo proton magnetic resonance spectroscopy (Cwik et al) 1996;40:512A

Nystagmus
horizontal canal benign paroxysmal positioning vertigo (h-BPPV): transition of canalolithiasis to cupulolithiasis (Steddin and Brandt) 1996;40:918

Observer variation
interobserver variability of single-photon emission computed tomography scan interpretation in children with language regression (Yaylali et al) 1996;40:311A

Occipital lobe
functional MRI of lateral occipitotemporal cortex during pursuit and motion perception (Barton et al) 1996;40:387
reversible occipital encephalopathy: a new name for an old syndrome (Frank et al) 1996;40:297A
value of single-photon emission computed tomography in evaluating occipital lobe epilepsy (Azhar et al) 1996;40:307A

Oculomotor nerve paralysis
primary immature teratoma of the leptomeninges in an 8-year-old child: unusual presentation with recurrent transient oculomotor nerve palsies and rapid progression to diffuse cerebral infarction (Robertson et al) 1996;40:333A

Oculopharyngeal muscular dystrophy; *see* **Muscular dystrophy**

Odontoid process
atlanto-axial dislocation with quadriplegia in one of the twins in a family with autosomal dominant odontoid hypoplasia (Shah and Fish) 1996;40:308A

Oligodendroglia
copolymer-1 suppresses the T-cell proliferative response to myelin oligodendrocyte glycoprotein (Milo et al) 1996;40:551A
cyclosporine induces neuronal apoptosis and selective oligodendrocyte death in cortical cultures (McDonald et al) 1996;40:750
neutrophil infiltration and neurological disease in transgenic mice expressing the chemokine KC in oligodendrocytes (Tani et al) 1996;40:554A
oligodendrocyte loss and preservation in early multiple sclerosis (Lucchinetti et al) 1996;40:522A
oligodendroglial and astroglial differentiation during development and remyelination (Mabie et al) 1996;40:546A

Olivopontocerebellar atrophy
decreased striatal monoaminergic terminals in olivopontocerebellar atrophy and multiple system atrophy demonstrated with positron emission tomography (Gilman et al) 1996;40:885
differences between multiple system atrophy and olivopontocerebellar atrophy (Quinn and Daniel) (Letter); (Sima and Lynch) (Reply) 1996;40:945
glial and neuronal cytoplasmic inclusions in familial olivopontocerebellar atrophy (Berciano and Ferrer) (Letter); (Gilman et al) (Reply) 1996;40:819

Open heart surgery; *see* **Heart surgery**

Ophthalmoplegia
autosomal dominant chronic progressive external ophthalmoplegia: a tale of two genomes (Shoubridge) 1996;40:693 (Editorial)
clonal expansion of mitochondrial DNA with multiple deletions in autosomal dominant progressive external ophthalmoplegia (Moslemi et al) 1996;40:707

Optic atrophy, hereditary
biochemical study of ND1/3460 Leber optic neuropathy with visual recovery (Leuzzi et al) 1996;40:299A

Optic nerve
peroxynitrite-mediated oxidative injury in optic nerve ischemia (Guy et al) 1996;40:496A

Organic acid disorders
organic acid disorders and the ketogenic diet (Demeritte et al) 1996;40:305A

Orthostatic headache; *see* **Headache**

Osteogenic protein-1; *see* **Transforming growth factor beta**

Osteomyelitis
acquired brachial plexopathy in neonates: an early sign of osteomyelitis (Sadlier and Connolly) 1996;40:320A
Outcomes assessment
clinical outcomes assessment in multiple sclerosis (Rudick et al) 1996;40:469 (Special report)
Oxidative stress
multitude of biotinylated proteins in neural cells: alteration by oxidative stress (Nguyen et al) 1996;40:299A
Oxygen
low levels of oxidative injury induce apoptosis of differentiated skeletal muscle cells (Selcen et al) 1996;40:549A

P84 neuronal adhesion molecules; *see* **Cell adhesion molecules, neuronal**
Pallidotomy; *see* **Globus pallidus, surgery**
Paralysis
childhood hereditary neuropathy with liability to pressure palsy (Poulin et al) 1996;40:327A
detection of motor cortex activation in paralytic amyotrophic lateral sclerosis patients without apparent muscle contraction (Shinohara et al) 1996;40:547A
Paraneoplastic syndromes
IgG subclasses of autoantibodies associated with human paraneoplastic neurological syndromes (Greenlee et al) 1996;40:492A
motor neuron disease: a paraneoplastic process associated with anti-Hu antibody and small-cell lung carcinoma (Verma et al) 1996;40:112
Paraparesis, tropical spastic
autoantibodies produced by patients with HTLV-I–associated myelopathy/tropical spastic paraparesis react exclusively with neurons: implications for immune-mediated damage to the CNS in retroviral-associated neurological disease (Levin et al) 1996;40:494A
human T-lymphotropic virus type I–associated myelopathy and tax gene expression in $CD4^+$ T lymphocytes (Moritoyo et al) 1996;40:84
Paraproteinemias
axonal neuropathy associated with monoclonal gammopathy of uncertain significance (Gorson and Ropper) 1996;40:539A
Parasympathomimetics
efficacy and safety of SB 202026 as a symptomatic treatment for Alzheimer's disease (Kumar) 1996;40:504A
Parkinson's disease, cerebrospinal fluid
dopaminergic neurotoxin, (*R*)-N-methylsalsolinol, increases in parkinsonian cerebrospinal fluid (Maruyama et al) 1996;40:119
Parkinson's disease, complications
extrapyramidal parkinsonism syndrome complicating systemic lupus erythematosus (Shahar et al) 1996;40:336A
Parkinson's disease, drug therapy
deprenyl and levodopa and Parkinson's disease progression (Fowler et al) 1996;40:267 (Letter)
deprenyl in Parkinson's disease (Korczyn and Nisipeanu) (Letter); (Olanow and Koller) (Reply) 1996;40:268
deprenyl's neuroprotective action remains unresolved (van Hilten et al) (Letter); (Olanow and Koller) (Reply) 1996;40:266
effect of lazabemide on the progression of disability in early Parkinson's disease (The Parkinson Study Group) 1996;40:99
Selegiline and mortality in Parkinson's disease (Olanow et al) 1996;40:841 (Point of view)
study design problems of DATATOP study analysis (Mäki-Ikola and Heinonen) (Letter); (Penney et al) (Reply) 1996;40:946
Parkinson's disease, epidemiology
late-onset atypical parkinsonism: a descriptive analysis (Singer et al) 1996;40:536A
Parkinson's disease, etiology
clinical and pathological features in hydrocarbon-induced parkinsonism (Pezzoli et al) 1996;40:922
Parkinson's disease, genetics
clinical genetic analysis of Parkinson's disease in the Contursi kindred (Golbe et al) 1996;40:767
genetic variability of the CYP 2D6 gene is not a risk factor for sporadic Parkinson's disease (Diederich et al) 1996;40:463
Parkinson's disease, metabolism
pattern of resting brain glucose utilization (rCMRGlc) in cognitively uncomplicated Parkinson's disease: focusing on cortico-subcortical circuits (Marié et al) 1996;40:536A
Parkinson's disease, mortality
Selegiline and mortality in Parkinson's disease (Olanow et al) 1996;40:841 (Point of view)
Parkinson's disease, pathology
Alzheimer's disease versus Lewy body disease: differences in perforant pathway pathology (Lippa et al) 1996;40:501A
impaired set-shifting ability in Parkinson's disease: relationships with striatofrontal circuit disruption and caudate nucleus dopamine denervation assessed with positron emission tomography (Marié et al) 1996;40:525A
in vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease (Kuhl et al) 1996;40:399
origin and functional consequences of the complex I defect in Parkinson's disease (Swerdlow et al) 1996;40:663
presynaptic monoaminergic vesicles in Parkinson's disease and normal aging (Frey et al) 1996;40:873
Parkinson's disease, physiopathology
comorbidity of the nonmotor symptoms of Parkinson's disease (Shulman et al) 1996;40:536A
Guamanian neurodegenerative disease: ultrastructural studies of skin (Ono et al) 1996;40:530A
pharmacological evidence for peripheral autonomic dysfunction in patients with Parkinson's disease and amyotrophic lateral sclerosis (Smith et al) 1996;40:530A
Parkinson's disease, psychology
comorbidity of the nonmotor symptoms of Parkinson's disease (Shulman et al) 1996;40:536A
Parkinson's disease, surgery
does bradykinesia improve after pallidotomy? (Overby et al) 1996;40:535A
GPi pallidotomy—have we made a dent in Parkinson's disease? (Olanow) 1996;40:341 (Editorial)
levodopa-induced dyskinesias are the main features improved by contralateral pallidotomy in Parkinson's disease: 2-year follow-up (Rabey et al) 1996;40:535A
pallidotomy for medically intractable Parkinson's disease: 2-year follow-up (Vitek et al) 1996;40:488A
posteroventral-medial pallidotomy for late-stage Parkinson's disease: a 2-year follow-up (Lang et al) 1996;40:538A
postural control in patients with Parkinson's disease after pallidotomy (Roberts-Warrior et al) 1996;40:534A
treatment of advanced Parkinson's disease by posterior GPi pallidotomy: 1-year results of a pilot study (Baron et al) 1996;40:355 (Expedited publication)

treatment of advanced Parkinson's disease with microelectrode-guided pallidotomy (Lai et al) 1996;40:534A
Parkinson's disease, therapy
efficacy of deep brain stimulation in the treatment of essential tremor and Parkinson's disease: 12-month follow-up (Busenbark et al) 1996;40:533A
high-frequency pallidal stimulation in Parkinson's disease (Pahwa et al) 1996;40:533A
unilateral stimulation of the globus pallidus internus in Parkinson's disease: bilateral improvement of major symptoms (van der Linden et al) 1996;40:538A
Paroxysmal nonepileptic events; *see* **Seizures**
Parvoviruses
bilateral brachial plexus neuritis following parvovirus B19 and cytomegalovirus infection (Maas et al) 1996;40:928
Paxillin
insulin-like growth factor-I stimulates the tyrosine phosphorylation of paxillin and focal adhesion kinase (Leventhal and Feldman) 1996;40:509A
Peer group
peer relationship problems are not related to tic severity in Tourette disorder (Camfield et al) 1996;40:333A
Pegapargase
reversible magnetic resonance imaging lesions due to pegapargase treatment of non-Hodgkin's lymphoma (Bushara and Rust) 1996;40:317A
Penumbra
metabolic status of the ultimately noninfarcted ischemic penumbra: a positron emission tomography study in humans (Baron et al) 1996;40:498A
Peptide hydrolases
proteolytic activity in amyotrophic lateral sclerosis IgG preparations (Nyormoi) 1996;40:701
Peptides
nitric oxide–induced programmed cell death: a rapid, dynamic molecular process that is reversible by peptide growth factors (Maiese et al) 1996;40:547A
Peripheral nerve diseases; *see also specific diseases*
acute neuromuscular disease following liver transplantation: a prospective study (Campellone et al) 1996;40:509A
role of magnetic resonance imaging in the evaluation of unexplained mononeuropathy in children and adolescents (Weig and McAvoy) 1996;40:326A
Perisylvian syndrome
congenital anomalies in children with perisylvian dysgenesis (Bingham et al) 1996;40:298A
pediatric presentation of congenital bilateral perisylvian syndrome: clinical and magnetic resonance imaging findings (Gropman et al) 1996;40:337A
Periventricular hemorrhage; *see* **Cerebral hemorrhage**
Periventricular leukomalacia; *see* **Leukomalacia, periventricular**
Peroneal nerve
diagnostic value of combined superficial peroneal nerve/peroneus brevis muscle biopsy in suspected vasculitis (Collins et al) 1996;40:545A
reflex sympathetic dystrophy associated with deep peroneal nerve entrapment (Parano and Trifiletti) 1996;40:315A
Peroneus brevis muscle
diagnostic value of combined superficial peroneal nerve/peroneus brevis muscle biopsy in suspected vasculitis (Collins et al) 1996;40:545A
Peroxynitrite
detection of nitrotyrosine immunoreactivity in experimental autoimmune encephalomyelitis–affected CNS tissues: evidence for the presence of peroxynitrite in inflammatory CNS demyelination (Cross et al) 1996;40:520A
peroxynitrite-mediated oxidative injury in optic nerve ischemia (Guy et al) 1996;40:496A
Pertussis toxins
neuronal platelet-activating factor receptor signal transduction involves a pertussis toxin-sensitive G-protein (Clark et al) 1996;40:289A
Pervasive development disorders; *see* **Child development disorders, pervasive**
Phenobarbital
therapeutic levels of phenobarbital inhibit development and maintenance of dendrites induced by osteogenic protein-1 (Johnson et al) 1996;40:286A
Phenotype
clinical phenotype of two missense mutations in the presenilin I gene in Japanese patients (Ikeda et al) 1996;40:912
molecular basis of phenotypic heterogeneity in siblings with spinal muscular atrophy (Parano et al) 1996;40:247
point mutation associated with a severe phenotype of neurofibromatosis 2 (MacCollin et al) 1996;40:440
Phentolamine
phentolamine pretreatment prevents a component of growth retardation and of inattention induced by prenatal cocaine exposure (Kosofsky et al) 1996;40:315A
Pigmentation disorders
speech and language disabilities in association with parietotemporal white matter abnormalities in hypomelanosis of Ito: an anatomical substrate for a behavioral phenotype? (Ruggieri et al) 1996;40:312A
Pituitary neoplasms
knockout mice exhibit pituitary tumors and larger forebrain than wild-type mice (Rivkin et al) 1996;40:292A
Placenta
placental abnormalities: insights into pathogenesis of cystic periventricular leukomalacia (Roland et al) 1996;40:321A
Plasma exchange
comparison of plasma exchange, intravenous immunoglobulin, and plasma exchange followed by intravenous immunoglobulin in the treatment of Guillain-Barré syndrome (Hughes and Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group) 1996;40:551A
predictors of outcome of the Guillain-Barré syndrome after treatment with high-dose intravenous immune globulins or plasma exchange (Visser et al) 1996;40:511A
Plasmapheresis
progressive encephalomyelitis with rigidity responsive to plasmapheresis and immunosuppression (Fogan) 1996;40:451
Plasminogen activator, tissue-type
safety and efficacy of intravenous recombinant tissue plasminogen activator in acute ischemic stroke: results of the ECASS three-hour cohort (Hacke et al) 1996;40:499A
Platelet activating factor
neuronal platelet-activating factor receptor signal transduction involves a pertussis toxin-sensitive G-protein (Clark et al) 1996;40:289A
Platelet activation
evidence of platelet activation in multiple sclerosis (Kolodny et al) 1996;40:520A

Polydactyly
large kindred with dominantly inherited hypothalamic hamartoma and polydactyly (Allen et al) 1996;40:309A
Polymerase chain reaction
HIV infection of dorsal root ganglion neurons detected by polymerase chain reaction–amplified in situ hybridization (Brannagan et al) 1996;40:510A
polymerase chain reaction assay for detection of spinal muscular atrophy heterozygotes (Berry-Kravis et al) 1996;40:294A
polymerase chain reaction–based detection of *Tropheryma whippelii* in central nervous system Whipple's disease (Lynch et al) 1996;40:535A
presence of herpes simplex DNA in surgical tissue from human epileptic seizure foci detected by polymerase chain reaction (Tourtellotte et al) 1996;40:505A
Polymorphism
apolipoprotein E and α_1-antichymotrypsin polymorphism in Alzheimer's disease (Nacmias et al) 1996;40:678
genetic studies in Alzheimer's disease with an NACP/α-synuclein polymorphism (Xia et al) 1996;40:207
lack of association of very low density lipoprotein receptor gene polymorphism with caucasian Alzheimer's disease (Okuizumi et al) 1996;40:251
Polyradiculoneuritis
Campylobacter jejuni infections and anti-GM1 antibodies in Guillain-Barré syndrome (Jacobs et al) 1996;40:181
close association of Guillain-Barré syndrome with antibodies to minor monosialogangliosides GM_{1b} and $GM_{1\alpha}$ (Tagawa et al) 1996;40:554A
comparison of plasma exchange, intravenous immunoglobulin, and plasma exchange followed by intravenous immunoglobulin in the treatment of Guillain-Barré syndrome (Hughes and Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group) 1996;40:551A
differential distribution of HLA alleles in two forms of Guillain-Barré syndrome (Monos et al) 1996;40:521A
does modern treatment improve the outcome of Guillain-Barré syndrome? (Rees et al) 1996;40:508A
intravenous immunoglobulin as therapy for pediatric Guillain-Barré syndrome (Abd-Allah et al) 1996;40:330A
lack of efficacy after treatment with intravenous immunoglobulin in pediatric Guillain-Barré syndrome (Smith et al) 1996;40:327A
molecular mimicry between cytomegalovirus and GM_2 ganglioside: pathogenesis of Guillain-Barré syndrome (Yuki et al) 1996;40:519A
predictors of outcome of the Guillain-Barré syndrome after treatment with high-dose intravenous immune globulins or plasma exchange (Visser et al) 1996;40:511A
production of and response to interleukin-2 by cultured lymphocytes from patients with Guillain-Barré syndrome (Yoshii et al) 1996;40:541A
Positron emission tomography; *see* **Tomography, emission-computed**
Posterior border zone infarction; *see* **Cerebral infarction**
Posture
postural control in patients with Parkinson's disease after pallidotomy (Roberts-Warrior et al) 1996;40:534A
Posturography; *see* **Urography**
Potassium channels
cerebrospinal fluid and serum from acquired neuromyotonia patients seropositive for anti–potassium channel antibodies label dentate nucleus neurons (Hart et al) 1996;40:554A
episodic ataxia and myokymia syndrome: a new mutation of potassium channel gene Kv1.1 (Çomu et al) 1996;40:684
Prednisone
prednisone therapy in Becker's muscular dystrophy (Johnsen and Johnson) 1996;40:328A
Premature infant; *see* **Infant, premature**
Presenilin gene
clinical phenotype of two missense mutations in the presenilin I gene in Japanese patients (Ikeda et al) 1996;40:912
presenilin gene analysis in Italian families with early-onset Alzheimer's disease (Sorbi et al) 1996;40:503A
prion-containing Kuru-like plaques in familial Alzheimer-like disease with concomitant β/A4 amyloid–containing plaques and a single mutation in the presenilin 1 gene (Kuljis et al) 1996;40:503A
Presynaptic monoaminergic vesicles
decreased striatal monoaminergic terminals in olivopontocerebellar atrophy and multiple system atrophy demonstrated with positron emission tomography (Gilman et al) 1996;40:885
presynaptic monoaminergic vesicles in Parkinson's disease and normal aging (Frey et al) 1996;40:873
Prions
inherited prion disease linked with a missense mutation at codon 105 in the prion protein gene (Yamada et al) 1996;40:500A
is hereditary inclusion body myopathy a "familial prion disease"? (Cervenáková et al) 1996;40:128 (Letter)
prion-containing Kuru-like plaques in familial Alzheimer-like disease with concomitant β/A4 amyloid–containing plaques and a single mutation in the presenilin 1 gene (Kuljis et al) 1996;40:503A
Proparacaine
topical transconjunctival therapy for typical face pain (Casey) 1996;40:507A
Propentofylline
activation positron emission tomography demonstrates neurotrophic properties of propentofylline in Alzheimer's disease (Mielke et al) 1996;40:501A
propentofylline protects rat brain from complete ischemia without adenosine receptor function (Haida et al) 1996;40:493A
Prosencephalon
knockout mice exhibit pituitary tumors and larger forebrain than wild-type mice (Rivkin et al) 1996;40:292A
transient forebrain ischemia in mice (Davis et al) 1996;40:528A
Prostaglandin-endoperoxide synthase
long-term elevation of cyclooxygenase-2, but not lipoxygenase, in regions synaptically distant from spreading depression (Caggiano et al) 1996;40:547A
Protein precursors
genetic studies in Alzheimer's disease with an NACP/α-synuclein polymorphism (Xia et al) 1996;40:207
Protein Tat; *see* **Gene products, Tat**
Proteolipids
T-cell reactivity to peptides of proteolipid protein and myelin basic protein in multiple sclerosis (Pender et al) 1996;40:552A
Proteolytic enzymes; *see* **Peptide hydrolases**
Proto-oncogenes
c-*myc* acts as a transcription factor for the eIF-4E promoter (Jones et al) 1996;40:334A

Proton nuclear magnetic resonance spectroscopy; *see* **Nuclear magnetic resonance**
PS-1/S182; *see* **Chromosomes, human, pair 14**
Psychiatric disorders; *see* **Mental disorders**
Ptosis; *see* **Blepharoptosis**
Purpura, thrombotic thrombocytopenic
altered mental status in thrombotic thrombocytopenic purpura is secondary to nonconvulsive status epilepticus (Garrett et al) 1996;40:245
Pyruvate dehydrogenase complex
clinical and molecular analysis of pyruvate dehydrogenase deficiency (Alvarez et al) 1996;40:289A

Quadriplegia
atlanto-axial dislocation with quadriplegia in one of the twins in a family with autosomal dominant odontoid hypoplasia (Shah and Fish) 1996;40:308A
Quality of life
quality of life in low-disability multiple sclerosis patients participating in a Phase III trial of interferon beta-1a for relapsing multiple sclerosis (Cookfair et al) 1996;40:550A

Radiosurgery
treatment of trigeminal neuralgia with the Leksell gamma knife (Young et al) 1996;40:507A
Radiotherapy
effect of methylphenidate in the postradiation attention and memory deficits in children (Torres et al) 1996;40:331A
survival and prognostic factors following radiation and chemotherapy for ependymomas in children: a children's cancer group study (Robertson et al) 1996;40:290A
Rasagiline mesylate
neuroprotection by rasagiline mesylate (TVP-1012) in experimental models of hypoxia and ischemia (Speiser et al) 1996;40:495A
Reading
impaired visual word processing in dyslexia revealed with magnetoencephalography (Salmelin et al) 1996;40:157
magnetic source imaging and the neural basis of dyslexia (Poeppel and Rowley) 1996;40:137 (Editorial)
Receptors, antigen, T-cell
recognition of myelin basic protein by mutated human T-cell receptors (Robinson et al) 1996;40:521A
T-cell receptor (TCR) peptide immunization in multiple sclerosis boosts TCR-specific Th2 cells and suppresses MBP-specific Th1 cells: report of a double-blind, placebo-controlled pilot trial (Bourdette et al) 1996;40:518A
Receptors, antigen, T-cell, gamma-delta
limited heterogeneity of γ/Δ T cells in autoimmune diseases: analysis of the VΔ2/JΔ3 T-cell receptor rearrangement in peripheral blood lymphocytes (Liedtke et al) 1996;40:515A
Receptors, cholinergic
congenital myasthenic syndrome with a single nucleotide deletion at the intron/exon boundary in exon 12 of the gene encoding the acetylcholine receptor ϵ subunit (Croxen et al) 1996;40:513A
end-plate acetylcholine receptor deficiency due to nonsense mutations in the ϵ subunit (Engel et al) 1996;40:810 (Expedited publication)
expression of messenger RNA encoding muscle acetylcholine receptor ϵ subunit in thymoma (MacLennan et al) 1996;40:513A
mutations in the muscle acetylcholine receptor α subunit gene in slow-channel congenital myasthenic syndrome (Beeson et al) 1996;40:487A
Receptors, dopamine
Brn-4 regulates transcription of the human D1A dopamine receptor gene (Mouradian et al) 1996;40:549A
striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease (Weeks et al) 1996;40:49
Receptors, GABA-benzodiazepine
benzodiazepine receptors in focal epilepsy with cortical dysgenesis: an ^{11}C-flumazenil PET study (Richardson et al) 1996;40:188
$GABA_A$ receptor active neurosteroids plasma profile in children with tuberous sclerosis complex (Romeo et al) 1996;40:323A
positron emission tomographic studies of cerebral benzodiazepine-receptor binding in chronic alcoholics (Gilman et al) 1996;40:163
Receptors, interleukin-2
circulating soluble CD8 and interleukin-2 receptor levels are measures of disease activity in idiopathic inflammatory myopathies (Okada et al) 1996;40:516A
Receptors, purinergic
bivalent analogs of adenosine: generation of receptor subtype specificity (Wollack and Jacobson) 1996;40:330A
propentofylline protects rat brain from complete ischemia without adenosine receptor function (Haida et al) 1996;40:493A
Receptors, serotonin
5-HTP–induced myoclonus is specifically mediated through the 5-HT_1 subsystem: implications for new drug development (Pappert et al) 1996;40:534A
Receptors, VLDL
lack of association of very low density lipoprotein receptor gene polymorphism with caucasian Alzheimer's disease (Okuizumi et al) 1996;40:251
Recombinant human nerve growth factor; *see* **Nerve growth factors**
Recombinant tissue plasminogen activator; *see* **Plasminogen activator, tissue-type**
Referral bias; *see* **Bias**
Reflex sympathetic dystrophy
reflex sympathetic dystrophy associated with deep peroneal nerve entrapment (Parano and Trifiletti) 1996;40:315A
Registries
causes of ischemic stroke in young adults: a comparison of two registries (Williams et al) 1996;40:497A
Remyelination; *see* **Myelin sheath**
Replantation
recovery of sympathetic skin responses after digit-to-digit replantation and toe-to-digit transplantation in humans (Chu) 1996;40:67
Replicative aging; *see* **Aging**
Respiratory chain complex I; *see* **Complex I**
Respiratory insufficiency
impaired central respiratory drive in myotonic dystrophy (Zifko et al) 1996;40:511A
Resting brain glucose; *see* **Glucose**
Retrovirus infections
autoantibodies produced by patients with HTLV-I–associated myelopathy/tropical spastic paraparesis react exclusively with neurons: implications for immune-mediated damage to the CNS in retroviral-associated neurological disease (Levin et al) 1996;40:494A
search for retrovirus in patients with multiple sclerosis (Hackett et al) 1996;40:805

Rett syndrome
characteristic patterns of dendritic protein expression in Down and Rett syndromes (Kaufmann et al) 1996;40:287A
Reverse transcription; *see* **Transcription, genetic**
Reviewers
Thanks to reviewers (Fishman) 1996;40:1
Rhabdomyolysis
trifunctional enzyme deficiency: adult presentation of a usually fatal β-oxidation defect (Schaefer et al) 1996;40:597
Rhombencephalon
"Joubert syndrome": a rhombencephalic segmentation anomaly (Maria et al) 1996;40:297A
Risk factors
case-control analysis of risk factors for intracerebral hemorrhage: the Northern Manhattan Stroke Study (Thomas et al) 1996;40:529A
genetic variability of the CYP 2D6 gene is not a risk factor for sporadic Parkinson's disease (Diederich et al) 1996;40:463
malignant transformation of cerebral low-grade gliomas in adults: an analysis of risk factors (Dropcho) 1996;40:489A
risk factors for Alzheimer's disease in women (Duara et al) 1996;40:500A
RNA
MELAS associated with a mutation in the valine transfer RNA gene of mitochondrial DNA (Taylor et al) 1996;40:459
mitochondrial DNA and RNA processing in MELAS (Kaufmann et al) 1996;40:172
RNA, messenger
abnormal mRNA leads to downregulation of glutamate transporter EAAT2 (GLT-1) expression in familial amyotrophic lateral sclerosis (Lin et al) 1996;40:540A
altered expression of *bcl-2* and *bax* mRNA in amyotrophic lateral sclerosis spinal cord motor neurons (Mu et al) 1996;40:379
apolipoprotein E and apolipoprotein E messenger RNA in muscle of inclusion body myositis and myopathies (Mirabella et al) 1996;40:864
Epstein-Barr virus transformation induces expression of *trk b* messenger RNA in human B lymphocytes (Eggers et al) 1996;40:518A
expression of messenger RNA encoding muscle acetylcholine receptor ϵ subunit in thymoma (MacLennan et al) 1996;40:513A
mutant GTP cyclohydrolase I mRNA levels contribute to dopa-responsive dystonia onset (Hirano et al) 1996;40:796
RNA binding proteins
isolation of RNA (CUG repeat) binding proteins from human muscle and brain: implications for myotonic dystrophy (Bhagwati and Ghatpande) 1996;40:543A
Robotics
application of robotics to assess the effect of manipulation of the impaired upper limb in stroke recovery (Aisen et al) 1996;40:522A

Saccades
"round the houses" sign in progressive supranuclear palsy (Quinn) (Letter); (Leigh) (Reply) 1996;40:951
Sarcolemma
sarcolemmal complement and IgM deposits in immune-mediated myopathies (Spuler and Engel) 1996;40:511A
Satellite diagnostic and treatment centers; *see* **Community health centers**
SB 202026; *see* **Parasympathomimetics**
Scapuloperoneal spinal muscular atrophy; *see* **Muscular atrophy, spinal**
Scatter factor; *see* **Cytokines**
Schwann cells
insulin-like growth factor-I prevents glucotoxicity in Schwann cells (Feldman et al) 1996;40:510A
Screening battery; *see* **Mass screening**
Seizures, analysis
low brain GABA level is associated with poor seizure control (Petroff et al) 1996;40:908
Seizures, cerebrospinal fluid
folinic acid-responsive intractable neonatal seizures associated with an unidentified cerebrospinal fluid compound (Torres et al) 1996;40:319A
Seizures, complications
ictal single-photon emission computed tomography findings in gelastic seizures secondary to hypothalamic hamartoma (Bebin et al) 1996;40:307A
Seizures, diagnosis
magnetic resonance evaluation in children with new onset of seizure (Klug et al) 1996;40:304A
paroxysmal nonepileptic events in children and adolescents (Costa et al) 1996;40:306A
Seizures, drug therapy
outcome of children treated with gabapentin (Hammer and Stack) 1996;40:304A
outcome of neonatal seizures associated with neonatal strokes in term infants (Wong and DeGrauw) 1996;40:287A
short-duration treatment of neonatal seizures: retrospective review of management and outcome (Bergin and Ichord) 1996;40:307A
what happens to children with epilepsy who experience a seizure recurrence after withdrawal of antiepileptic drugs? (Shinnar et al) 1996;40:301A
Seizures, epidemiology
epidemiology of Lennox-Gastaut syndrome and multiple seizure types in Atlanta children (Trevathan et al) 1996;40:301A
Seizures, etiology
causes and outcome of seizures in liver transplant recipients (Wijdicks et al) 1996;40:505A
early posttraumatic seizures are more common after nonaccidental head injury than other types of head injury (Gilles) 1996;40:316A
familial hypomagnesemia with seizures, migraine, and stroke-like events (Selcen et al) 1996;40:336A
Seizures, pathology
hemifacial seizures and cerebellar ganglioglioma: an epilepsy syndrome of infancy with seizures of cerebellar origin (Harvey et al) 1996;40:91
low brain GABA levels remote from the seizure focus are associated with poor seizure control in patients with complex partial epilepsy (Petroff et al) 1996;40:506A
Seizures, physiopathology
recurrent afebrile seizures in children initially diagnosed as having febrile seizures (Trifiletti et al) 1996;40:327A
Seizures, therapy
seizure precautions: are they appropriate in patients with seizures? (Conry et al) 1996;40:306A
Selegiline
deprenyl and levodopa and Parkinson's disease progression (Fowler et al) 1996;40:267 (Letter)

deprenyl in Parkinson's disease (Korczyn and Nisipeanu) (Letter); (Olanow and Koller) (Reply) 1996;40:268
deprenyl's neuroprotective action remains unresolved (van Hilten et al) (Letter); (Olanow and Koller) (Reply) 1996;40:266
Selegiline and mortality in Parkinson's disease (Olanow et al) 1996;40:841 (Point of view)
study design problems of DATATOP study analysis (Mäki-Ikola and Heinonen) (Letter); (Penney et al) (Reply) 1996;40:946
Self-concept
diversity and plasticity of self-determinant recognition during the early development of multiple sclerosis (Tuohy et al) 1996;40:519A
Sensory neurons; *see* **Neurons, afferent**
Serotonin
brain serotonin synthesis rate measured with [^{11}C]α-methyl-tryptophan positron emission tomography in normal and autistic subjects (Chugani et al) 1996;40:296A
mapping afferents of rabbit neostriatum: serotonin (anatomical evaluation of rabbit as a potential model of Huntington's disease) (Phelix and Russell) 1996;40:532A
Severe Mini-Mental State Examination; *see* **Mini-Mental State Examination**
Siderosis
surgical management of superficial siderosis following cervical nerve root avulsion (Tapscott et al) 1996;40:936
Signal transduction
neuronal platelet-activating factor receptor signal transduction involves a pertussis toxin-sensitive G-protein (Clark et al) 1996;40:289A
Single-photon emission-computed tomography; *see* **Tomography, emission-computed, single-photon**
Skeletal muscle; *see* **Muscle**
Skin
diagnostic utility of the nerve-muscle-skin biopsy in pediatric neurology practice (Miller et al) 1996;40:328A
Guamanian neurodegenerative disease: ultrastructural studies of skin (Ono et al) 1996;40:530A
Sleep
dysmaturity index derived from electroencephalographic sleep analyses to document brain adaptation to conditions of prematurity (Scher et al) 1996;40:320A
electrical status epilepticus during sleep can mimic a progressive neurological disorder (Cusmai et al) 1996;40:305A
epilepsy in children with brain injuries: impact on sleep (Gupta et al) 1996;40:304A
sleep and amitriptyline enhance the sensitivity of electroencephalograms in children with a pervasive developmental disorder and language regression (Kollros et al) 1996;40:303A
study of brain adaptation from neonatal to infancy periods using spectral electroencephalographic-sleep analyses (Scher et al) 1996;40:320A
Sleep disorders
new alternative in the pharmacological management of somnolence: a Phase III study of modafinil in narcolepsy (Fry) 1996;40:493A
sleep disorders after traumatic brain injury: analysis of common moderating variables (Dabrowski et al) 1996;40:317A
Small cell lung carcinoma; *see* **Carcinoma, oat cell**
Somnolence; *see* **Sleep disorders**
Sotos syndrome; *see* **Brain, abnormalities**
Spasm
skeletal muscle–specific immunotoxin for the treatment of focal muscle spasm (Hott et al) 1996;40:539A
Spasms, infantile
hemifacial seizures and cerebellar ganglioglioma: an epilepsy syndrome of infancy with seizures of cerebellar origin (Harvey et al) 1996;40:91
phase I trial of a novel anticonvulsant for infantile spasms: safety and hormonal effects of a corticotropin-releasing hormone antagonist in humans (Baram et al) 1996;40:285A
Spastic paraplegia, hereditary
genetic heterogeneity in autosomal dominant familial spastic paraplegia in the Japanese (Matsuura et al) 1996;40:531A
"pure" autosomal dominant spastic paraplegia with late-onset dementia: a family study (Webb et al) 1996;40:530A
X-linked spastic paraplegia: clinical features, magnetic resonance imaging, and molecular studies (Morse and Carrier) 1996;40:313A
Spasticity; *see* **Muscle spasticity**
Spectroscopy
cerebral near-infrared spectroscopy in children undergoing heart surgery (Wollert and Eckel) (Letter); (du Plessis et al) (Reply) 1996;40:818
Speech; *see also* **Language**
preoperative localization of speech-related brain areas in glioma patients (Herholz et al) 1996;40:489A
repetitive transcranial magnetic stimulation of the dominant hemisphere can disrupt visual naming as well as speech in temporal lobe epilepsy patients (Wassermann et al) 1996;40:525A
speech-induced changes in corticospinal excitability (Tokimura et al) 1996;40:628
Speech disorders
speech and language disabilities in association with parietotemporal white matter abnormalities in hypomelanosis of Ito: an anatomical substrate for a behavioral phenotype? (Ruggieri et al) 1996;40:312A
Spinal cord
altered expression of *bcl-2* and *bax* mRNA in amyotrophic lateral sclerosis spinal cord motor neurons (Mu et al) 1996;40:379
speech-induced changes in corticospinal excitability (Tokimura et al) 1996;40:628
Spinal cord diseases
human T-cell lymphotropic virus type II–associated myelopathy: clinical and immunologic profiles (Lehky et al) 1996;40:714
Spinal muscular atrophy; *see* **Muscular atrophy, spinal**
Spinocerebellar degeneration
(CAG)nC configuration and repeat size in Machado-Joseph disease gene (Matsumura et al) 1996;40:530A
candidate gene analysis in spinocerebellar ataxia type 4 (SCA4) (Flanigan et al) 1996;40:487A
cognitive deficits in Machado-Joseph disease (Maruff et al) 1996;40:421
haplotype analysis indicates an independent origin of a Machado-Joseph disease allele in an African-American family (Chabrashvili et al) 1996;40:532A
posturography and electronystagmography discriminate between spinocerebellar ataxia type 1 (SCA1) and type 3 (SCA3/Machado-Joseph disease) patients (Subramony et al) 1996;40:533A

Spinocerebellar degeneration (*continued*)
regional and cellular expression of the Machado-Joseph disease gene in brains of normal and affected individuals (Nishiyama et al) 1996;40:776
somatic mosaicism in the central nervous system in spinocerebellar ataxia type 1 and Machado-Joseph disease (Lopes-Cendes et al) 1996;40:199
Spreading cortical depression
long-term elevation of cyclooxygenase-2, but not lipoxygenase, in regions synaptically distant from spreading depression (Caggiano et al) 1996;40:547A
Status epilepticus
altered mental status in thrombotic thrombocytopenic purpura is secondary to nonconvulsive status epilepticus (Garrett et al) 1996;40:245
electrical status epilepticus during sleep can mimic a progressive neurological disorder (Cusmai et al) 1996;40:305A
neuroprotective effects of adrenalectomy in the kainic acid model of limbic status epilepticus in adult rat (Dure et al) 1996;40:287A
status epilepticus after cerebral stroke (Berges et al) 1996;40:528A
Stem cells
different cytokine families regulate neuronal and glial differentiation from neural progenitor cells (Mehler et al) 1996;40:546A
Steroids
$GABA_A$ receptor active neurosteroids plasma profile in children with tuberous sclerosis complex (Romeo et al) 1996;40:323A
increased neurosteroid synthesis after brain injury (Romeo et al) 1996;40:315A
periventricular-intraventricular hemorrhage (1993–1995) following introduction of antenatal steroids (Perlman and Risser) 1996;40:295A
pervasive developmental disorder/autism versus Landau-Kleffner syndrome: steroid-responsive encephalopathy characterized by language and social interactive impairment (Mott et al) 1996;40:332A
Stress
chronic stress in infancy results in downregulation of corticotropin-releasing hormone gene expression in the hypothalamus (Gilles and Baram) 1996;40:322A
Stroke; *see* **Cerebrovascular disorders**
Sturge-Weber syndrome
proton magnetic resonance spectroscopy in children with Sturge-Weber syndrome (Moore et al) 1996;40:313A
Subacute sclerosing panencephalitis
resurgence of subacute sclerosing panencephalitis in Philadelphia in 1995 (Dlugos) 1996;40:311A
Subcortical band heterotopia; *see* **Choristoma**
Substance abuse
fetal cocaine exposure and neurological outcome in school-aged children (Chiriboga et al) 1996;40:323A
phentolamine pretreatment prevents a component of growth retardation and of inattention induced by prenatal cocaine exposure (Kosofsky et al) 1996;40:315A
"silent" CNS injury in chronic toluene and other drug abusers: a prospective, blinded analysis of 140 individuals (Rosenberg et al) 1996;40:494A
striatal dopamine, dopamine transporter, and vesicular monoamine transporter in chronic cocaine users (Wilson et al) 1996;40:428
Sudden death; *see* **Death, sudden**
Superoxide
nitric oxide and superoxide anion interactions in neurologic disease (Dawson) 1996;40:487A
Supranuclear palsy, progressive
'round the houses' sign in progressive supranuclear palsy (Quinn) (Letter); (Leigh) (Reply) 1996;40:951
Supratentorial neoplasms
grading and naming of pediatric supratentorial astrocytic tumors (Brown et al) 1996;40:335A
recurrent supratentorial gliomas: salvage therapy with oral etoposide (Chamberlain) 1996;40:335A
Susceptibility artifacts; *see* **Artifacts**
Sympathetic nervous system
recovery of sympathetic skin responses after digit-to-digit replantation and toe-to-digit transplantation in humans (Chu) 1996;40:67
Systemic lupus erythematosus; *see* **Lupus erythematosus, systemic**

T-cell receptors; *see* **Receptors, antigen, T-cell**
T-lymphocytes
α/β T cells and immunoglobulins protect mice from Theiler's virus–induced encephalitis whereas Class I MHC/$CD8^+$ T cells protect against demyelination (Drescher et al) 1996;40:517A
circulating soluble CD8 and interleukin-2 receptor levels are measures of disease activity in idiopathic inflammatory myopathies (Okada et al) 1996;40:516A
Class I MHC and/or $CD8^+$ T cells are necessary for clinical deficits in a mouse model of multiple sclerosis (Rivera-Quinones et al) 1996;40:517A
copolymer-1 suppresses the T-cell proliferative response to myelin oligodendrocyte glycoprotein (Milo et al) 1996;40:551A
decreased expression of the apoptosis inhibitor Bcl-2 in T cells in the central nervous system in experimental autoimmune encephalomyelitis (Pender et al) 1996;40:552A
human T-lymphotropic virus type I–associated myelopathy and tax gene expression in $CD4^+$ T lymphocytes (Moritoyo et al) 1996;40:84
identification of a novel H-$2D^b$–restricted cytotoxic T-cell epitope in the VP-2 capsid protein of Theiler's virus (Borson et al) 1996;40:514A
immune deviation from a Th1 toward a Th2-type T-cell response occurs during recovery from monophasic experimental autoimmune encephalomyelitis (Jensen et al) 1996;40:522A
interferon β-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9 (Stüve et al) 1996;40:853
interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis (Leppert et al) 1996;40:846
limited heterogeneity of γ/Δ T cells in autoimmune diseases: analysis of the VΔ2/JΔ3 T-cell receptor rearrangement in peripheral blood lymphocytes (Liedtke et al) 1996;40:515A
mechanism of $\gamma\Delta$ T-cell cytotoxicity in multiple sclerosis (Zeine et al) 1996;40:555A
T-cell reactivity to peptides of proteolipid protein and myelin basic protein in multiple sclerosis (Pender et al) 1996;40:552A
T-cell receptor (TCR) peptide immunization in multiple

sclerosis boosts TCR-specific Th2 cells and suppresses MBP-specific Th1 cells: report of a double-blind, placebo-controlled pilot trial (Bourdette et al) 1996;40:518A

Tacrolimus; *see* **FK-506**

Task performance and analysis
correspondence of binaural task performance to location of brainstem lesions (Aharonson et al) 1996;40:546A

Tat protein; *see* **Gene products, Tat**

Tau proteins
neurodegenerative disorders with extensive tau pathology: a comparative study and review (Feany and Dickson) 1996;40:139 (Neurological progress)

Tax genes; *see* **Genes, pX**

Teaching
careers in academic neurology, 1996 (Spencer) 1996;40:123 (Point of view)
early American professorships in neurology (Goetz and Pappert) 1996;40:258 (History of neurology)

Telomere
similar telomere lengths in normal and dystrophic muscle indicate that replicative aging is not the cause of progression in Duchenne muscular dystrophy (Oexle et al) 1996;40:294A

Temporal lobe
functional MRI of lateral occipitotemporal cortex during pursuit and motion perception (Barton et al) 1996;40:387
mesial atrophy and outcome after amygdalohippocampectomy or temporal lobe removal (Arruda et al) 1996;40:446
normalization of contralateral metabolic function following temporal lobectomy demonstrated by ^{1}H magnetic resonance spectroscopic imaging (Hugg et al) 1996;40:236

Temporal lobe epilepsy; *see* **Epilepsy, temporal lobe**

Tension headache
acetazolamide challenge confirms vascular versus tension headaches (Meyer et al) 1996;40:507A

Teratoma
primary immature teratoma of the leptomeninges in an 8-year-old child: unusual presentation with recurrent transient oculomotor nerve palsies and rapid progression to diffuse cerebral infarction (Robertson et al) 1996;40:333A

Tetanus
intrathecal baclofen for the treatment of severe generalized tetanus (Deibert et al) 1996;40:512A

Thalamic diseases
brainstem and thalamic lesions in dentatorubropallidoluysian atrophy (Tomiyasu et al) 1996;40:523A

Thalamus
stereotactic radiosurgical thalamotomy and pallidotomy for treatment of movement disorders (Young et al) 1996;40:537A

Thalassemia
stroke in children with β-thalassemia major: role of hypertransfusion (Trifiletti et al) 1996;40:336A

Thallium 201 single-photon emission-computed tomography; *see* **Tomography, emission-computed, single-photon**

Theiler's virus; *see* **Encephalomyelitis virus, murine**

Thiazides
thiazides promote ischemic neuronal injury in vivo (Yamada et al) 1996;40:314A

311C90; *see* **Zolmitriptan**

Thromboembolism
microvascular endothelial cell activation in the central nervous system is associated with cancer and cerebral thromboembolism (Rogers et al) 1996;40:492A

Thrombolytic therapy
urokinase for acute ischemic stroke (Suarez et al) 1996;40:499A

Thrombotic thrombocytopenic purpura; *see* **Purpura, thrombotic thrombocytopenic**

Thymectomy
incidence of myasthenic crises in pediatric myasthenia gravis after thymectomy (Sivak et al) 1996;40:327A

Thymidine kinase
glioblastoma gene therapy: strategies for optimizing clinical application of the TK/GCV system (Sturtz et al) 1996;40:489A

Thymoma
expression of messenger RNA encoding muscle acetylcholine receptor ϵ subunit in thymoma (MacLennan et al) 1996;40:513A

Thymus gland
Epstein-Barr virus genome is absent in myasthenic thymic tissue (Woolfenden et al) 1996;40:540A

Tic
peer relationship problems are not related to tic severity in Tourette disorder (Camfield et al) 1996;40:333A

Tocopherol; *see* **Vitamin E**

Toes, transplantation
recovery of sympathetic skin responses after digit-to-digit replantation and toe-to-digit transplantation in humans (Chu) 1996;40:67

Toluene
"silent" CNS injury in chronic toluene and other drug abusers: a prospective, blinded analysis of 140 individuals (Rosenberg et al) 1996;40:494A

Tomography, emission-computed
activation positron emission tomography demonstrates neurotrophic properties of propentofylline in Alzheimer's disease (Mielke et al) 1996;40:501A
benzodiazepine receptors in focal epilepsy with cortical dysgenesis: an ^{11}C-flumazenil PET study (Richardson et al) 1996;40:188
brain serotonin synthesis rate measured with [^{11}C]α-methyl-tryptophan positron emission tomography in normal and autistic subjects (Chugani et al) 1996;40:296A
clinical application of thallium 201 single-photon emission-computed tomography and fluorodeoxyglucose-positron emission tomography in childhood brain tumors (Smietana et al) 1996;40:333A
decreased striatal monoaminergic terminals in olivopontocerebellar atrophy and multiple system atrophy demonstrated with positron emission tomography (Gilman et al) 1996;40:885
diagnosis of glioma with C-11-methionine positron emission tomography (Herholz et al) 1996;40:490A
effects of healthy aging on regional cerebral metabolic rates of glucose: assessment with positron emission tomography and statistical parametric mapping (Petit-Taboué et al) 1996;40:501A
fluorodeoxyglucose positron emission tomography in children and adolescents with frontal lobe epilepsy (Gaillard et al) 1996;40:305A
fluorodeoxyglucose positron emission tomography in pediatric patients with neurofibromatosis type 1 (Molloy et al) 1996;40:325A

Tomography, emission-computed (*continued*)
impaired set-shifting ability in Parkinson's disease: relationships with striatofrontal circuit disruption and caudate nucleus dopamine denervation assessed with positron emission tomography (Marié et al) 1996;40:525A
metabolic status of the ultimately noninfarcted ischemic penumbra: a positron emission tomography study in humans (Baron et al) 1996;40:498A
positron emission tomographic studies of cerebral benzodiazepine-receptor binding in chronic alcoholics (Gilman et al) 1996;40:163
usefulness of 18-fluorodeoxyglucose positron emission tomography in pediatric neurology patients (Molloy et al) 1996;40:313A

Tomography, emission-computed, single-photon
clinical application of thallium 201 single-photon emission-computed tomography and fluorodeoxyglucose-positron emission tomography in childhood brain tumors (Smietana et al) 1996;40:333A
ictal single-photon emission computed tomography findings in gelastic seizures secondary to hypothalamic hamartoma (Bebin et al) 1996;40:307A
improved localization of epileptic focus by ictal single-photon emission computed tomography using continuous electroencephalographic analysis and background subtraction to determine time of injection (Koo et al) 1996;40:303A
interobserver variability of single-photon emission computed tomography scan interpretation in children with language regression (Yaylali et al) 1996;40:311A
single-photon emission computed tomography and developmental disorders of the neocortex (Spalice et al) 1996;40:299A
single-photon emission computed tomography in childhood absence epilepsy (Spalice et al) 1996;40:312A
value of single-photon emission computed tomography in evaluating occipital lobe epilepsy (Azhar et al) 1996;40:307A

Tomography, x-ray computed
computed tomographic imaging in neurofibromatosis (Tonsgard et al) 1996;40:311A
emergency computed tomography utilization in a children's hospital (Chaves-Carballo and Gavini) 1996;40:314A

Tonic pupil
Adie-Holmes pupils, motor and sensory neuropathy, pyramidal tract involvement and autosomic dysfunction in a family (Haenggeli and De Vivo) 1996;40:329A

Toprimate
efficacy of toprimate in Lennox-Gastaut syndrome (Kugler et al) 1996;40:303A

Torticollis
exclusion of the DYT1 locus in familial torticollis (Bressman et al) 1996;40:681

Tourette syndrome
peer relationship problems are not related to tic severity in Tourette disorder (Camfield et al) 1996;40:333A

Toxoplasmosis, congenital
congenital lymphocytic choriomeningitis virus infection: a disorder closely mimicking congenital toxoplasmosis and cytomegalovirus infection (Wright et al) 1996;40:319A

Transcranial magnetic stimulation; *see* **Magnetic stimulation**

Transcription, genetic
reverse transcription and the bipotential replication of mitochondrial DNA (Naviaux et al) 1996;40:293A

Transcription factor, Sp3
deficient expression in multiple sclerosis of the inhibitory transcription factor Sp3 in mononuclear blood cells (Grekova et al) 1996;40:108

Transcription factors
Brn-4 regulates transcription of the human D1A dopamine receptor gene (Mouradian et al) 1996;40:549A
c-*myc* acts as a transcription factor for the eIF-4E promoter (Jones et al) 1996;40:334A

Transfection
astrocytes from adult brains as vehicles for gene transfer into the central nervous system: grafting and the host response (Azizi) 1996;40:549A

Transforming growth factor beta
therapeutic levels of phenobarbital inhibit development and maintenance of dendrites induced by osteogenic protein-1 (Johnson et al) 1996;40:286A

Transient ischemic attack; *see* **Cerebral ischemia, transient**

Transplantation; *see also specific organs*
recovery of sympathetic skin responses after digit-to-digit replantation and toe-to-digit transplantation in humans (Chu) 1996;40:67

Tremor
efficacy of deep brain stimulation in the treatment of essential tremor and Parkinson's disease: 12-month follow-up (Busenbark et al) 1996;40:533A
specificity of ethanol in essential tremor (Rajput) (Letter); (Boecker and Brooks) (Reply) 1996;40:950

Trifunctional enzyme deficiency; *see* **Enzymes**

Trigeminal neuralgia
treatment of trigeminal neuralgia with the Leksell gamma knife (Young et al) 1996;40:507A

Trinucleotide repeats
(CAG)nC configuration and repeat size in Machado-Joseph disease gene (Matsumura et al) 1996;40:530A
isolation of RNA (CUG repeat) binding proteins from human muscle and brain: implications for myotonic dystrophy (Bhagwati and Ghatpande) 1996;40:543A
lack of correlation between CTG repeat size and skeletal myopathology in myotonic dystrophy (Shaibani et al) 1996;40:543A
regional and cellular expression of the Machado-Joseph disease gene in brains of normal and affected individuals (Nishiyama et al) 1996;40:776

Triplets
mitochondrial encephalomyopathy in discordant triplets (Johns et al) 1996;40:532A

Tropheryma whippelii
diagnostic guidelines in central nervous system Whipple's disease (Louis et al) 1996;40:561 (Neurological progress)
polymerase chain reaction–based detection of *Tropheryma whippelii* in central nervous system Whipple's disease (Lynch et al) 1996;40:535A

Tryptophan
eosinophilia myalgia syndrome: development of a murine model and roles of "pure" and "contaminated" L-tryptophan (Rosenberg et al) 1996;40:517A

Tuberin
loss of tuberin from cerebral tissues with tuberous sclerosis and astrocytoma (Mizuguchi et al) 1996;40:941

Tuberous sclerosis
$GABA_A$ receptor active neurosteroids plasma profile in children with tuberous sclerosis complex (Romeo et al) 1996;40:323A
loss of tuberin from cerebral tissues with tuberous sclerosis and astrocytoma (Mizuguchi et al) 1996;40:941

sequential evaluation of patients with tuberous sclerosis to detect complications: a protocol based on the natural history (Roach et al) 1996;40:334A
Tubulin
fragmentation of neocortical neurites in pediatric human immunodeficiency virus-1-associated central nervous system disease: an immunoperoxidase study of tubulin epitopes in postmortem brains (Katsetos et al) 1996;40:309A
Tumor necrosis factor
multiple sclerosis: effect of clinical disease activity, disability status, and interferon beta-1b treatment on blood and CSF-ICAM-1, tumor necrosis factor receptor, and other immunological parameters (Baumhefner et al) 1996;40:552A
Twins
atlanto-axial dislocation with quadriplegia in one of the twins in a family with autosomal dominant odontoid hypoplasia (Shah and Fish) 1996;40:308A
cerebral adrenoleukodystrophy (ALD) in only one of monozygotic twins with an identical ALD genotype (Korenke et al) 1996;40:254
familial temporal lobe epilepsy: a common disorder identified in twins (Berkovic et al) 1996;40:227
Tyrosine
cerebrospinal fluid protein tyrosine nitration in neonates: marker of brain NO production (Hills et al) 1996;40:324A
insulin-like growth factor-I stimulates the tyrosine phosphorylation of paxillin and focal adhesion kinase (Leventhal and Feldman) 1996;40:509A
insulin-like growth factor-I stimulates tyrosine phosphorylation of MAP kinases and neurite outgrowth in human neuroblastoma cells (Kim et al) 1996;40:510A
marked enhancement of brain protein tyrosine nitration by dystonia-producing toxin 3-nitropropionic acid: implications for mechanisms of neurotoxicity (Takai et al) 1996;40:323A

Ultrasonography
cost-effectiveness of Doppler ultrasound screening for asymptomatic carotid stenosis (Powers and Derdeyn) 1996;40:526A
value of head ultrasound in infants with macrocephaly (Smith and Maytal) 1996;40:312A
Upgaze palsy; *see* **Eye movements**
Upper limb; *see* **Arm**
Uric acid
elevated uric acid levels in the first postnatal day are associated with periventricular hemorrhage and cystic periventricular leukomalacia in premature infants (Perlman and Risser) 1996;40:321A
serum uric acid, age at disease onset, and rate of disease progression in Alzheimer's disease (Sevush and Mallia) 1996;40:501A
Urine
myelin basic protein-like material in urine: a developmental profile (Percy et al) 1996;40:297A
urinary myelin basic protein-like material as a correlate of the progression of multiple sclerosis (Giovannoni et al) (Letter); (Whitaker et al) (Reply) 1996;40:128
Urography
posturography and electronystagmography discriminate between spinocerebellar ataxia type 1 (SCA1) and type 3 (SCA3/Machado-Joseph disease) patients (Subramony et al) 1996;40:533A
Urokinase
expression of the urokinase plasminogen activator in adult human CNS microglial cells (Dore-Duffy et al) 1996;40:516A
urokinase for acute ischemic stroke (Suarez et al) 1996;40:499A

Vagus nerve
left vagal nerve stimulation to control refractory epilepsy (Murphy et al) 1996;40:303A
Vascular headache
acetazolamide challenge confirms vascular versus tension headaches (Meyer et al) 1996;40:507A
Vasculitis
diagnostic value of combined superficial peroneal nerve/peroneus brevis muscle biopsy in suspected vasculitis (Collins et al) 1996;40:545A
Vegetative state; *see* **Coma**
Vertebral artery
basilar artery occlusion in children: clinical presentations and pathogenetic implications of accompanying vertebral artery occlusion (Muriello et al) 1996;40:337A
Vertebrobasilar insufficiency
cardiac sources of embolism are a determinant of microemboli in patients with vertebrobasilar ischemia (Koennecke et al) 1996;40:528A
misleading magnetic resonance angiography in patients with posterior circulation occlusive disease (Belden et al) 1996;40:498A
Vertigo
horizontal canal benign paroxysmal positioning vertigo (h-BPPV): transition of canalolithiasis to cupulolithiasis (Steddin and Brandt) 1996;40:918
Very low density lipoproteins; *see* **Lipoproteins, VLDL**
Vesicular monoamine transporter
striatal dopamine, dopamine transporter, and vesicular monoamine transporter in chronic cocaine users (Wilson et al) 1996;40:428
Vincristine
factors predicting disease control in children with progressive low-grade gliomas treated with carboplatin and vincristine chemotherapy (Packer et al) 1996;40:292A
is early complete response in recurrent malignant gliomas treated with cisplatin, VP-16, and vincristine related to anticonvulsants? (Phuphanich et al) 1996;40:490A
Virchow-Robin space
perivascular spaces in pediatric brain magnetic resonance imaging: frequency, variation, clinical significance (Richards and Morse) 1996;40:336A
Viruses; *see also specific viruses*
lack of interferon-β gene expression in virus-infected neuronal cells: implications on virus persistence (Dhib-Jalbut and Xia) 1996;40:494A
Vision disorders
biochemical study of ND1/3460 Leber optic neuropathy with visual recovery (Leuzzi et al) 1996;40:299A
visuoconstructive and motor skills in children with vertical human immunodeficiency-1 infection (Preston et al) 1996;40:309A
Vitamin E
amyotrophic lateral sclerosis and vitamin E (Keane) 1996;40:480 (Historical intelligence)
study design problems of DATATOP study analysis (Mäki-Ikola and Heinonen) (Letter); (Penney et al) (Reply) 1996;40:946

Vomiting
recurrent vomiting following mild head injury is related to migraine (Jan et al) 1996;40:337A
VP-16; *see* **Etoposide**

Whipple's disease; *see* **Lipodystrophy, intestinal**
White matter
predicting dementia in white matter disease: magnetic resonance imaging, magnetic resonance spectroscopy, and neuropsychology (Balthazor et al) 1996;40:290A
speech and language disabilities in association with parietotemporal white matter abnormalities in hypomelanosis of Ito: an anatomical substrate for a behavioral phenotype? (Ruggieri et al) 1996;40:312A
Women
effects of estrogen on cognitive function in nondemented postmenopausal women (Jacobs et al) 1996;40:502A
risk factors for Alzheimer's disease in women (Duara et al) 1996;40:500A
Word processing
impaired visual word processing in dyslexia revealed with magnetoencephalography (Salmelin et al) 1996; 40:157

X chromosome
linkage analysis of "double cortex"/X-linked lissencephaly (Gleeson et al) 1996;40:290A
physical mapping of X-linked lissencephaly and SBH (XLIS) (Ross et al) 1996;40:289A
X-linked dominant Charcot-Marie-Tooth disease: novel connexin 32 mutations and their relationship to clinical and pathological disease (Tan et al) 1996;40:545A
X-linked nonprogressive congenital cerebellar hypoplasia: clinical description and mapping to chromosome Xq (Illarioshkin et al) 1996;40:75
X-linked spastic paraplegia: clinical features, magnetic resonance imaging, and molecular studies (Morse and Carrier) 1996;40:313A

Zolmitriptan
summary of the efficacy of 311C90: a new acute treatment for migraine (Klein) 1996;40:506A